data_2mkv_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mkv _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.6 p . . . . . 0 N--CA 1.463 0.206 0 N-CA-C 111.553 0.205 . . . . 0.0 111.553 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 29.5 mmm-85 -71.47 -55.35 8.05 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 119.635 -0.826 . . . . 0.0 109.92 178.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -92.66 -2.85 55.75 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.833 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.53 -42.36 99.75 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 121.116 -0.564 . . . . 0.0 112.572 -178.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.72 -44.32 98.06 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.901 -179.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.7 tp -59.78 -48.18 82.71 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.616 -0.433 . . . . 0.0 110.801 -178.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 90.3 mt -61.7 -44.07 98.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.921 0.391 . . . . 0.0 111.427 -179.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -60.26 -46.41 89.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.441 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.74 -42.69 89.38 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.781 -177.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.49 -40.33 97.58 Favored Glycine 0 CA--C 1.526 0.759 0 C-N-CA 120.352 -0.928 . . . . 0.0 110.943 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 93.6 mt -65.8 -36.49 83.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.416 0.627 . . . . 0.0 109.792 178.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -59.81 -48.5 81.43 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.262 -179.488 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 54.1 m-85 -60.23 -41.39 93.02 Favored 'General case' 0 C--O 1.236 0.39 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -178.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 89.9 mt -58.26 -44.5 88.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 C-N-CA 120.188 -0.605 . . . . 0.0 110.284 -179.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.9 t -57.38 -40.32 73.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.839 -179.279 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.36 -37.1 92.6 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.0 tp -58.61 -47.5 84.13 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.284 -0.566 . . . . 0.0 109.711 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 59.3 tp -55.49 -35.46 65.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.151 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 87.0 mt -59.88 -42.22 88.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 120.948 0.404 . . . . 0.0 110.665 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 91.7 mt -58.76 -40.44 83.91 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.241 -0.583 . . . . 0.0 110.425 -179.196 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 11.1 mp -60.73 -30.21 69.84 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.786 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 40.5 t -58.71 -41.44 86.35 Favored 'General case' 0 CA--C 1.518 -0.259 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 20.5 ttp180 . . . . . 0 C--N 1.328 -0.356 0 C-N-CA 120.485 -0.486 . . . . 0.0 110.155 179.294 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.464 0.242 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 78.4 ttt180 -73.54 -55.37 6.4 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 119.686 -0.805 . . . . 0.0 110.025 178.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 53.6 p30 -92.45 -1.76 56.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.848 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.3 -42.98 99.92 Favored Glycine 0 CA--C 1.526 0.76 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.265 -178.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.97 -43.59 98.97 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 120.734 -0.746 . . . . 0.0 111.728 -179.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.494 ' N ' ' CD2' ' A' ' 29' ' ' LEU . 4.0 mm? -59.53 -47.82 84.04 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.628 -0.429 . . . . 0.0 110.835 -178.436 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 90.7 mt -61.71 -44.11 98.22 Favored 'Isoleucine or valine' 0 C--O 1.237 0.422 0 CA-C-O 120.846 0.355 . . . . 0.0 111.414 -179.494 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -60.45 -46.8 88.76 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.335 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.79 -41.84 87.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.66 -178.214 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.38 -40.83 98.09 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 120.38 -0.914 . . . . 0.0 110.921 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 93.3 mt -67.0 -37.95 85.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.276 0.56 . . . . 0.0 109.952 178.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.28 -47.69 84.92 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.08 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 93.4 t80 -59.14 -46.99 86.93 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.958 -0.564 . . . . 0.0 112.318 -178.198 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.1 mt -57.98 -44.35 86.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 C-N-CA 120.726 -0.389 . . . . 0.0 111.013 -178.412 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 55.9 t -57.9 -40.5 76.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.599 -179.276 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.51 -36.4 91.23 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.75 -0.54 . . . . 0.0 111.75 -179.404 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 91.4 mt -60.02 -43.65 95.12 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.073 -0.651 . . . . 0.0 109.711 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.5 mt -58.43 -35.6 72.34 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.142 -178.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 86.6 mt -60.04 -43.04 91.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.067 0.46 . . . . 0.0 110.655 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 90.9 mt -58.91 -39.86 82.78 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 120.443 -0.503 . . . . 0.0 110.276 -179.24 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -60.07 -31.53 70.09 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-O 120.691 0.282 . . . . 0.0 110.912 -179.653 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 69.5 m -59.43 -40.37 86.53 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 59.0 ttt85 . . . . . 0 C--N 1.33 -0.263 0 C-N-CA 120.478 -0.489 . . . . 0.0 109.957 178.774 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 1.1 p . . . . . 0 N--CA 1.462 0.17 0 N-CA-C 111.822 0.305 . . . . 0.0 111.822 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 61.3 ttp180 -72.84 -54.41 8.86 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.019 179.023 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -92.94 -2.85 55.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.485 -0.78 . . . . 0.0 112.02 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.59 -43.16 99.65 Favored Glycine 0 CA--C 1.526 0.775 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.335 -178.724 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.89 -44.28 98.05 Favored Glycine 0 CA--C 1.526 0.731 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.012 -179.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.4 mt -60.4 -47.44 86.06 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.334 -0.546 . . . . 0.0 110.767 -178.523 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 5.0 mm -62.13 -43.9 98.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.739 0.304 . . . . 0.0 111.185 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.1 t80 -60.77 -46.58 89.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.255 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.66 -42.5 88.58 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.586 -178.213 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.72 -40.47 98.11 Favored Glycine 0 CA--C 1.524 0.642 0 C-N-CA 120.271 -0.966 . . . . 0.0 110.688 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 96.7 mt -67.23 -38.02 84.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.288 0.566 . . . . 0.0 109.811 178.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.6 -47.71 85.02 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.013 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 92.3 t80 -59.23 -47.2 86.22 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 115.903 -0.589 . . . . 0.0 112.146 -178.404 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 89.9 mt -57.8 -43.11 83.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 C-N-CA 120.868 -0.333 . . . . 0.0 110.437 -178.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 56.3 t -57.04 -40.06 70.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.451 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.83 -36.89 92.77 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 111.481 -0.648 . . . . 0.0 111.481 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 62.2 tp -58.25 -47.27 84.09 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.307 -0.557 . . . . 0.0 109.503 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 92.8 mt -57.49 -33.61 68.19 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.37 -178.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 41.2 mm -60.34 -42.86 92.28 Favored 'Isoleucine or valine' 0 C--O 1.236 0.387 0 CA-C-O 120.874 0.369 . . . . 0.0 110.237 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 92.1 mt -59.46 -39.39 83.47 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.115 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 59.2 tp -59.05 -35.28 73.06 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.53 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 46.7 t -59.15 -40.61 86.07 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 110.135 -0.321 . . . . 0.0 110.135 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.276 0 C-N-CA 120.354 -0.538 . . . . 0.0 110.186 179.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 2.1 p . . . . . 0 N--CA 1.465 0.278 0 N-CA-C 111.85 0.315 . . . . 0.0 111.85 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 59.0 ttt85 -72.51 -54.83 8.13 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 119.884 -0.726 . . . . 0.0 110.06 179.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -93.09 -2.65 55.31 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.873 -179.785 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.46 -43.57 99.14 Favored Glycine 0 CA--C 1.527 0.829 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.299 -178.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -63.1 -43.47 98.69 Favored Glycine 0 CA--C 1.527 0.84 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.163 -179.186 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 89.5 mt -60.37 -47.12 87.42 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.447 -0.501 . . . . 0.0 111.386 -177.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 40.1 pt -69.34 -37.56 75.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 120.487 -0.485 . . . . 0.0 111.382 -179.257 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.3 t80 -61.94 -47.64 83.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.961 0.41 . . . . 0.0 110.889 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.74 -42.14 92.5 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.76 -178.468 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.17 -40.2 96.92 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.731 -0.948 . . . . 0.0 110.731 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.5 tp -67.28 -39.5 86.04 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.423 0.63 . . . . 0.0 109.61 178.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -59.5 -48.79 80.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.435 -179.157 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -60.77 -40.62 93.2 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 111.962 0.356 . . . . 0.0 111.962 -178.432 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.4 mt -58.92 -44.73 91.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 C-N-CA 120.404 -0.518 . . . . 0.0 110.53 -179.025 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 56.3 t -57.88 -39.73 72.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.731 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.83 -37.23 93.33 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.605 -0.598 . . . . 0.0 111.605 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.0 tp -58.89 -47.38 85.17 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.689 -0.405 . . . . 0.0 110.118 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.5 mt -58.39 -34.87 71.21 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.397 -178.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 86.8 mt -60.21 -43.52 93.43 Favored 'Isoleucine or valine' 0 C--O 1.238 0.489 0 CA-C-O 120.797 0.332 . . . . 0.0 110.963 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 92.1 mt -59.66 -39.1 83.3 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.924 -0.31 . . . . 0.0 110.483 -179.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 59.0 tp -59.92 -35.69 75.42 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.88 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 75.5 m -59.58 -39.22 83.4 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.347 -179.619 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.313 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 2.7 p . . . . . 0 N--CA 1.469 0.51 0 N-CA-C 113.471 0.915 . . . . 0.0 113.471 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.445 ' NE ' ' OD1' ' A' ' 26' ' ' ASN . 4.1 ptm180 -80.04 -54.26 5.95 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 119.576 -0.85 . . . . 0.0 110.712 178.781 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . 0.445 ' OD1' ' NE ' ' A' ' 25' ' ' ARG . 34.3 m120 -91.44 -3.09 57.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.1 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -60.93 -42.0 99.53 Favored Glycine 0 CA--C 1.525 0.704 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.872 -179.243 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.28 -42.15 99.7 Favored Glycine 0 CA--C 1.525 0.668 0 C-N-CA 120.85 -0.69 . . . . 0.0 111.405 -179.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.4 mt -59.69 -46.81 87.93 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.367 -178.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 90.9 mt -60.82 -43.67 95.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.787 0.327 . . . . 0.0 110.917 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.0 t80 -60.29 -46.85 88.42 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.277 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.14 -42.6 86.21 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.875 -0.33 . . . . 0.0 111.417 -177.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.23 -40.08 96.84 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 60.3 tp -64.89 -39.85 94.19 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.214 0.53 . . . . 0.0 109.877 178.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.94 -46.0 92.47 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.281 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -59.84 -48.62 80.96 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.354 -178.25 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.404 HD12 HG22 ' A' ' 37' ' ' ILE . 92.1 mt -59.19 -48.75 85.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 N-CA-C 112.185 0.439 . . . . 0.0 112.185 -177.562 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 29.3 m -56.67 -35.45 45.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.485 -179.002 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -61.8 -38.51 96.08 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 111.815 -0.514 . . . . 0.0 111.815 -179.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.4 tp -59.0 -47.11 86.37 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.319 -0.552 . . . . 0.0 109.696 -179.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.9 mt -57.26 -34.13 68.32 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.278 -178.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 88.5 mt -60.74 -42.98 94.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.885 0.374 . . . . 0.0 110.822 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 91.6 mt -59.0 -39.49 81.99 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.141 -179.258 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 94.7 mt -60.71 -33.16 72.47 Favored 'General case' 0 C--O 1.238 0.455 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.975 -179.57 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 70.3 m -58.44 -40.51 82.76 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? . . . . . 0 C--N 1.328 -0.335 0 C-N-CA 120.677 -0.409 . . . . 0.0 110.522 178.967 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.0 p . . . . . 0 N--CA 1.464 0.256 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 90.7 mtm180 -73.13 -55.35 6.6 Favored 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 119.716 -0.794 . . . . 0.0 110.109 178.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -93.42 -1.43 55.8 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.439 -0.8 . . . . 0.0 112.081 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.06 -43.32 99.58 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.529 -178.518 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.88 -43.9 98.58 Favored Glycine 0 CA--C 1.526 0.773 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.829 -179.134 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.6 tp -59.52 -48.38 81.89 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.642 -178.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 92.4 mt -61.66 -44.41 98.64 Favored 'Isoleucine or valine' 0 C--O 1.236 0.348 0 CA-C-O 120.894 0.378 . . . . 0.0 111.526 -179.443 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.6 t80 -60.72 -46.58 89.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.152 -179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.81 -41.79 87.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.482 -178.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.59 -41.02 98.66 Favored Glycine 0 CA--C 1.525 0.691 0 C-N-CA 120.427 -0.892 . . . . 0.0 111.002 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 95.0 mt -67.16 -37.91 84.57 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.18 0.514 . . . . 0.0 110.114 178.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.51 -47.65 85.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.162 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 93.1 t80 -59.4 -46.81 87.63 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 116.083 -0.508 . . . . 0.0 112.227 -178.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.7 mm -57.57 -44.35 84.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.705 -178.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.1 t -57.2 -39.79 69.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.701 -179.318 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.67 -36.91 92.6 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 -179.794 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.4 tp -58.9 -48.23 82.16 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.007 -0.677 . . . . 0.0 109.891 -179.573 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 10.9 mp -56.19 -33.1 64.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.437 -178.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 4.7 mm -60.77 -43.81 96.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.455 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -57.12 -40.78 77.75 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.282 -0.567 . . . . 0.0 110.243 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 10.3 mp -60.96 -30.27 70.15 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.057 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 39.9 t -59.36 -41.44 89.25 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 -179.468 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.5 ttt-85 . . . . . 0 C--N 1.329 -0.289 0 C-N-CA 120.33 -0.548 . . . . 0.0 110.488 179.233 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.4 t . . . . . 0 C--O 1.226 -0.181 0 N-CA-C 111.919 0.341 . . . . 0.0 111.919 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -72.95 -54.23 9.2 Favored 'General case' 0 C--N 1.323 -0.584 0 C-N-CA 119.472 -0.891 . . . . 0.0 109.855 178.482 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -91.99 -1.14 57.41 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.336 -179.094 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.41 -41.86 99.63 Favored Glycine 0 CA--C 1.528 0.872 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.353 -178.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.71 -44.83 97.38 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.926 -179.161 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.7 tp -59.77 -47.92 83.75 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.865 -178.358 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.1 mt -62.11 -43.6 97.96 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 CA-C-O 120.904 0.383 . . . . 0.0 111.458 -179.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 91.6 t80 -60.62 -46.14 91.41 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.272 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.77 -42.36 88.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.341 -0.391 . . . . 0.0 111.622 -178.209 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.23 -40.13 96.92 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.6 tp -67.7 -39.87 84.36 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-O 121.422 0.63 . . . . 0.0 109.918 178.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -59.56 -49.02 79.38 Favored 'General case' 0 C--O 1.225 -0.236 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.581 -178.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -60.78 -40.48 92.72 Favored 'General case' 0 C--O 1.236 0.351 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -178.567 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.3 mt -58.55 -44.76 90.01 Favored 'Isoleucine or valine' 0 C--O 1.235 0.326 0 C-N-CA 120.256 -0.578 . . . . 0.0 110.549 -179.065 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 53.7 t -58.66 -40.15 78.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.794 -179.596 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.28 -36.05 89.85 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 111.773 -0.531 . . . . 0.0 111.773 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 92.6 mt -60.28 -43.23 96.42 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 119.934 -0.706 . . . . 0.0 109.515 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 59.4 tp -56.69 -37.25 70.62 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.905 -179.193 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 4.7 mm -59.52 -42.14 87.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.89 0.376 . . . . 0.0 110.614 -179.495 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 91.0 mt -58.64 -39.99 82.11 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.303 -0.559 . . . . 0.0 110.416 -179.093 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 10.8 mp -60.96 -30.11 70.05 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 120.709 0.29 . . . . 0.0 111.12 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 42.6 t -58.74 -42.34 88.56 Favored 'General case' 0 CA--C 1.518 -0.266 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 179.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 15.8 tpt180 . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.769 178.707 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 2.4 p . . . . . 0 N--CA 1.465 0.318 0 N-CA-C 112.112 0.412 . . . . 0.0 112.112 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 63.2 ttm-85 -75.26 -54.64 6.76 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.273 179.04 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -93.19 -1.32 56.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.589 -0.732 . . . . 0.0 112.141 -179.485 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -62.18 -43.63 98.84 Favored Glycine 0 CA--C 1.528 0.86 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.688 -178.624 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -62.05 -45.44 96.09 Favored Glycine 0 CA--C 1.527 0.813 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.088 -179.015 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.1 mt -60.18 -46.23 90.44 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.533 -0.467 . . . . 0.0 111.281 -178.124 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.3 mt -62.08 -45.51 98.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 CA-C-O 120.815 0.341 . . . . 0.0 111.565 -179.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.1 t80 -61.77 -47.03 87.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.922 0.391 . . . . 0.0 111.253 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.53 -41.63 90.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.495 -178.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.94 -40.36 98.28 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 120.589 -0.815 . . . . 0.0 111.164 -179.609 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 98.5 mt -69.85 -39.36 76.42 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.324 0.583 . . . . 0.0 110.019 178.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.9 -48.0 83.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.192 -179.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -59.64 -46.54 88.69 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.102 -0.499 . . . . 0.0 112.297 -178.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 89.3 mt -58.44 -44.53 89.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 C-N-CA 121.016 -0.273 . . . . 0.0 111.283 -178.23 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.9 t -58.33 -39.57 74.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 120.818 0.342 . . . . 0.0 110.722 -179.485 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.86 -37.3 93.49 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.2 tp -58.8 -48.46 81.21 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.372 -179.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 10.8 mp -57.36 -34.07 68.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.536 -178.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 39.5 mm -60.58 -43.32 94.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.391 0 CA-C-O 121.026 0.441 . . . . 0.0 110.922 -179.276 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 90.9 mt -60.51 -39.86 89.31 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.684 -0.406 . . . . 0.0 110.67 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 9.8 mp -60.59 -30.98 70.16 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.261 -179.404 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 74.2 m -63.08 -39.61 95.24 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.783 0.325 . . . . 0.0 110.463 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.2 tpm_? . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.649 179.694 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 35.5 m . . . . . 0 N--CA 1.466 0.351 0 N-CA-C 112.632 0.605 . . . . 0.0 112.632 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 18.7 tpp180 -73.08 -54.95 7.24 Favored 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 119.689 -0.804 . . . . 0.0 110.244 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -91.86 -2.06 57.03 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 115.543 -0.753 . . . . 0.0 111.95 -179.089 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.45 -42.79 99.85 Favored Glycine 0 CA--C 1.526 0.751 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.576 -178.678 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.04 -45.17 97.14 Favored Glycine 0 CA--C 1.525 0.713 0 C-N-CA 120.652 -0.785 . . . . 0.0 111.879 -178.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.441 ' CD1' ' N ' ' A' ' 29' ' ' LEU . 10.2 mp -60.09 -47.96 83.71 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.755 -178.676 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.1 mt -62.37 -44.62 99.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.722 0.296 . . . . 0.0 111.624 -179.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -61.22 -46.97 88.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.63 0.252 . . . . 0.0 111.526 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.18 -42.6 91.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.547 -178.05 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.84 -40.81 98.77 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.811 -0.915 . . . . 0.0 110.811 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.6 tp -67.22 -41.37 85.83 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.436 0.636 . . . . 0.0 109.713 178.689 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.61 -47.84 84.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.001 -1.0 . . . . 0.0 110.224 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 92.3 t80 -59.39 -47.41 85.54 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.933 -0.576 . . . . 0.0 112.506 -178.242 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 5.4 mm -58.13 -43.34 85.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.545 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.3 t -57.76 -39.72 72.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.558 -179.36 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -61.08 -37.44 93.92 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.577 -0.609 . . . . 0.0 111.577 -179.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.5 tp -58.17 -46.47 85.68 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 94.7 mt -58.31 -33.89 69.99 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.714 -0.676 . . . . 0.0 111.431 -178.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 89.4 mt -60.35 -45.13 96.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 CA-C-O 120.745 0.307 . . . . 0.0 111.416 -179.208 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . 0.447 ' N ' ' CD2' ' A' ' 43' ' ' LEU . 4.0 mm? -59.39 -38.95 81.83 Favored 'General case' 0 C--O 1.234 0.254 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.529 -179.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 59.2 tp -59.42 -35.88 74.84 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.697 -179.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 75.7 m -60.28 -38.34 83.29 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.667 -0.242 . . . . 0.0 110.49 -179.68 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.3 tmt_? . . . . . 0 C--N 1.33 -0.272 0 C-N-CA 119.999 -0.68 . . . . 0.0 110.027 179.75 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.4 t . . . . . 0 N--CA 1.464 0.225 0 N-CA-C 111.75 0.278 . . . . 0.0 111.75 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 62.8 ttm-85 -71.82 -54.04 11.4 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 119.562 -0.855 . . . . 0.0 109.705 178.273 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 33.8 m120 -92.58 -1.54 56.83 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.366 -0.834 . . . . 0.0 112.083 -179.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.42 -42.28 99.73 Favored Glycine 0 CA--C 1.528 0.878 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.289 -178.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.83 -43.91 98.58 Favored Glycine 0 CA--C 1.526 0.76 0 C-N-CA 120.747 -0.74 . . . . 0.0 111.709 -179.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.8 tp -59.5 -47.9 83.74 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.622 -178.464 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.5 mt -61.85 -44.06 98.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 120.94 0.4 . . . . 0.0 111.59 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 91.8 t80 -60.65 -46.3 90.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.221 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.88 -41.73 87.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.46 -178.202 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.61 -40.49 97.98 Favored Glycine 0 CA--C 1.525 0.684 0 C-N-CA 120.434 -0.889 . . . . 0.0 111.043 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.2 tp -67.53 -40.69 85.07 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.396 0.617 . . . . 0.0 109.776 178.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.03 -47.49 85.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.179 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 93.3 t80 -58.97 -46.73 87.38 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -178.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 91.0 mt -58.24 -43.68 86.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.96 -178.423 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.6 t -58.38 -40.73 79.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.77 -179.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.58 -36.6 91.81 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 111.609 -0.597 . . . . 0.0 111.609 -179.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.3 tp -58.79 -45.81 89.0 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 91.5 mt -57.66 -35.81 71.05 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.277 -178.454 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.449 ' O ' ' OG ' ' A' ' 45' ' ' SER . 85.8 mt -59.89 -43.41 92.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.051 0.453 . . . . 0.0 110.501 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 60.3 tp -56.95 -41.06 77.58 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.134 -179.485 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 95.0 mt -60.4 -34.29 73.71 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.658 -178.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.546 ' HG ' ' N ' ' A' ' 46' ' ' ARG . 96.3 p -57.73 -38.52 75.45 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.546 ' N ' ' HG ' ' A' ' 45' ' ' SER . 2.8 tmt_? . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.509 178.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . 0.526 ' C ' ' HE1' ' A' ' 4' ' ' TRP . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 . . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -119.13 151.74 37.77 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.004 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 84.2 mtt85 57.45 60.6 2.81 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.343 179.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' TRP . . . . . 0.526 ' HE1' ' C ' ' A' ' 1' ' ' LEU . 95.5 m95 -85.85 -4.66 59.22 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.527 179.582 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 94.0 t80 -75.31 135.48 40.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.534 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.9 pp -117.19 176.33 5.19 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.483 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 82.83 2.91 90.68 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.557 -1.017 . . . . 0.0 110.557 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.81 31.73 8.05 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.0 t -121.08 88.75 45.5 Favored Pre-proline 0 CA--C 1.533 0.298 0 N-CA-C 110.599 -0.149 . . . . 0.0 110.599 -179.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -58.57 -172.26 0.05 OUTLIER 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.622 2.215 . . . . 0.0 112.072 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -71.48 -18.88 62.27 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.393 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 83.89 2.35 89.66 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.448 -0.661 . . . . 0.0 111.448 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -85.88 -74.17 0.42 Allowed 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.672 -0.411 . . . . 0.0 110.272 179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 58.0 t -127.8 125.99 66.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.062 179.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.6 m-20 -126.32 77.77 72.06 Favored Pre-proline 0 C--N 1.332 -0.181 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.744 -179.131 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.446 ' C ' ' H ' ' A' ' 18' ' ' TYR . 92.0 Cg_endo -83.9 32.14 0.51 Allowed 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 123.011 2.474 . . . . 0.0 112.635 -179.491 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 47.9 m-85 -60.07 -3.2 0.54 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.144 -179.445 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.446 ' H ' ' C ' ' A' ' 16' ' ' PRO . 85.6 m-85 -60.31 -37.98 82.26 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -60.29 -47.9 84.02 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 178.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.429 ' O ' ' OG1' ' A' ' 23' ' ' THR . 11.6 m-20 -76.43 -18.18 58.95 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.741 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.488 ' O ' ' CG1' ' A' ' 24' ' ' VAL . 76.1 t80 -63.71 -38.63 91.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.564 -179.594 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -57.51 -36.95 72.22 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.115 -178.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.506 ' O ' ' N ' ' A' ' 27' ' ' GLY . 78.6 p -64.65 -25.34 67.91 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.677 -0.409 . . . . 0.0 110.552 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.488 ' CG1' ' O ' ' A' ' 21' ' ' TYR . 4.6 p -44.71 -23.19 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.553 -179.125 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 29.5 mmm-85 -71.47 -55.35 8.05 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 119.635 -0.826 . . . . 0.0 109.92 178.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -92.66 -2.85 55.75 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.833 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.53 -42.36 99.75 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 121.116 -0.564 . . . . 0.0 112.572 -178.813 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.72 -44.32 98.06 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.901 -179.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.7 tp -59.78 -48.18 82.71 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.616 -0.433 . . . . 0.0 110.801 -178.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 90.3 mt -61.7 -44.07 98.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.921 0.391 . . . . 0.0 111.427 -179.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -60.26 -46.41 89.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.441 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.74 -42.69 89.38 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.781 -177.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.49 -40.33 97.58 Favored Glycine 0 CA--C 1.526 0.759 0 C-N-CA 120.352 -0.928 . . . . 0.0 110.943 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 93.6 mt -65.8 -36.49 83.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.416 0.627 . . . . 0.0 109.792 178.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -59.81 -48.5 81.43 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.262 -179.488 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 54.1 m-85 -60.23 -41.39 93.02 Favored 'General case' 0 C--O 1.236 0.39 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -178.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 89.9 mt -58.26 -44.5 88.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 C-N-CA 120.188 -0.605 . . . . 0.0 110.284 -179.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.9 t -57.38 -40.32 73.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.839 -179.279 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.36 -37.1 92.6 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.0 tp -58.61 -47.5 84.13 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.284 -0.566 . . . . 0.0 109.711 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 59.3 tp -55.49 -35.46 65.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.151 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 87.0 mt -59.88 -42.22 88.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 120.948 0.404 . . . . 0.0 110.665 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 91.7 mt -58.76 -40.44 83.91 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.241 -0.583 . . . . 0.0 110.425 -179.196 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 11.1 mp -60.73 -30.21 69.84 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.786 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 40.5 t -58.71 -41.44 86.35 Favored 'General case' 0 CA--C 1.518 -0.259 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 20.5 ttp180 -60.51 -36.95 79.61 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.485 -0.486 . . . . 0.0 110.155 179.294 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.427 ' O ' ' O ' ' A' ' 50' ' ' SER . 15.0 ttp180 -56.12 -31.16 63.04 Favored 'General case' 0 N--CA 1.462 0.163 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.403 -178.516 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -59.23 -37.72 78.21 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.002 -0.679 . . . . 0.0 110.146 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 84.5 mtp180 -87.99 -54.41 4.24 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 119.768 -0.773 . . . . 0.0 109.854 178.505 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.427 ' O ' ' O ' ' A' ' 47' ' ' ARG . 67.3 m -71.6 139.41 49.34 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.623 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 175.62 -171.16 44.27 Favored Glycine 0 CA--C 1.523 0.594 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -102.75 13.66 56.35 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -133.1 25.16 4.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.741 0.305 . . . . 0.0 110.549 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.675 ' NZ ' ' HE ' ' A' ' 56' ' ' ARG . 65.3 tttp 42.2 80.1 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.181 -179.573 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -100.41 -3.11 31.68 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.63 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.675 ' HE ' ' NZ ' ' A' ' 54' ' ' LYS . 41.7 ptt180 -70.1 -25.42 63.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.058 -179.7 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 55.3 ttp180 38.17 54.36 1.71 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.247 179.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 72.2 tp60 -135.18 131.46 36.76 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.615 -179.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 20.8 tt -142.56 136.69 27.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.166 179.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 84.2 m-20 -108.3 126.18 52.54 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.658 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -130.98 146.79 52.5 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.451 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -94.03 135.47 35.35 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.52 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.478 ' OE1' ' N ' ' A' ' 63' ' ' GLU . 39.1 mp0 -70.77 149.32 95.17 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.27 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo . . . . . 0 N--CA 1.493 1.468 0 C-N-CA 122.151 1.901 . . . . 0.0 111.964 179.941 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.486 ' CG ' ' H ' ' A' ' 3' ' ' ARG . 34.2 t0 -72.08 -173.41 1.04 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.739 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.486 ' H ' ' CG ' ' A' ' 2' ' ' ASP . 84.2 mtt85 -89.52 -3.05 58.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.357 179.687 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' TRP . . . . . . . . . . . . . 50.1 t-105 -85.4 -25.97 26.71 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.737 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -76.43 141.76 41.27 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.765 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 12.1 tp -116.9 -134.61 0.34 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.026 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 81.94 3.41 90.59 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.65 64.0 3.26 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 68.2 m -128.83 149.55 72.57 Favored Pre-proline 0 CA--C 1.532 0.268 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -69.36 148.63 68.06 Favored 'Trans proline' 0 N--CA 1.496 1.619 0 C-N-CA 121.975 1.784 . . . . 0.0 112.223 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 73.7 mmtt -94.54 -3.25 50.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.354 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 81.07 7.1 88.92 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -101.46 -37.24 8.52 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.955 0.407 . . . . 0.0 110.523 179.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 10.7 p -155.76 161.46 2.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.45 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.2 m-20 -125.66 76.28 70.02 Favored Pre-proline 0 C--N 1.331 -0.234 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.518 -179.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -81.24 -5.49 12.78 Favored 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.958 2.439 . . . . 0.0 112.435 -179.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.5 ' O ' ' N ' ' A' ' 21' ' ' TYR . 91.2 t80 -59.78 -44.06 94.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.635 -179.568 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -59.44 -48.66 80.81 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 120.442 -0.503 . . . . 0.0 110.142 -179.243 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 86.2 m-85 -68.72 -36.66 78.72 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.012 0.434 . . . . 0.0 110.213 179.372 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -81.77 -7.98 59.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.085 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.5 ' N ' ' O ' ' A' ' 17' ' ' PHE . 93.7 t80 -61.85 -46.08 91.0 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.405 -179.349 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -60.01 -38.47 82.75 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.846 0.355 . . . . 0.0 110.549 -179.558 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.52 ' O ' ' N ' ' A' ' 27' ' ' GLY . 98.8 m -61.57 -41.97 98.17 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.998 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -42.05 -24.05 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.287 -0.415 . . . . 0.0 112.107 -178.001 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.401 ' N ' ' O ' ' A' ' 23' ' ' THR . 78.4 ttt180 -73.54 -55.37 6.4 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 119.686 -0.805 . . . . 0.0 110.025 178.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 53.6 p30 -92.45 -1.76 56.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.848 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.52 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.3 -42.98 99.92 Favored Glycine 0 CA--C 1.526 0.76 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.265 -178.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.97 -43.59 98.97 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 120.734 -0.746 . . . . 0.0 111.728 -179.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.494 ' N ' ' CD2' ' A' ' 29' ' ' LEU . 4.0 mm? -59.53 -47.82 84.04 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.628 -0.429 . . . . 0.0 110.835 -178.436 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 90.7 mt -61.71 -44.11 98.22 Favored 'Isoleucine or valine' 0 C--O 1.237 0.422 0 CA-C-O 120.846 0.355 . . . . 0.0 111.414 -179.494 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -60.45 -46.8 88.76 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.335 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.79 -41.84 87.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.66 -178.214 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.38 -40.83 98.09 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 120.38 -0.914 . . . . 0.0 110.921 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 93.3 mt -67.0 -37.95 85.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.276 0.56 . . . . 0.0 109.952 178.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.28 -47.69 84.92 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.08 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 93.4 t80 -59.14 -46.99 86.93 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.958 -0.564 . . . . 0.0 112.318 -178.198 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.1 mt -57.98 -44.35 86.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 C-N-CA 120.726 -0.389 . . . . 0.0 111.013 -178.412 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 55.9 t -57.9 -40.5 76.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.599 -179.276 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.51 -36.4 91.23 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.75 -0.54 . . . . 0.0 111.75 -179.404 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 91.4 mt -60.02 -43.65 95.12 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.073 -0.651 . . . . 0.0 109.711 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.5 mt -58.43 -35.6 72.34 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.142 -178.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 86.6 mt -60.04 -43.04 91.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.067 0.46 . . . . 0.0 110.655 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 90.9 mt -58.91 -39.86 82.78 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 120.443 -0.503 . . . . 0.0 110.276 -179.24 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -60.07 -31.53 70.09 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-O 120.691 0.282 . . . . 0.0 110.912 -179.653 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 69.5 m -59.43 -40.37 86.53 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 59.0 ttt85 -60.72 -36.57 79.17 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 120.478 -0.489 . . . . 0.0 109.957 178.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 15.2 ttp180 -54.97 -29.96 58.07 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.527 -178.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 93.8 t80 -58.16 -47.56 82.99 Favored 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 120.653 -0.419 . . . . 0.0 110.136 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -86.38 -54.84 4.19 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 120.374 -0.53 . . . . 0.0 110.861 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 48.0 t -61.66 -43.79 98.18 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.688 -178.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 100.32 -18.66 55.1 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 -179.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.86 146.55 9.21 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 112.069 -0.413 . . . . 0.0 112.069 178.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 47.9 m-20 69.97 -147.84 0.1 Allowed 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.362 -0.419 . . . . 0.0 110.836 -179.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 82.1 tttt -163.21 161.51 24.96 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.307 -179.46 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -90.17 0.43 57.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.921 0.391 . . . . 0.0 110.555 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 77.9 ttt-85 -68.44 -30.19 69.01 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.445 -179.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 91.4 mtm180 -59.36 -40.65 87.13 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.588 -0.445 . . . . 0.0 110.655 -178.595 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -134.41 108.05 7.93 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.816 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 87.0 mt -124.36 131.67 72.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.873 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -64.73 127.82 33.17 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.443 -0.503 . . . . 0.0 110.231 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 52.7 tp10 -153.18 148.77 27.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.092 -179.535 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -63.58 -39.68 95.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.789 0.328 . . . . 0.0 110.909 179.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -128.98 75.95 79.78 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.881 -179.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo . . . . . 0 C--N 1.307 -1.654 0 C-N-CA 122.844 2.362 . . . . 0.0 112.21 -179.783 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . 0.52 ' N ' ' OD1' ' A' ' 20' ' ' ASP . 83.9 mt . . . . . 0 N--CA 1.492 1.641 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -87.58 103.19 15.32 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.627 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -77.66 152.26 33.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.637 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' TRP . . . . . . . . . . . . . 29.6 m-90 -99.1 15.69 25.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.461 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -108.26 112.9 25.61 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.504 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 98.0 mt -67.79 -40.05 83.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.129 0.49 . . . . 0.0 109.992 179.259 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.78 -8.3 79.82 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 -179.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 118.53 12.94 7.06 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 110.616 -0.993 . . . . 0.0 110.616 -179.29 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 80.7 p -82.65 150.63 63.23 Favored Pre-proline 0 CA--C 1.534 0.341 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -67.96 -84.24 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 121.949 1.766 . . . . 0.0 112.839 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -71.97 -22.68 61.41 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.68 -0.236 . . . . 0.0 111.408 -178.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.56 19.12 71.89 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.119 -0.793 . . . . 0.0 111.119 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -63.83 126.37 27.41 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 27.5 m -140.96 161.97 22.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.096 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.413 ' N ' ' OD1' ' A' ' 15' ' ' ASP . 37.5 p-10 -133.36 63.73 66.43 Favored Pre-proline 0 N--CA 1.463 0.181 0 C-N-CA 120.96 -0.296 . . . . 0.0 110.979 179.738 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -84.12 31.67 0.51 Allowed 'Trans proline' 0 C--N 1.307 -1.62 0 C-N-CA 122.981 2.454 . . . . 0.0 112.242 179.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.417 ' O ' ' N ' ' A' ' 21' ' ' TYR . 80.8 m-85 -61.86 -41.66 98.11 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 120.654 -0.419 . . . . 0.0 110.674 -179.449 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -60.55 -47.52 85.82 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.14 -0.624 . . . . 0.0 110.068 -179.183 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 86.9 t80 -65.92 -45.75 80.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.347 0.594 . . . . 0.0 110.07 178.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' A' ' 1' ' ' LEU . 97.8 m-20 -71.28 -14.28 62.17 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.191 -0.913 . . . . 0.0 111.441 -179.139 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.417 ' N ' ' O ' ' A' ' 17' ' ' PHE . 94.4 t80 -62.69 -45.49 92.55 Favored 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 120.496 -0.482 . . . . 0.0 110.322 -179.755 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -60.08 -39.61 86.68 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.853 -179.207 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.528 ' O ' ' N ' ' A' ' 27' ' ' GLY . 68.3 p -66.09 -31.15 71.85 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 121.0 -0.28 . . . . 0.0 110.855 -179.793 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.417 ' CG1' ' O ' ' A' ' 21' ' ' TYR . 1.1 p -44.13 -24.1 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.822 -178.623 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 61.3 ttp180 -72.84 -54.41 8.86 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.019 179.023 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -92.94 -2.85 55.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.485 -0.78 . . . . 0.0 112.02 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.59 -43.16 99.65 Favored Glycine 0 CA--C 1.526 0.775 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.335 -178.724 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.89 -44.28 98.05 Favored Glycine 0 CA--C 1.526 0.731 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.012 -179.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.4 mt -60.4 -47.44 86.06 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.334 -0.546 . . . . 0.0 110.767 -178.523 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 5.0 mm -62.13 -43.9 98.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.739 0.304 . . . . 0.0 111.185 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.1 t80 -60.77 -46.58 89.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.255 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.66 -42.5 88.58 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.586 -178.213 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.72 -40.47 98.11 Favored Glycine 0 CA--C 1.524 0.642 0 C-N-CA 120.271 -0.966 . . . . 0.0 110.688 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 96.7 mt -67.23 -38.02 84.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.288 0.566 . . . . 0.0 109.811 178.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.6 -47.71 85.02 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.013 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 92.3 t80 -59.23 -47.2 86.22 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 115.903 -0.589 . . . . 0.0 112.146 -178.404 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 89.9 mt -57.8 -43.11 83.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 C-N-CA 120.868 -0.333 . . . . 0.0 110.437 -178.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 56.3 t -57.04 -40.06 70.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.451 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.83 -36.89 92.77 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 111.481 -0.648 . . . . 0.0 111.481 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 62.2 tp -58.25 -47.27 84.09 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.307 -0.557 . . . . 0.0 109.503 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 92.8 mt -57.49 -33.61 68.19 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.37 -178.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 41.2 mm -60.34 -42.86 92.28 Favored 'Isoleucine or valine' 0 C--O 1.236 0.387 0 CA-C-O 120.874 0.369 . . . . 0.0 110.237 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 92.1 mt -59.46 -39.39 83.47 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.115 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 59.2 tp -59.05 -35.28 73.06 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.53 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 46.7 t -59.15 -40.61 86.07 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 110.135 -0.321 . . . . 0.0 110.135 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.02 -39.17 81.11 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 120.354 -0.538 . . . . 0.0 110.186 179.61 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 80.3 ttt180 -58.8 -32.23 69.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.027 -179.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 93.9 t80 -59.17 -48.69 80.67 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 120.369 -0.532 . . . . 0.0 109.922 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.41 ' O ' ' CB ' ' A' ' 50' ' ' SER . 0.9 OUTLIER -65.19 -55.25 19.61 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.058 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.41 ' CB ' ' O ' ' A' ' 49' ' ' ARG . 0.7 OUTLIER 76.27 175.86 0.21 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.002 179.427 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 112.74 126.03 4.52 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.44 1.87 74.16 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -179.155 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 34.1 m120 -101.22 10.61 40.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.931 0.396 . . . . 0.0 110.04 179.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.435 ' O ' ' O ' ' A' ' 57' ' ' ARG . 73.8 mmtt -96.73 -0.67 47.88 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.335 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -62.26 -43.65 98.34 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.896 0.379 . . . . 0.0 110.269 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -73.6 -31.76 63.74 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.867 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.435 ' O ' ' O ' ' A' ' 54' ' ' LYS . 43.7 ttm180 -138.66 136.56 36.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.102 -179.532 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -66.72 152.6 45.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.241 179.662 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 21.4 tt -61.7 147.52 10.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.676 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -104.14 130.83 51.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.434 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 60.9 mp0 -63.22 -40.22 96.84 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.237 179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 60.2 p30 -158.66 170.46 22.12 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.041 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.6 tp10 -134.67 75.87 61.8 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.448 179.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo . . . . . 0 C--N 1.307 -1.613 0 C-N-CA 122.724 2.283 . . . . 0.0 112.184 -179.979 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 61.0 tp . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.52 ' O ' ' CD1' ' A' ' 4' ' ' TRP . 37.4 t70 -86.85 84.02 7.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.632 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 40.47 44.35 1.69 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.867 179.174 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' TRP . . . . . 0.52 ' CD1' ' O ' ' A' ' 2' ' ' ASP . 93.5 m95 -104.84 10.45 34.44 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.482 -0.327 . . . . 0.0 110.578 179.57 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 50.5 p90 -145.4 151.01 37.57 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.983 179.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 60.1 tp -65.05 -44.23 89.69 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-O 121.083 0.468 . . . . 0.0 110.129 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 71.43 29.32 68.29 Favored Glycine 0 CA--C 1.524 0.594 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.804 179.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -96.69 118.86 6.15 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 110.389 -1.084 . . . . 0.0 110.389 179.434 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 92.9 p -83.22 151.1 62.37 Favored Pre-proline 0 CA--C 1.535 0.382 0 C-N-CA 121.328 -0.149 . . . . 0.0 110.884 -178.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -63.96 -153.36 0.02 OUTLIER 'Trans proline' 0 N--CA 1.497 1.69 0 C-N-CA 122.282 1.988 . . . . 0.0 111.654 179.06 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -71.37 -22.15 61.93 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.83 0.348 . . . . 0.0 110.152 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.64 2.45 90.64 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.718 -0.553 . . . . 0.0 111.718 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.437 ' OD1' ' O ' ' A' ' 13' ' ' ASP . 52.6 t0 -117.42 19.54 13.98 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 120.904 0.383 . . . . 0.0 110.271 179.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 35.3 m -143.16 149.01 18.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.241 179.043 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -129.59 67.02 78.48 Favored Pre-proline 0 C--N 1.331 -0.202 0 CA-C-N 116.614 -0.266 . . . . 0.0 110.517 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -72.16 -14.57 28.77 Favored 'Trans proline' 0 N--CA 1.493 1.461 0 C-N-CA 122.686 2.257 . . . . 0.0 112.644 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.494 ' O ' ' N ' ' A' ' 21' ' ' TYR . 82.7 m-85 -59.94 -40.58 89.43 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.103 -179.042 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 44.7 m-85 -60.37 -42.11 95.14 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.571 -179.489 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -67.47 -41.03 85.27 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 178.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.43 ' O ' ' OD1' ' A' ' 20' ' ' ASP . 57.9 t0 -72.73 -25.83 61.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.457 179.123 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.494 ' N ' ' O ' ' A' ' 17' ' ' PHE . 91.2 t80 -62.04 -43.48 98.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.093 -178.816 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -58.19 -39.62 79.42 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.82 -178.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.525 ' O ' ' N ' ' A' ' 27' ' ' GLY . 66.6 p -66.11 -26.93 67.69 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.718 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.487 ' CG1' ' O ' ' A' ' 21' ' ' TYR . 2.1 p -44.52 -23.51 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.85 -178.5 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 59.0 ttt85 -72.51 -54.83 8.13 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 119.884 -0.726 . . . . 0.0 110.06 179.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -93.09 -2.65 55.31 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.873 -179.785 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.46 -43.57 99.14 Favored Glycine 0 CA--C 1.527 0.829 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.299 -178.667 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -63.1 -43.47 98.69 Favored Glycine 0 CA--C 1.527 0.84 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.163 -179.186 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 89.5 mt -60.37 -47.12 87.42 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.447 -0.501 . . . . 0.0 111.386 -177.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 40.1 pt -69.34 -37.56 75.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 120.487 -0.485 . . . . 0.0 111.382 -179.257 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.3 t80 -61.94 -47.64 83.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.961 0.41 . . . . 0.0 110.889 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.74 -42.14 92.5 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.76 -178.468 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.17 -40.2 96.92 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.731 -0.948 . . . . 0.0 110.731 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.5 tp -67.28 -39.5 86.04 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.423 0.63 . . . . 0.0 109.61 178.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -59.5 -48.79 80.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.435 -179.157 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -60.77 -40.62 93.2 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 111.962 0.356 . . . . 0.0 111.962 -178.432 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.4 mt -58.92 -44.73 91.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 C-N-CA 120.404 -0.518 . . . . 0.0 110.53 -179.025 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 56.3 t -57.88 -39.73 72.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.731 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.83 -37.23 93.33 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.605 -0.598 . . . . 0.0 111.605 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.0 tp -58.89 -47.38 85.17 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.689 -0.405 . . . . 0.0 110.118 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.5 mt -58.39 -34.87 71.21 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.397 -178.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 86.8 mt -60.21 -43.52 93.43 Favored 'Isoleucine or valine' 0 C--O 1.238 0.489 0 CA-C-O 120.797 0.332 . . . . 0.0 110.963 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 92.1 mt -59.66 -39.1 83.3 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.924 -0.31 . . . . 0.0 110.483 -179.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 59.0 tp -59.92 -35.69 75.42 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.88 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 75.5 m -59.58 -39.22 83.4 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.347 -179.619 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.526 ' NH1' ' OG ' ' A' ' 50' ' ' SER . 0.3 OUTLIER -61.88 -38.14 87.2 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.23 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.665 HH12 ' N ' ' A' ' 52' ' ' GLY . 0.0 OUTLIER -57.29 -27.58 62.27 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.389 -179.776 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 93.7 t80 -59.85 -48.05 83.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.047 0.451 . . . . 0.0 110.173 179.796 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -61.76 -52.43 64.25 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 119.865 -0.734 . . . . 0.0 109.25 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.526 ' OG ' ' NH1' ' A' ' 46' ' ' ARG . 74.0 m -70.48 140.54 51.93 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.923 -179.847 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -64.0 -43.16 97.78 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 179.183 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.665 ' N ' HH12 ' A' ' 47' ' ' ARG . . . 73.19 54.36 7.01 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 -179.486 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 54.2 p30 -97.82 17.73 17.39 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.68 0.276 . . . . 0.0 111.005 -179.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 25.5 mmtp -60.81 -39.87 90.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.454 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -61.37 -42.0 97.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.111 0.481 . . . . 0.0 109.712 179.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -68.03 -36.15 79.44 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.847 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 93.9 mtm-85 57.5 36.72 27.26 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.611 -179.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 64.4 tt0 -135.4 131.99 36.97 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.227 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . 0.422 ' O ' ' OD1' ' A' ' 60' ' ' ASN . 45.5 pt -130.17 148.24 33.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.857 179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' A' ' 59' ' ' ILE . 83.7 m-20 -146.85 143.44 28.58 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.962 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 49.76 42.74 24.14 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.303 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 60.1 p30 -155.68 170.86 21.05 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.802 179.64 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -142.33 74.68 20.28 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.663 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_exo . . . . . 0 C--N 1.306 -1.664 0 C-N-CA 122.704 2.269 . . . . 0.0 112.122 -179.996 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 81.0 mt . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.425 ' OD1' ' O ' ' A' ' 2' ' ' ASP . 53.6 p-10 -126.05 82.46 2.07 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.565 179.811 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 90.4 mtm180 -103.68 -2.24 26.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.134 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' TRP . . . . . 0.522 ' CE3' ' O ' ' A' ' 4' ' ' TRP . 77.0 t90 -120.64 2.73 10.67 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.489 -179.749 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.416 ' O ' ' C ' ' A' ' 6' ' ' LEU . 92.1 m-85 -123.42 140.29 53.16 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.467 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.416 ' C ' ' O ' ' A' ' 5' ' ' TYR . 90.3 mt -34.27 143.55 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.924 -179.124 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 93.18 -11.79 71.13 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.164 -1.174 . . . . 0.0 110.164 -179.005 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -83.85 174.55 51.45 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 179.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 68.9 m -84.27 148.86 53.99 Favored Pre-proline 0 CA--C 1.532 0.262 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -68.62 -85.02 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.429 0 C-N-CA 121.886 1.724 . . . . 0.0 112.113 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -93.97 -11.72 30.26 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.735 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.16 16.49 80.66 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 111.284 -0.726 . . . . 0.0 111.284 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.429 ' OD1' ' O ' ' A' ' 13' ' ' ASP . 67.6 t0 -160.24 51.5 0.31 Allowed 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.832 -0.347 . . . . 0.0 110.858 179.729 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 26.8 m -146.99 153.39 12.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.496 179.001 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.412 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 37.5 p-10 -132.89 65.57 74.42 Favored Pre-proline 0 C--N 1.331 -0.222 0 CA-C-O 120.772 0.32 . . . . 0.0 110.569 179.734 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -80.12 6.0 5.61 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 C-N-CA 123.229 2.619 . . . . 0.0 112.701 -179.654 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 82.3 m-85 -60.98 -42.45 98.37 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.4 -0.52 . . . . 0.0 111.339 -178.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 31.0 p90 -69.47 -27.38 65.17 Favored 'General case' 0 C--N 1.331 -0.206 0 C-N-CA 120.618 -0.433 . . . . 0.0 111.023 -179.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 93.8 t80 -61.01 -48.76 80.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.108 0.48 . . . . 0.0 109.869 179.501 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 -67.87 -28.82 67.86 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.755 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.474 ' O ' ' CG1' ' A' ' 24' ' ' VAL . 89.8 t80 -62.61 -44.29 96.66 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.694 -179.537 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.406 ' O ' ' CG ' ' A' ' 25' ' ' ARG . 98.4 mt-10 -58.33 -38.81 77.89 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -179.091 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.494 ' O ' ' N ' ' A' ' 27' ' ' GLY . 97.3 m -63.6 -37.03 85.79 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.866 0.365 . . . . 0.0 111.13 179.696 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.474 ' CG1' ' O ' ' A' ' 21' ' ' TYR . 2.7 p -38.27 -23.73 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.51 0 N-CA-C 113.471 0.915 . . . . 0.0 113.471 -176.714 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.451 ' N ' ' O ' ' A' ' 23' ' ' THR . 4.1 ptm180 -80.04 -54.26 5.95 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 119.576 -0.85 . . . . 0.0 110.712 178.781 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . 0.445 ' OD1' ' NE ' ' A' ' 25' ' ' ARG . 34.3 m120 -91.44 -3.09 57.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.1 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -60.93 -42.0 99.53 Favored Glycine 0 CA--C 1.525 0.704 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.872 -179.243 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.28 -42.15 99.7 Favored Glycine 0 CA--C 1.525 0.668 0 C-N-CA 120.85 -0.69 . . . . 0.0 111.405 -179.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.4 mt -59.69 -46.81 87.93 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.367 -178.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 90.9 mt -60.82 -43.67 95.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.787 0.327 . . . . 0.0 110.917 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.0 t80 -60.29 -46.85 88.42 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.277 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.14 -42.6 86.21 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.875 -0.33 . . . . 0.0 111.417 -177.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.23 -40.08 96.84 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 60.3 tp -64.89 -39.85 94.19 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.214 0.53 . . . . 0.0 109.877 178.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.94 -46.0 92.47 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.281 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -59.84 -48.62 80.96 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.354 -178.25 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.404 HD12 HG22 ' A' ' 37' ' ' ILE . 92.1 mt -59.19 -48.75 85.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 N-CA-C 112.185 0.439 . . . . 0.0 112.185 -177.562 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 29.3 m -56.67 -35.45 45.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.485 -179.002 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -61.8 -38.51 96.08 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 111.815 -0.514 . . . . 0.0 111.815 -179.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.4 tp -59.0 -47.11 86.37 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.319 -0.552 . . . . 0.0 109.696 -179.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.9 mt -57.26 -34.13 68.32 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.278 -178.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 88.5 mt -60.74 -42.98 94.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.885 0.374 . . . . 0.0 110.822 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 91.6 mt -59.0 -39.49 81.99 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.141 -179.258 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 94.7 mt -60.71 -33.16 72.47 Favored 'General case' 0 C--O 1.238 0.455 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.975 -179.57 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 70.3 m -58.44 -40.51 82.76 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.496 ' HE ' ' N ' ' A' ' 51' ' ' GLY . 3.7 tmt_? -61.06 -37.43 82.62 Favored 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 120.677 -0.409 . . . . 0.0 110.522 178.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.26 -29.35 57.93 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.868 -178.509 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 34.7 m-85 -59.28 -39.53 83.24 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 119.693 -0.803 . . . . 0.0 109.926 179.449 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.487 ' O ' ' CB ' ' A' ' 50' ' ' SER . 71.7 mtp85 -93.11 -52.26 4.65 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 178.1 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.487 ' CB ' ' O ' ' A' ' 49' ' ' ARG . 1.0 OUTLIER 85.72 40.55 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.384 -179.539 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.496 ' N ' ' HE ' ' A' ' 46' ' ' ARG . . . 82.43 0.21 89.66 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 55.92 -129.01 46.7 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 179.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -75.84 149.93 37.75 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 110.151 -0.314 . . . . 0.0 110.151 179.467 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -140.35 133.98 30.25 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.62 179.35 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 26.1 pttm -113.52 -34.26 5.62 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.324 179.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.405 ' O ' ' C ' ' A' ' 57' ' ' ARG . 83.6 mtp180 -68.48 -37.87 80.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.521 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.405 ' C ' ' O ' ' A' ' 56' ' ' ARG . 81.1 mtp180 35.02 -130.35 0.08 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.329 179.799 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 24.0 mp0 -136.36 129.58 31.52 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.57 179.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 44.9 pt -130.92 -32.04 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.926 0.393 . . . . 0.0 110.66 179.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.614 HD22 ' CG ' ' A' ' 63' ' ' GLU . 47.2 p30 -168.19 159.55 10.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.329 179.676 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 53.0 tp10 -63.21 -45.2 92.77 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.398 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 27.4 t0 -166.79 166.65 15.6 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.731 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.614 ' CG ' HD22 ' A' ' 60' ' ' ASN . 97.0 mt-10 -129.99 70.85 82.25 Favored Pre-proline 0 C--N 1.332 -0.164 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.627 179.773 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo . . . . . 0 C--N 1.308 -1.603 0 C-N-CA 122.665 2.243 . . . . 0.0 112.1 -179.88 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 80.7 mt . . . . . 0 N--CA 1.489 1.477 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -118.06 158.12 25.59 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.135 -0.484 . . . . 0.0 109.968 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -128.88 9.3 5.81 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.873 0.368 . . . . 0.0 110.073 179.278 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' TRP . . . . . . . . . . . . . 23.1 m-90 -105.74 13.55 29.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.649 -179.615 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.533 ' CD2' ' O ' ' A' ' 6' ' ' LEU . 38.9 p90 -91.32 164.31 13.9 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.967 0.413 . . . . 0.0 110.924 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.533 ' O ' ' CD2' ' A' ' 5' ' ' TYR . 90.5 mt -47.5 159.88 0.13 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.835 -178.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 84.69 2.45 88.71 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -88.07 131.86 10.88 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 81.0 p -105.81 150.43 39.16 Favored Pre-proline 0 CA--C 1.535 0.377 0 N-CA-C 110.504 -0.184 . . . . 0.0 110.504 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -71.39 84.35 0.95 Allowed 'Trans proline' 0 N--CA 1.494 1.552 0 C-N-CA 122.223 1.948 . . . . 0.0 112.135 179.67 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -73.86 -9.5 58.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.765 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.8 8.41 58.18 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.771 -0.931 . . . . 0.0 110.771 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -64.74 -66.02 0.6 Allowed 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.044 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.8 m -143.81 148.94 18.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.766 178.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.406 ' N ' ' OD1' ' A' ' 15' ' ' ASP . 40.9 p-10 -129.93 64.67 73.0 Favored Pre-proline 0 C--N 1.332 -0.164 0 CA-C-O 120.652 0.263 . . . . 0.0 110.636 -179.631 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -74.25 -6.88 19.06 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.847 2.364 . . . . 0.0 112.427 -179.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.448 ' O ' ' N ' ' A' ' 21' ' ' TYR . 81.6 m-85 -60.04 -40.46 89.46 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.09 -179.204 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -60.13 -45.65 92.3 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.165 -0.614 . . . . 0.0 109.939 -179.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -61.92 -46.62 88.54 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.275 0.559 . . . . 0.0 109.952 178.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.415 ' O ' ' OG1' ' A' ' 23' ' ' THR . 97.8 m-20 -75.75 -11.24 59.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.356 -0.838 . . . . 0.0 111.45 -179.697 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.479 ' O ' ' CG1' ' A' ' 24' ' ' VAL . 88.2 t80 -63.26 -44.04 96.28 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.43 -179.712 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 mm-40 -58.82 -38.5 78.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.803 -178.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.524 ' O ' ' N ' ' A' ' 27' ' ' GLY . 75.6 p -65.45 -26.64 68.04 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.781 -0.368 . . . . 0.0 110.577 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.479 ' CG1' ' O ' ' A' ' 21' ' ' TYR . 3.0 p -43.83 -23.36 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.717 -178.617 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 90.7 mtm180 -73.13 -55.35 6.6 Favored 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 119.716 -0.794 . . . . 0.0 110.109 178.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -93.42 -1.43 55.8 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.439 -0.8 . . . . 0.0 112.081 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.06 -43.32 99.58 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.529 -178.518 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.88 -43.9 98.58 Favored Glycine 0 CA--C 1.526 0.773 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.829 -179.134 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.6 tp -59.52 -48.38 81.89 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.642 -178.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 92.4 mt -61.66 -44.41 98.64 Favored 'Isoleucine or valine' 0 C--O 1.236 0.348 0 CA-C-O 120.894 0.378 . . . . 0.0 111.526 -179.443 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.6 t80 -60.72 -46.58 89.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.152 -179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.81 -41.79 87.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.482 -178.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.59 -41.02 98.66 Favored Glycine 0 CA--C 1.525 0.691 0 C-N-CA 120.427 -0.892 . . . . 0.0 111.002 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 95.0 mt -67.16 -37.91 84.57 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.18 0.514 . . . . 0.0 110.114 178.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.51 -47.65 85.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.162 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 93.1 t80 -59.4 -46.81 87.63 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 116.083 -0.508 . . . . 0.0 112.227 -178.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.7 mm -57.57 -44.35 84.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.705 -178.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.1 t -57.2 -39.79 69.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.701 -179.318 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.67 -36.91 92.6 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 -179.794 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.4 tp -58.9 -48.23 82.16 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.007 -0.677 . . . . 0.0 109.891 -179.573 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 10.9 mp -56.19 -33.1 64.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.437 -178.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 4.7 mm -60.77 -43.81 96.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.455 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -57.12 -40.78 77.75 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.282 -0.567 . . . . 0.0 110.243 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 10.3 mp -60.96 -30.27 70.15 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.057 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 39.9 t -59.36 -41.44 89.25 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 -179.468 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.5 ttt-85 -62.34 -39.86 94.48 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.33 -0.548 . . . . 0.0 110.488 179.233 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.442 ' O ' ' OG ' ' A' ' 50' ' ' SER . 0.0 OUTLIER -56.8 -30.98 64.22 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.389 -178.761 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -64.24 -40.48 96.1 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.162 -0.615 . . . . 0.0 111.263 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -62.59 -53.36 55.81 Favored 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 119.328 -0.949 . . . . 0.0 108.976 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.53 ' O ' ' NH1' ' A' ' 57' ' ' ARG . 61.6 m 53.56 27.0 6.13 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.834 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 41.99 87.29 0.01 OUTLIER Glycine 0 CA--C 1.527 0.821 0 N-CA-C 110.931 -0.867 . . . . 0.0 110.931 179.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -174.84 171.39 44.55 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 179.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -63.75 -42.06 97.91 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.859 0.362 . . . . 0.0 110.62 179.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -129.11 150.4 50.52 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.424 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 62.3 mttp -59.88 -43.1 94.93 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.606 -178.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.519 ' O ' ' CB ' ' A' ' 57' ' ' ARG . 83.8 mtp180 -70.06 -20.06 63.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.631 -0.259 . . . . 0.0 110.88 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.53 ' NH1' ' O ' ' A' ' 50' ' ' SER . 12.1 tpp180 90.29 -138.76 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.369 0 O-C-N 123.699 0.624 . . . . 0.0 110.901 -179.596 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.416 ' O ' ' OD2' ' A' ' 62' ' ' ASP . 78.7 mt-30 -136.88 137.14 39.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.17 179.022 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.6 pt -62.04 -24.82 35.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.519 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 33.5 m120 -69.88 157.32 37.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.513 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 77.4 mm-40 37.35 -122.18 0.2 Allowed 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.181 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.416 ' OD2' ' O ' ' A' ' 58' ' ' GLN . 65.5 m-20 42.64 -128.97 0.68 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.453 -179.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -70.51 149.16 95.56 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.276 179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo . . . . . 0 N--CA 1.492 1.419 0 C-N-CA 122.134 1.89 . . . . 0.0 112.071 179.877 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . 0.529 ' O ' ' NE1' ' A' ' 4' ' ' TRP . 60.7 tp . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 53.1 p-10 -81.46 -176.92 6.28 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.835 -179.779 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 66.8 ttp85 60.83 65.27 1.04 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.677 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' TRP . . . . . 0.529 ' NE1' ' O ' ' A' ' 1' ' ' LEU . 98.3 m95 -88.03 -16.32 33.98 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.1 179.578 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.535 ' CD2' ' O ' ' A' ' 6' ' ' LEU . 81.0 t80 -143.64 140.61 30.19 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.197 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.535 ' O ' ' CD2' ' A' ' 5' ' ' TYR . 90.4 mt -69.26 154.99 41.15 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 -179.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 85.19 34.18 15.33 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 -178.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -85.11 116.32 4.29 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 179.604 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 69.7 m -128.58 152.17 78.07 Favored Pre-proline 0 CA--C 1.533 0.302 0 C-N-CA 121.362 -0.135 . . . . 0.0 110.944 -179.17 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_exo -51.33 143.34 34.51 Favored 'Trans proline' 0 N--CA 1.497 1.726 0 C-N-CA 121.963 1.776 . . . . 0.0 112.057 179.388 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -90.25 0.82 57.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.308 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 81.37 1.28 90.0 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 56.3 t0 44.0 67.72 0.63 Allowed 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 11.8 p -149.72 147.28 16.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.054 -179.64 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.9 m-20 -118.03 84.72 22.1 Favored Pre-proline 0 CA--C 1.533 0.292 0 CA-C-N 115.923 -0.58 . . . . 0.0 109.815 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -83.27 34.88 0.55 Allowed 'Trans proline' 0 N--CA 1.49 1.312 0 C-N-CA 122.889 2.392 . . . . 0.0 113.412 -178.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 -59.65 -16.0 23.19 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.711 -0.395 . . . . 0.0 110.224 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 92.5 t80 -59.22 -43.8 92.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.792 179.504 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 90.6 t80 -57.72 -37.72 74.03 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.029 0.442 . . . . 0.0 109.935 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -70.72 -7.91 48.26 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.535 179.561 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 78.6 t80 -61.47 -43.28 99.15 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.51 -178.762 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 53.1 tp10 -58.91 -46.5 87.76 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.231 -0.588 . . . . 0.0 109.515 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.518 ' O ' ' N ' ' A' ' 27' ' ' GLY . 97.8 m -64.52 -44.46 90.8 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 121.019 0.437 . . . . 0.0 110.473 179.198 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.4 t -44.86 -24.8 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.919 -178.212 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -72.95 -54.23 9.2 Favored 'General case' 0 C--N 1.323 -0.584 0 C-N-CA 119.472 -0.891 . . . . 0.0 109.855 178.482 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -91.99 -1.14 57.41 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.336 -179.094 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.41 -41.86 99.63 Favored Glycine 0 CA--C 1.528 0.872 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.353 -178.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.71 -44.83 97.38 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.926 -179.161 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.7 tp -59.77 -47.92 83.75 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.865 -178.358 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.1 mt -62.11 -43.6 97.96 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 CA-C-O 120.904 0.383 . . . . 0.0 111.458 -179.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 91.6 t80 -60.62 -46.14 91.41 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.272 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.77 -42.36 88.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.341 -0.391 . . . . 0.0 111.622 -178.209 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.23 -40.13 96.92 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.6 tp -67.7 -39.87 84.36 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-O 121.422 0.63 . . . . 0.0 109.918 178.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -59.56 -49.02 79.38 Favored 'General case' 0 C--O 1.225 -0.236 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.581 -178.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -60.78 -40.48 92.72 Favored 'General case' 0 C--O 1.236 0.351 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -178.567 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.3 mt -58.55 -44.76 90.01 Favored 'Isoleucine or valine' 0 C--O 1.235 0.326 0 C-N-CA 120.256 -0.578 . . . . 0.0 110.549 -179.065 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 53.7 t -58.66 -40.15 78.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.794 -179.596 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.28 -36.05 89.85 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 111.773 -0.531 . . . . 0.0 111.773 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 92.6 mt -60.28 -43.23 96.42 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 119.934 -0.706 . . . . 0.0 109.515 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 59.4 tp -56.69 -37.25 70.62 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.905 -179.193 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 4.7 mm -59.52 -42.14 87.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.89 0.376 . . . . 0.0 110.614 -179.495 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 91.0 mt -58.64 -39.99 82.11 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.303 -0.559 . . . . 0.0 110.416 -179.093 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 10.8 mp -60.96 -30.11 70.05 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 120.709 0.29 . . . . 0.0 111.12 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 42.6 t -58.74 -42.34 88.56 Favored 'General case' 0 CA--C 1.518 -0.266 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 179.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 15.8 tpt180 -61.0 -36.91 80.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.769 178.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.445 ' O ' ' O ' ' A' ' 50' ' ' SER . 12.5 ttp180 -55.25 -26.9 42.72 Favored 'General case' 0 C--O 1.231 0.127 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.514 -178.425 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -60.18 -37.9 81.6 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 119.905 -0.718 . . . . 0.0 110.358 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 84.9 mtp180 -89.07 -54.96 3.88 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 119.919 -0.712 . . . . 0.0 110.282 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.445 ' O ' ' O ' ' A' ' 47' ' ' ARG . 90.3 p -95.4 159.25 15.09 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.782 -179.759 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 70.07 22.56 77.28 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.431 ' O ' ' OD1' ' A' ' 53' ' ' ASN . . . -59.18 132.78 52.4 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.431 ' OD1' ' O ' ' A' ' 52' ' ' GLY . 82.9 m-20 -147.34 137.23 23.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.648 0.261 . . . . 0.0 110.66 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 56.7 mtmt -141.23 58.67 1.53 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.338 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -111.87 5.7 19.11 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.604 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 5.4 tpp85 -118.75 8.38 11.82 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.847 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 96.3 mtm-85 -133.78 148.53 51.37 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.232 179.68 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 98.5 mt-30 -134.42 153.29 51.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.661 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 47.5 pt -122.84 156.54 28.29 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.813 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 32.5 m120 -115.53 153.47 31.11 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.932 -179.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -67.61 154.07 42.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.462 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -61.68 144.64 54.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.998 0.427 . . . . 0.0 110.697 -179.83 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -70.67 149.38 95.33 Favored Pre-proline 0 CA--C 1.532 0.272 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.259 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo . . . . . 0 N--CA 1.494 1.541 0 C-N-CA 122.077 1.851 . . . . 0.0 112.021 179.862 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . 0.429 ' H1 ' ' H ' ' A' ' 7' ' ' GLY . 1.9 mp . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 58.0 p30 -127.02 177.73 6.45 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.666 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 16.3 ttm180 39.91 -146.67 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.363 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' TRP . . . . . . . . . . . . . 86.7 t90 -85.97 -26.17 25.63 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.794 0.33 . . . . 0.0 110.831 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -79.57 143.9 34.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.623 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 89.9 mt -127.63 135.92 50.92 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.025 179.289 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.429 ' H ' ' H1 ' ' A' ' 1' ' ' LEU . . . 78.91 5.1 88.83 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.214 -0.754 . . . . 0.0 111.214 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -68.54 149.26 49.51 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 111.575 -0.61 . . . . 0.0 111.575 -179.358 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 46.4 t -86.23 133.26 41.06 Favored Pre-proline 0 CA--C 1.538 0.505 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_exo -46.91 133.37 17.8 Favored 'Trans proline' 0 N--CA 1.495 1.576 0 C-N-CA 121.133 1.222 . . . . 0.0 111.501 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -94.39 2.37 55.79 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.07 -0.513 . . . . 0.0 111.319 -179.175 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.04 20.76 75.31 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 -179.467 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 -53.4 -67.44 0.25 Allowed 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 35.6 m -142.59 145.97 22.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.998 -0.547 . . . . 0.0 109.806 178.488 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -129.67 68.2 80.2 Favored Pre-proline 0 C--N 1.331 -0.197 0 CA-C-O 120.755 0.312 . . . . 0.0 110.471 -179.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -74.56 -6.38 18.19 Favored 'Trans proline' 0 N--CA 1.493 1.455 0 C-N-CA 122.717 2.278 . . . . 0.0 112.373 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.451 ' O ' ' N ' ' A' ' 21' ' ' TYR . 81.9 m-85 -61.27 -40.23 93.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.148 -179.278 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 82.9 m-85 -59.83 -45.49 92.2 Favored 'General case' 0 C--N 1.331 -0.234 0 C-N-CA 120.315 -0.554 . . . . 0.0 110.277 -178.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 88.7 m-85 -69.5 -37.71 77.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.213 0.53 . . . . 0.0 109.864 178.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.407 ' O ' ' OG1' ' A' ' 23' ' ' THR . 40.8 t0 -75.43 -15.67 60.42 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.43 -0.804 . . . . 0.0 110.969 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.493 ' O ' ' CG1' ' A' ' 24' ' ' VAL . 90.5 t80 -62.5 -44.23 96.89 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.948 -179.358 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 79.2 mm-40 -57.58 -38.86 75.56 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 120.721 -0.391 . . . . 0.0 110.67 -178.469 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.533 ' O ' ' N ' ' A' ' 27' ' ' GLY . 72.3 p -67.83 -27.52 66.79 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.651 179.686 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.493 ' CG1' ' O ' ' A' ' 21' ' ' TYR . 2.4 p -42.5 -24.05 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.149 -0.478 . . . . 0.0 112.112 -177.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 63.2 ttm-85 -75.26 -54.64 6.76 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.273 179.04 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -93.19 -1.32 56.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.589 -0.732 . . . . 0.0 112.141 -179.485 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -62.18 -43.63 98.84 Favored Glycine 0 CA--C 1.528 0.86 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.688 -178.624 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -62.05 -45.44 96.09 Favored Glycine 0 CA--C 1.527 0.813 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.088 -179.015 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.1 mt -60.18 -46.23 90.44 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.533 -0.467 . . . . 0.0 111.281 -178.124 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.3 mt -62.08 -45.51 98.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 CA-C-O 120.815 0.341 . . . . 0.0 111.565 -179.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.1 t80 -61.77 -47.03 87.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.922 0.391 . . . . 0.0 111.253 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.53 -41.63 90.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.495 -178.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.94 -40.36 98.28 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 120.589 -0.815 . . . . 0.0 111.164 -179.609 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 98.5 mt -69.85 -39.36 76.42 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.324 0.583 . . . . 0.0 110.019 178.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.9 -48.0 83.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.192 -179.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -59.64 -46.54 88.69 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.102 -0.499 . . . . 0.0 112.297 -178.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 89.3 mt -58.44 -44.53 89.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 C-N-CA 121.016 -0.273 . . . . 0.0 111.283 -178.23 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.9 t -58.33 -39.57 74.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 120.818 0.342 . . . . 0.0 110.722 -179.485 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.86 -37.3 93.49 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.2 tp -58.8 -48.46 81.21 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.372 -179.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 10.8 mp -57.36 -34.07 68.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.536 -178.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 39.5 mm -60.58 -43.32 94.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.391 0 CA-C-O 121.026 0.441 . . . . 0.0 110.922 -179.276 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 90.9 mt -60.51 -39.86 89.31 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.684 -0.406 . . . . 0.0 110.67 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 9.8 mp -60.59 -30.98 70.16 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.261 -179.404 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 74.2 m -63.08 -39.61 95.24 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.783 0.325 . . . . 0.0 110.463 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.2 tpm_? -61.8 -39.97 93.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.649 179.694 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.699 HH22 ' H ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -65.27 -24.15 67.23 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.811 -178.974 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 89.6 t80 -60.51 -49.86 75.88 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.053 179.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 42.3 mmm-85 -62.0 -51.97 65.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.609 -179.19 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.527 ' OG ' ' NH2' ' A' ' 47' ' ' ARG . 88.2 p -68.72 -21.95 64.37 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.546 -0.297 . . . . 0.0 111.278 -179.757 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.475 ' N ' ' O ' ' A' ' 47' ' ' ARG . . . 60.31 -130.46 48.83 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.498 ' O ' ' N ' ' A' ' 54' ' ' LYS . . . -44.16 145.23 1.79 Allowed Glycine 0 CA--C 1.526 0.748 0 N-CA-C 111.449 -0.661 . . . . 0.0 111.449 -178.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.421 ' O ' ' O ' ' A' ' 54' ' ' LYS . 8.0 p-10 -45.66 88.38 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.859 0.362 . . . . 0.0 111.437 -179.217 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.699 ' H ' HH22 ' A' ' 47' ' ' ARG . 10.6 tptp 44.86 98.32 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.923 179.477 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -62.96 -38.78 92.46 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.197 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 13.6 tpp85 -67.81 -37.07 81.51 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.845 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 55.69 -150.62 0.42 Allowed 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.703 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 72.3 tp60 -132.56 132.6 42.73 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.818 0.342 . . . . 0.0 110.268 179.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 20.2 tt -71.14 -35.28 57.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.505 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -99.78 153.07 19.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.876 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 58.09 62.58 2.0 Allowed 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.415 -179.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -63.07 145.23 55.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.168 179.534 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.432 ' OE1' ' N ' ' A' ' 63' ' ' GLU . 40.4 mp0 -70.5 149.2 95.58 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.291 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo . . . . . 0 N--CA 1.493 1.45 0 C-N-CA 122.163 1.908 . . . . 0.0 112.062 179.895 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . 0.634 ' H3 ' ' CD1' ' A' ' 1' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.655 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 . . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -67.8 174.01 3.95 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.22 -178.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 62.71 171.29 0.14 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.399 -0.819 . . . . 0.0 109.68 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' TRP . . . . . . . . . . . . . 37.6 p90 -126.13 -27.9 3.2 Favored 'General case' 0 C--O 1.232 0.154 0 CA-C-O 120.777 0.322 . . . . 0.0 110.642 179.308 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.436 ' OH ' ' O ' ' A' ' 8' ' ' GLY . 91.3 t80 -140.35 127.31 20.73 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.242 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 55.6 tp -158.32 156.09 29.96 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 109.93 -179.645 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.74 -3.47 81.28 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 179.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.436 ' O ' ' OH ' ' A' ' 5' ' ' TYR . . . 60.78 -125.18 37.65 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.773 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 23.2 t -126.83 79.9 71.63 Favored Pre-proline 0 C--N 1.331 -0.219 0 N-CA-C 110.432 -0.21 . . . . 0.0 110.432 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -77.25 160.19 32.84 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 C-N-CA 122.557 2.171 . . . . 0.0 112.582 -179.575 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 57.4 mtmt -77.69 -7.92 57.17 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.435 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.73 1.29 57.53 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 66.9 t0 -100.45 104.71 16.13 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 179.128 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 11.6 p -135.25 124.73 42.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-O 120.851 0.358 . . . . 0.0 110.735 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 42.2 p-10 -162.74 58.56 0.8 Allowed Pre-proline 0 CA--C 1.531 0.225 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.827 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.534 ' C ' ' H ' ' A' ' 18' ' ' TYR . 51.5 Cg_endo -68.77 -20.24 40.07 Favored 'Trans proline' 0 N--CA 1.496 1.653 0 C-N-CA 122.823 2.348 . . . . 0.0 112.891 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -57.48 -1.1 0.08 Allowed 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.94 -0.304 . . . . 0.0 111.701 -177.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.534 ' H ' ' C ' ' A' ' 16' ' ' PRO . 96.9 m-85 -110.05 -46.04 3.52 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.814 0.34 . . . . 0.0 110.404 178.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -90.26 -14.51 33.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.562 -179.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.435 ' O ' ' CG1' ' A' ' 24' ' ' VAL . 35.1 t70 -61.62 -45.5 93.79 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.891 -0.324 . . . . 0.0 111.217 -179.576 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -65.15 -40.99 95.14 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.565 -179.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -70.62 -50.03 41.28 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.541 -179.649 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.554 ' O ' ' N ' ' A' ' 27' ' ' GLY . 97.2 m -65.55 -50.45 65.11 Favored 'General case' 0 C--O 1.222 -0.364 0 N-CA-C 113.315 0.857 . . . . 0.0 113.315 -177.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.435 ' CG1' ' O ' ' A' ' 20' ' ' ASP . 35.5 m -46.98 -25.55 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 112.632 0.605 . . . . 0.0 112.632 -177.41 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 18.7 tpp180 -73.08 -54.95 7.24 Favored 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 119.689 -0.804 . . . . 0.0 110.244 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -91.86 -2.06 57.03 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 115.543 -0.753 . . . . 0.0 111.95 -179.089 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.554 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.45 -42.79 99.85 Favored Glycine 0 CA--C 1.526 0.751 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.576 -178.678 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.04 -45.17 97.14 Favored Glycine 0 CA--C 1.525 0.713 0 C-N-CA 120.652 -0.785 . . . . 0.0 111.879 -178.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.441 ' CD1' ' N ' ' A' ' 29' ' ' LEU . 10.2 mp -60.09 -47.96 83.71 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.755 -178.676 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.1 mt -62.37 -44.62 99.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.722 0.296 . . . . 0.0 111.624 -179.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -61.22 -46.97 88.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.63 0.252 . . . . 0.0 111.526 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.18 -42.6 91.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.547 -178.05 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.84 -40.81 98.77 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.811 -0.915 . . . . 0.0 110.811 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.6 tp -67.22 -41.37 85.83 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.436 0.636 . . . . 0.0 109.713 178.689 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.61 -47.84 84.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.001 -1.0 . . . . 0.0 110.224 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 92.3 t80 -59.39 -47.41 85.54 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.933 -0.576 . . . . 0.0 112.506 -178.242 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 5.4 mm -58.13 -43.34 85.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.545 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.3 t -57.76 -39.72 72.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.558 -179.36 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -61.08 -37.44 93.92 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.577 -0.609 . . . . 0.0 111.577 -179.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.5 tp -58.17 -46.47 85.68 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 94.7 mt -58.31 -33.89 69.99 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.714 -0.676 . . . . 0.0 111.431 -178.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 89.4 mt -60.35 -45.13 96.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 CA-C-O 120.745 0.307 . . . . 0.0 111.416 -179.208 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.447 ' N ' ' CD2' ' A' ' 43' ' ' LEU . 4.0 mm? -59.39 -38.95 81.83 Favored 'General case' 0 C--O 1.234 0.254 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.529 -179.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 59.2 tp -59.42 -35.88 74.84 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.697 -179.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 75.7 m -60.28 -38.34 83.29 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.667 -0.242 . . . . 0.0 110.49 -179.68 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.3 tmt_? -59.54 -44.09 93.31 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 119.999 -0.68 . . . . 0.0 110.027 179.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.429 ' O ' ' OG ' ' A' ' 50' ' ' SER . 0.0 OUTLIER -58.44 -27.42 64.34 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.682 -179.554 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 93.1 t80 -61.04 -49.3 77.95 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.048 -0.661 . . . . 0.0 109.746 179.299 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.418 ' O ' ' C ' ' A' ' 50' ' ' SER . 0.0 OUTLIER -64.01 -56.65 13.55 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.398 -179.9 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.43 ' O ' ' OD1' ' A' ' 53' ' ' ASN . 39.3 m 35.1 -113.16 0.07 Allowed 'General case' 0 N--CA 1.462 0.162 0 CA-C-O 120.993 0.425 . . . . 0.0 110.968 179.811 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -55.92 146.08 32.29 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 110.44 -1.064 . . . . 0.0 110.44 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 95.93 19.72 28.14 Favored Glycine 0 CA--C 1.528 0.872 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 -179.269 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.43 ' OD1' ' O ' ' A' ' 50' ' ' SER . 55.1 p30 -156.48 174.86 14.81 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.674 0.273 . . . . 0.0 110.556 179.29 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 73.3 mmtt 52.49 55.43 9.11 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.244 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -60.56 -40.07 90.27 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.553 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.517 ' NH1' ' O ' ' A' ' 64' ' ' PRO . 99.5 mtt180 -68.32 -37.86 81.01 Favored 'General case' 0 C--N 1.331 -0.216 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.412 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 28.0 ttm105 58.89 33.26 22.93 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.024 179.336 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -106.23 148.6 27.74 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.913 0.387 . . . . 0.0 110.449 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.2 pt -94.52 5.8 7.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.911 -179.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 64.6 t30 -82.84 112.39 19.61 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.472 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 80.7 mm-40 -89.13 -4.95 58.13 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.616 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -60.82 -43.03 98.75 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.635 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -130.94 79.69 71.03 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.677 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . 0.517 ' O ' ' NH1' ' A' ' 56' ' ' ARG . 37.3 Cg_exo . . . . . 0 C--N 1.308 -1.561 0 C-N-CA 122.677 2.251 . . . . 0.0 112.08 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . 0.526 ' O ' ' NH1' ' A' ' 3' ' ' ARG . 0.2 OUTLIER . . . . . 0 N--CA 1.489 1.512 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 . . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -69.22 147.3 51.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.674 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.526 ' NH1' ' O ' ' A' ' 1' ' ' LEU . 7.5 ptp85 -164.67 69.81 0.17 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.755 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' TRP . . . . . . . . . . . . . 5.1 p90 -116.06 -5.06 11.94 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.509 179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 54.6 p90 -76.85 174.06 10.98 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.958 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 8.5 mp -38.48 143.67 0.13 Allowed 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.785 -179.393 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.81 -9.47 77.62 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -178.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 57.35 -118.32 12.17 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 179.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 55.5 m -123.54 79.56 54.77 Favored Pre-proline 0 CA--C 1.532 0.28 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -74.7 160.93 40.34 Favored 'Trans proline' 0 N--CA 1.495 1.567 0 C-N-CA 122.355 2.036 . . . . 0.0 112.977 -178.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -94.07 -23.19 18.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.555 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.49 9.44 77.97 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 111.106 -0.798 . . . . 0.0 111.106 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 57.7 p30 -142.83 32.76 1.4 Allowed 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.081 -179.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 10.7 p -140.73 137.75 35.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.017 0.437 . . . . 0.0 110.756 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 33.0 t70 -131.42 76.52 75.41 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.889 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -77.0 -8.38 17.71 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.643 2.228 . . . . 0.0 113.094 -178.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -61.74 -41.46 97.69 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.687 -179.58 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -60.11 -48.83 80.07 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.546 -179.222 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 85.6 m-85 -69.74 -35.32 74.87 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.882 0.373 . . . . 0.0 110.57 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -77.43 -8.37 57.63 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.87 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -62.06 -45.28 94.23 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.837 -0.345 . . . . 0.0 110.169 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -59.89 -40.91 90.36 Favored 'General case' 0 C--N 1.324 -0.521 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.238 -179.462 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.538 ' O ' ' N ' ' A' ' 27' ' ' GLY . 73.6 p -70.97 -39.38 72.57 Favored 'General case' 0 C--O 1.224 -0.288 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.747 179.69 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.4 t -45.16 -24.36 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.75 -178.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 62.8 ttm-85 -71.82 -54.04 11.4 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 119.562 -0.855 . . . . 0.0 109.705 178.273 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 33.8 m120 -92.58 -1.54 56.83 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.366 -0.834 . . . . 0.0 112.083 -179.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.538 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.42 -42.28 99.73 Favored Glycine 0 CA--C 1.528 0.878 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.289 -178.886 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.83 -43.91 98.58 Favored Glycine 0 CA--C 1.526 0.76 0 C-N-CA 120.747 -0.74 . . . . 0.0 111.709 -179.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.8 tp -59.5 -47.9 83.74 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.622 -178.464 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.5 mt -61.85 -44.06 98.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 120.94 0.4 . . . . 0.0 111.59 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 91.8 t80 -60.65 -46.3 90.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.221 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.88 -41.73 87.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.46 -178.202 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.61 -40.49 97.98 Favored Glycine 0 CA--C 1.525 0.684 0 C-N-CA 120.434 -0.889 . . . . 0.0 111.043 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.2 tp -67.53 -40.69 85.07 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.396 0.617 . . . . 0.0 109.776 178.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.03 -47.49 85.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.179 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 93.3 t80 -58.97 -46.73 87.38 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -178.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 91.0 mt -58.24 -43.68 86.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.96 -178.423 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.6 t -58.38 -40.73 79.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.77 -179.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.58 -36.6 91.81 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 111.609 -0.597 . . . . 0.0 111.609 -179.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.3 tp -58.79 -45.81 89.0 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 91.5 mt -57.66 -35.81 71.05 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.277 -178.454 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.449 ' O ' ' OG ' ' A' ' 45' ' ' SER . 85.8 mt -59.89 -43.41 92.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.051 0.453 . . . . 0.0 110.501 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 60.3 tp -56.95 -41.06 77.58 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.134 -179.485 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 95.0 mt -60.4 -34.29 73.71 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.658 -178.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.546 ' HG ' ' N ' ' A' ' 46' ' ' ARG . 96.3 p -57.73 -38.52 75.45 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.546 ' N ' ' HG ' ' A' ' 45' ' ' SER . 2.8 tmt_? -63.06 -35.35 79.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.509 178.676 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? -54.08 -29.08 42.96 Favored 'General case' 0 CA--C 1.52 -0.194 0 CA-C-N 116.59 -0.277 . . . . 0.0 111.187 -177.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -62.12 -39.77 93.64 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 119.936 -0.705 . . . . 0.0 110.135 178.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.558 ' CB ' ' HE ' ' A' ' 56' ' ' ARG . 11.3 mpt_? -88.73 -6.95 57.09 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.253 -179.757 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.554 ' HG ' ' N ' ' A' ' 51' ' ' GLY . 48.9 p -81.18 -150.93 0.08 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.764 179.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.554 ' N ' ' HG ' ' A' ' 50' ' ' SER . . . 83.79 4.56 88.73 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 179.838 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 112.57 -162.43 12.39 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 57.27 84.59 0.09 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.654 0.264 . . . . 0.0 110.78 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -69.94 60.52 0.17 Allowed 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 121.077 0.465 . . . . 0.0 110.304 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 62.4 mttp -108.15 17.38 22.35 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.72 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.558 ' HE ' ' CB ' ' A' ' 49' ' ' ARG . 80.4 mmt-85 -101.76 5.59 41.33 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.521 -179.774 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 17.8 ptm180 -138.11 159.46 41.98 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.774 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 25.0 mp0 -71.61 141.24 49.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.948 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.1 pt -127.43 0.52 3.74 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.587 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 55.7 p30 -160.34 159.87 31.72 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.807 179.69 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 80.8 mm-40 -82.58 -13.53 56.39 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.481 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -61.96 -42.5 99.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.542 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -131.0 79.56 71.2 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.483 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo . . . . . 0 C--N 1.308 -1.556 0 C-N-CA 122.636 2.224 . . . . 0.0 112.205 -179.946 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.6 p . . . . . 0 N--CA 1.463 0.206 0 N-CA-C 111.553 0.205 . . . . 0.0 111.553 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 29.5 mmm-85 -71.47 -55.35 8.05 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 119.635 -0.826 . . . . 0.0 109.92 178.878 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -92.66 -2.85 55.75 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.833 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.53 -42.36 99.75 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 121.116 -0.564 . . . . 0.0 112.572 -178.813 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.72 -44.32 98.06 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.901 -179.009 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.7 tp -59.78 -48.18 82.71 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.616 -0.433 . . . . 0.0 110.801 -178.371 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 90.3 mt -61.7 -44.07 98.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.921 0.391 . . . . 0.0 111.427 -179.37 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -60.26 -46.41 89.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.441 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.74 -42.69 89.38 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.781 -177.923 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.49 -40.33 97.58 Favored Glycine 0 CA--C 1.526 0.759 0 C-N-CA 120.352 -0.928 . . . . 0.0 110.943 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 93.6 mt -65.8 -36.49 83.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.416 0.627 . . . . 0.0 109.792 178.494 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -59.81 -48.5 81.43 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.262 -179.488 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 54.1 m-85 -60.23 -41.39 93.02 Favored 'General case' 0 C--O 1.236 0.39 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -178.315 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 89.9 mt -58.26 -44.5 88.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 C-N-CA 120.188 -0.605 . . . . 0.0 110.284 -179.114 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.9 t -57.38 -40.32 73.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.839 -179.279 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.36 -37.1 92.6 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.0 tp -58.61 -47.5 84.13 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.284 -0.566 . . . . 0.0 109.711 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 59.3 tp -55.49 -35.46 65.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.151 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 87.0 mt -59.88 -42.22 88.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 120.948 0.404 . . . . 0.0 110.665 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 91.7 mt -58.76 -40.44 83.91 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.241 -0.583 . . . . 0.0 110.425 -179.196 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.47 HD12 ' N ' ' A' ' 44' ' ' LEU . 11.1 mp -60.73 -30.21 69.84 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.786 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 40.5 t -58.71 -41.44 86.35 Favored 'General case' 0 CA--C 1.518 -0.259 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 20.5 ttp180 . . . . . 0 C--N 1.328 -0.356 0 C-N-CA 120.485 -0.486 . . . . 0.0 110.155 179.294 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.464 0.242 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 78.4 ttt180 -73.54 -55.37 6.4 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 119.686 -0.805 . . . . 0.0 110.025 178.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 53.6 p30 -92.45 -1.76 56.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.848 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.3 -42.98 99.92 Favored Glycine 0 CA--C 1.526 0.76 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.265 -178.825 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.97 -43.59 98.97 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 120.734 -0.746 . . . . 0.0 111.728 -179.234 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.527 HD22 ' N ' ' A' ' 29' ' ' LEU . 4.0 mm? -59.53 -47.82 84.04 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.628 -0.429 . . . . 0.0 110.835 -178.436 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 90.7 mt -61.71 -44.11 98.22 Favored 'Isoleucine or valine' 0 C--O 1.237 0.422 0 CA-C-O 120.846 0.355 . . . . 0.0 111.414 -179.494 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -60.45 -46.8 88.76 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.335 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.79 -41.84 87.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.66 -178.214 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.38 -40.83 98.09 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 120.38 -0.914 . . . . 0.0 110.921 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 93.3 mt -67.0 -37.95 85.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.276 0.56 . . . . 0.0 109.952 178.729 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.28 -47.69 84.92 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.08 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.461 ' CE2' HD11 ' A' ' 40' ' ' LEU . 93.4 t80 -59.14 -46.99 86.93 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.958 -0.564 . . . . 0.0 112.318 -178.198 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.1 mt -57.98 -44.35 86.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 C-N-CA 120.726 -0.389 . . . . 0.0 111.013 -178.412 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 55.9 t -57.9 -40.5 76.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.599 -179.276 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.51 -36.4 91.23 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.75 -0.54 . . . . 0.0 111.75 -179.404 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.461 HD11 ' CE2' ' A' ' 36' ' ' PHE . 91.4 mt -60.02 -43.65 95.12 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.073 -0.651 . . . . 0.0 109.711 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.5 mt -58.43 -35.6 72.34 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.142 -178.792 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 86.6 mt -60.04 -43.04 91.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.067 0.46 . . . . 0.0 110.655 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 90.9 mt -58.91 -39.86 82.78 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 120.443 -0.503 . . . . 0.0 110.276 -179.24 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -60.07 -31.53 70.09 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-O 120.691 0.282 . . . . 0.0 110.912 -179.653 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 69.5 m -59.43 -40.37 86.53 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 59.0 ttt85 . . . . . 0 C--N 1.33 -0.263 0 C-N-CA 120.478 -0.489 . . . . 0.0 109.957 178.774 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 1.1 p . . . . . 0 N--CA 1.462 0.17 0 N-CA-C 111.822 0.305 . . . . 0.0 111.822 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 61.3 ttp180 -72.84 -54.41 8.86 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.019 179.023 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -92.94 -2.85 55.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.485 -0.78 . . . . 0.0 112.02 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.59 -43.16 99.65 Favored Glycine 0 CA--C 1.526 0.775 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.335 -178.724 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.89 -44.28 98.05 Favored Glycine 0 CA--C 1.526 0.731 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.012 -179.009 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.4 mt -60.4 -47.44 86.06 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.334 -0.546 . . . . 0.0 110.767 -178.523 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 5.0 mm -62.13 -43.9 98.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.739 0.304 . . . . 0.0 111.185 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.1 t80 -60.77 -46.58 89.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.255 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.66 -42.5 88.58 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.586 -178.213 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.72 -40.47 98.11 Favored Glycine 0 CA--C 1.524 0.642 0 C-N-CA 120.271 -0.966 . . . . 0.0 110.688 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 96.7 mt -67.23 -38.02 84.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.288 0.566 . . . . 0.0 109.811 178.691 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.6 -47.71 85.02 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.013 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 92.3 t80 -59.23 -47.2 86.22 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 115.903 -0.589 . . . . 0.0 112.146 -178.404 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 89.9 mt -57.8 -43.11 83.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 C-N-CA 120.868 -0.333 . . . . 0.0 110.437 -178.721 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 56.3 t -57.04 -40.06 70.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.451 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.83 -36.89 92.77 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 111.481 -0.648 . . . . 0.0 111.481 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 62.2 tp -58.25 -47.27 84.09 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.307 -0.557 . . . . 0.0 109.503 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 92.8 mt -57.49 -33.61 68.19 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.37 -178.711 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 41.2 mm -60.34 -42.86 92.28 Favored 'Isoleucine or valine' 0 C--O 1.236 0.387 0 CA-C-O 120.874 0.369 . . . . 0.0 110.237 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 92.1 mt -59.46 -39.39 83.47 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.115 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 59.2 tp -59.05 -35.28 73.06 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.53 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 46.7 t -59.15 -40.61 86.07 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 110.135 -0.321 . . . . 0.0 110.135 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.276 0 C-N-CA 120.354 -0.538 . . . . 0.0 110.186 179.61 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 2.1 p . . . . . 0 N--CA 1.465 0.278 0 N-CA-C 111.85 0.315 . . . . 0.0 111.85 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 59.0 ttt85 -72.51 -54.83 8.13 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 119.884 -0.726 . . . . 0.0 110.06 179.033 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -93.09 -2.65 55.31 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.873 -179.785 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.46 -43.57 99.14 Favored Glycine 0 CA--C 1.527 0.829 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.299 -178.667 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -63.1 -43.47 98.69 Favored Glycine 0 CA--C 1.527 0.84 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.163 -179.186 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 89.5 mt -60.37 -47.12 87.42 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.447 -0.501 . . . . 0.0 111.386 -177.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 40.1 pt -69.34 -37.56 75.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 120.487 -0.485 . . . . 0.0 111.382 -179.257 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.3 t80 -61.94 -47.64 83.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.961 0.41 . . . . 0.0 110.889 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.74 -42.14 92.5 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.76 -178.468 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.17 -40.2 96.92 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.731 -0.948 . . . . 0.0 110.731 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.5 tp -67.28 -39.5 86.04 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.423 0.63 . . . . 0.0 109.61 178.338 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -59.5 -48.79 80.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.435 -179.157 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -60.77 -40.62 93.2 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 111.962 0.356 . . . . 0.0 111.962 -178.432 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.4 mt -58.92 -44.73 91.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 C-N-CA 120.404 -0.518 . . . . 0.0 110.53 -179.025 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 56.3 t -57.88 -39.73 72.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.731 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.83 -37.23 93.33 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.605 -0.598 . . . . 0.0 111.605 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.0 tp -58.89 -47.38 85.17 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.689 -0.405 . . . . 0.0 110.118 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.5 mt -58.39 -34.87 71.21 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.397 -178.385 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 86.8 mt -60.21 -43.52 93.43 Favored 'Isoleucine or valine' 0 C--O 1.238 0.489 0 CA-C-O 120.797 0.332 . . . . 0.0 110.963 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 92.1 mt -59.66 -39.1 83.3 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.924 -0.31 . . . . 0.0 110.483 -179.537 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 59.0 tp -59.92 -35.69 75.42 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.88 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 75.5 m -59.58 -39.22 83.4 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.347 -179.619 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.313 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.23 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 2.7 p . . . . . 0 N--CA 1.469 0.51 0 N-CA-C 113.471 0.915 . . . . 0.0 113.471 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.445 ' NE ' ' OD1' ' A' ' 26' ' ' ASN . 4.1 ptm180 -80.04 -54.26 5.95 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 119.576 -0.85 . . . . 0.0 110.712 178.781 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ASN . . . . . 0.445 ' OD1' ' NE ' ' A' ' 25' ' ' ARG . 34.3 m120 -91.44 -3.09 57.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.1 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -60.93 -42.0 99.53 Favored Glycine 0 CA--C 1.525 0.704 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.872 -179.243 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.28 -42.15 99.7 Favored Glycine 0 CA--C 1.525 0.668 0 C-N-CA 120.85 -0.69 . . . . 0.0 111.405 -179.536 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.4 mt -59.69 -46.81 87.93 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.367 -178.808 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 90.9 mt -60.82 -43.67 95.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.787 0.327 . . . . 0.0 110.917 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.0 t80 -60.29 -46.85 88.42 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.277 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.14 -42.6 86.21 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.875 -0.33 . . . . 0.0 111.417 -177.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.23 -40.08 96.84 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 60.3 tp -64.89 -39.85 94.19 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.214 0.53 . . . . 0.0 109.877 178.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.409 ' O ' HG22 ' A' ' 38' ' ' VAL . . . -60.94 -46.0 92.47 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.281 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -59.84 -48.62 80.96 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.354 -178.25 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 92.1 mt -59.19 -48.75 85.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 N-CA-C 112.185 0.439 . . . . 0.0 112.185 -177.562 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.409 HG22 ' O ' ' A' ' 35' ' ' ALA . 29.3 m -56.67 -35.45 45.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.485 -179.002 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -61.8 -38.51 96.08 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 111.815 -0.514 . . . . 0.0 111.815 -179.727 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.4 tp -59.0 -47.11 86.37 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.319 -0.552 . . . . 0.0 109.696 -179.521 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.9 mt -57.26 -34.13 68.32 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.278 -178.433 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 88.5 mt -60.74 -42.98 94.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.885 0.374 . . . . 0.0 110.822 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 91.6 mt -59.0 -39.49 81.99 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.141 -179.258 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 94.7 mt -60.71 -33.16 72.47 Favored 'General case' 0 C--O 1.238 0.455 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.975 -179.57 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 70.3 m -58.44 -40.51 82.76 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? . . . . . 0 C--N 1.328 -0.335 0 C-N-CA 120.677 -0.409 . . . . 0.0 110.522 178.967 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.0 p . . . . . 0 N--CA 1.464 0.256 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 90.7 mtm180 -73.13 -55.35 6.6 Favored 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 119.716 -0.794 . . . . 0.0 110.109 178.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -93.42 -1.43 55.8 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.439 -0.8 . . . . 0.0 112.081 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.06 -43.32 99.58 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.529 -178.518 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.88 -43.9 98.58 Favored Glycine 0 CA--C 1.526 0.773 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.829 -179.134 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.6 tp -59.52 -48.38 81.89 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.642 -178.536 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 92.4 mt -61.66 -44.41 98.64 Favored 'Isoleucine or valine' 0 C--O 1.236 0.348 0 CA-C-O 120.894 0.378 . . . . 0.0 111.526 -179.443 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.6 t80 -60.72 -46.58 89.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.152 -179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.81 -41.79 87.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.482 -178.119 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.59 -41.02 98.66 Favored Glycine 0 CA--C 1.525 0.691 0 C-N-CA 120.427 -0.892 . . . . 0.0 111.002 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.404 HD23 ' HA ' ' A' ' 34' ' ' LEU . 95.0 mt -67.16 -37.91 84.57 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.18 0.514 . . . . 0.0 110.114 178.819 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.51 -47.65 85.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.162 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 93.1 t80 -59.4 -46.81 87.63 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 116.083 -0.508 . . . . 0.0 112.227 -178.426 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.7 mm -57.57 -44.35 84.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.705 -178.522 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.1 t -57.2 -39.79 69.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.701 -179.318 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.67 -36.91 92.6 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 -179.794 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.4 tp -58.9 -48.23 82.16 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.007 -0.677 . . . . 0.0 109.891 -179.573 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.454 ' N ' HD12 ' A' ' 41' ' ' LEU . 10.9 mp -56.19 -33.1 64.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.437 -178.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 4.7 mm -60.77 -43.81 96.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.455 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' LEU . . . . . 0.414 HD13 ' HA ' ' A' ' 43' ' ' LEU . 4.2 mm? -57.12 -40.78 77.75 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.282 -0.567 . . . . 0.0 110.243 -179.738 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.46 HD12 ' N ' ' A' ' 44' ' ' LEU . 10.3 mp -60.96 -30.27 70.15 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.057 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 39.9 t -59.36 -41.44 89.25 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 -179.468 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.5 ttt-85 . . . . . 0 C--N 1.329 -0.289 0 C-N-CA 120.33 -0.548 . . . . 0.0 110.488 179.233 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.4 t . . . . . 0 C--O 1.226 -0.181 0 N-CA-C 111.919 0.341 . . . . 0.0 111.919 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -72.95 -54.23 9.2 Favored 'General case' 0 C--N 1.323 -0.584 0 C-N-CA 119.472 -0.891 . . . . 0.0 109.855 178.482 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -91.99 -1.14 57.41 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.336 -179.094 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.41 -41.86 99.63 Favored Glycine 0 CA--C 1.528 0.872 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.353 -178.917 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.71 -44.83 97.38 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.926 -179.161 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.7 tp -59.77 -47.92 83.75 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.865 -178.358 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.1 mt -62.11 -43.6 97.96 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 CA-C-O 120.904 0.383 . . . . 0.0 111.458 -179.523 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 91.6 t80 -60.62 -46.14 91.41 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.272 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.77 -42.36 88.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.341 -0.391 . . . . 0.0 111.622 -178.209 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.23 -40.13 96.92 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.6 tp -67.7 -39.87 84.36 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-O 121.422 0.63 . . . . 0.0 109.918 178.526 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -59.56 -49.02 79.38 Favored 'General case' 0 C--O 1.225 -0.236 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.581 -178.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -60.78 -40.48 92.72 Favored 'General case' 0 C--O 1.236 0.351 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -178.567 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.3 mt -58.55 -44.76 90.01 Favored 'Isoleucine or valine' 0 C--O 1.235 0.326 0 C-N-CA 120.256 -0.578 . . . . 0.0 110.549 -179.065 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 53.7 t -58.66 -40.15 78.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.794 -179.596 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.28 -36.05 89.85 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 111.773 -0.531 . . . . 0.0 111.773 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 40' ' ' LEU . 92.6 mt -60.28 -43.23 96.42 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 119.934 -0.706 . . . . 0.0 109.515 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 59.4 tp -56.69 -37.25 70.62 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.905 -179.193 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 4.7 mm -59.52 -42.14 87.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.89 0.376 . . . . 0.0 110.614 -179.495 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 91.0 mt -58.64 -39.99 82.11 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.303 -0.559 . . . . 0.0 110.416 -179.093 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.407 HD12 ' N ' ' A' ' 44' ' ' LEU . 10.8 mp -60.96 -30.11 70.05 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 120.709 0.29 . . . . 0.0 111.12 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 42.6 t -58.74 -42.34 88.56 Favored 'General case' 0 CA--C 1.518 -0.266 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 179.623 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 15.8 tpt180 . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.769 178.707 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 2.4 p . . . . . 0 N--CA 1.465 0.318 0 N-CA-C 112.112 0.412 . . . . 0.0 112.112 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 63.2 ttm-85 -75.26 -54.64 6.76 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.273 179.04 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -93.19 -1.32 56.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.589 -0.732 . . . . 0.0 112.141 -179.485 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -62.18 -43.63 98.84 Favored Glycine 0 CA--C 1.528 0.86 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.688 -178.624 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -62.05 -45.44 96.09 Favored Glycine 0 CA--C 1.527 0.813 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.088 -179.015 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.1 mt -60.18 -46.23 90.44 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.533 -0.467 . . . . 0.0 111.281 -178.124 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.3 mt -62.08 -45.51 98.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 CA-C-O 120.815 0.341 . . . . 0.0 111.565 -179.532 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.1 t80 -61.77 -47.03 87.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.922 0.391 . . . . 0.0 111.253 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.53 -41.63 90.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.495 -178.375 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.94 -40.36 98.28 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 120.589 -0.815 . . . . 0.0 111.164 -179.609 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 98.5 mt -69.85 -39.36 76.42 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.324 0.583 . . . . 0.0 110.019 178.682 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.9 -48.0 83.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.192 -179.685 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -59.64 -46.54 88.69 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.102 -0.499 . . . . 0.0 112.297 -178.478 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 89.3 mt -58.44 -44.53 89.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 C-N-CA 121.016 -0.273 . . . . 0.0 111.283 -178.23 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.9 t -58.33 -39.57 74.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 120.818 0.342 . . . . 0.0 110.722 -179.485 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.86 -37.3 93.49 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.2 tp -58.8 -48.46 81.21 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.372 -179.321 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.481 ' N ' HD12 ' A' ' 41' ' ' LEU . 10.8 mp -57.36 -34.07 68.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.536 -178.964 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 39.5 mm -60.58 -43.32 94.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.391 0 CA-C-O 121.026 0.441 . . . . 0.0 110.922 -179.276 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 90.9 mt -60.51 -39.86 89.31 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.684 -0.406 . . . . 0.0 110.67 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 9.8 mp -60.59 -30.98 70.16 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.261 -179.404 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 74.2 m -63.08 -39.61 95.24 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.783 0.325 . . . . 0.0 110.463 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.2 tpm_? . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.649 179.694 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 35.5 m . . . . . 0 N--CA 1.466 0.351 0 N-CA-C 112.632 0.605 . . . . 0.0 112.632 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 18.7 tpp180 -73.08 -54.95 7.24 Favored 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 119.689 -0.804 . . . . 0.0 110.244 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -91.86 -2.06 57.03 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 115.543 -0.753 . . . . 0.0 111.95 -179.089 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.45 -42.79 99.85 Favored Glycine 0 CA--C 1.526 0.751 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.576 -178.678 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.04 -45.17 97.14 Favored Glycine 0 CA--C 1.525 0.713 0 C-N-CA 120.652 -0.785 . . . . 0.0 111.879 -178.818 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.588 ' N ' HD12 ' A' ' 29' ' ' LEU . 10.2 mp -60.09 -47.96 83.71 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.755 -178.676 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.1 mt -62.37 -44.62 99.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.722 0.296 . . . . 0.0 111.624 -179.413 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -61.22 -46.97 88.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.63 0.252 . . . . 0.0 111.526 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.18 -42.6 91.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.547 -178.05 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.84 -40.81 98.77 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.811 -0.915 . . . . 0.0 110.811 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.6 tp -67.22 -41.37 85.83 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.436 0.636 . . . . 0.0 109.713 178.689 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.61 -47.84 84.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.001 -1.0 . . . . 0.0 110.224 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 92.3 t80 -59.39 -47.41 85.54 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.933 -0.576 . . . . 0.0 112.506 -178.242 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 5.4 mm -58.13 -43.34 85.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.545 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.3 t -57.76 -39.72 72.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.558 -179.36 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.412 ' HA2' HD12 ' A' ' 42' ' ' ILE . . . -61.08 -37.44 93.92 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.577 -0.609 . . . . 0.0 111.577 -179.762 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.5 tp -58.17 -46.47 85.68 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 94.7 mt -58.31 -33.89 69.99 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.714 -0.676 . . . . 0.0 111.431 -178.719 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.412 HD12 ' HA2' ' A' ' 39' ' ' GLY . 89.4 mt -60.35 -45.13 96.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 CA-C-O 120.745 0.307 . . . . 0.0 111.416 -179.208 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' LEU . . . . . 0.472 HD22 ' N ' ' A' ' 43' ' ' LEU . 4.0 mm? -59.39 -38.95 81.83 Favored 'General case' 0 C--O 1.234 0.254 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.529 -179.83 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 59.2 tp -59.42 -35.88 74.84 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.697 -179.646 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 75.7 m -60.28 -38.34 83.29 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.667 -0.242 . . . . 0.0 110.49 -179.68 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.3 tmt_? . . . . . 0 C--N 1.33 -0.272 0 C-N-CA 119.999 -0.68 . . . . 0.0 110.027 179.75 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.4 t . . . . . 0 N--CA 1.464 0.225 0 N-CA-C 111.75 0.278 . . . . 0.0 111.75 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 62.8 ttm-85 -71.82 -54.04 11.4 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 119.562 -0.855 . . . . 0.0 109.705 178.273 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 33.8 m120 -92.58 -1.54 56.83 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.366 -0.834 . . . . 0.0 112.083 -179.284 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.42 -42.28 99.73 Favored Glycine 0 CA--C 1.528 0.878 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.289 -178.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.83 -43.91 98.58 Favored Glycine 0 CA--C 1.526 0.76 0 C-N-CA 120.747 -0.74 . . . . 0.0 111.709 -179.195 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.8 tp -59.5 -47.9 83.74 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.622 -178.464 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.5 mt -61.85 -44.06 98.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 120.94 0.4 . . . . 0.0 111.59 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 91.8 t80 -60.65 -46.3 90.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.221 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.88 -41.73 87.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.46 -178.202 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.61 -40.49 97.98 Favored Glycine 0 CA--C 1.525 0.684 0 C-N-CA 120.434 -0.889 . . . . 0.0 111.043 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.2 tp -67.53 -40.69 85.07 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.396 0.617 . . . . 0.0 109.776 178.738 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.03 -47.49 85.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.179 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 93.3 t80 -58.97 -46.73 87.38 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -178.124 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 91.0 mt -58.24 -43.68 86.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.96 -178.423 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.6 t -58.38 -40.73 79.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.77 -179.322 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.58 -36.6 91.81 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 111.609 -0.597 . . . . 0.0 111.609 -179.53 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.3 tp -58.79 -45.81 89.0 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 91.5 mt -57.66 -35.81 71.05 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.277 -178.454 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 85.8 mt -59.89 -43.41 92.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.051 0.453 . . . . 0.0 110.501 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 60.3 tp -56.95 -41.06 77.58 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.134 -179.485 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 95.0 mt -60.4 -34.29 73.71 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.658 -178.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 96.3 p -57.73 -38.52 75.45 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.726 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 2.8 tmt_? . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.509 178.676 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' LEU . . . . . 0.555 ' C ' ' HE1' ' A' ' 4' ' ' TRP . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 . . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -119.13 151.74 37.77 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.004 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 84.2 mtt85 57.45 60.6 2.81 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.343 179.507 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' TRP . . . . . 0.555 ' HE1' ' C ' ' A' ' 1' ' ' LEU . 95.5 m95 -85.85 -4.66 59.22 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.527 179.582 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 94.0 t80 -75.31 135.48 40.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.534 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.9 pp -117.19 176.33 5.19 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.483 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 82.83 2.91 90.68 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.557 -1.017 . . . . 0.0 110.557 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.81 31.73 8.05 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.0 t -121.08 88.75 45.5 Favored Pre-proline 0 CA--C 1.533 0.298 0 N-CA-C 110.599 -0.149 . . . . 0.0 110.599 -179.684 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -58.57 -172.26 0.05 OUTLIER 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.622 2.215 . . . . 0.0 112.072 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -71.48 -18.88 62.27 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.393 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 83.89 2.35 89.66 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.448 -0.661 . . . . 0.0 111.448 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -85.88 -74.17 0.42 Allowed 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.672 -0.411 . . . . 0.0 110.272 179.772 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.603 HG12 ' HD3' ' A' ' 16' ' ' PRO . 58.0 t -127.8 125.99 66.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.062 179.685 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.6 m-20 -126.32 77.77 72.06 Favored Pre-proline 0 C--N 1.332 -0.181 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.744 -179.131 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.603 ' HD3' HG12 ' A' ' 14' ' ' VAL . 92.0 Cg_endo -83.9 32.14 0.51 Allowed 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 123.011 2.474 . . . . 0.0 112.635 -179.491 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 47.9 m-85 -60.07 -3.2 0.54 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.144 -179.445 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.423 ' H ' ' C ' ' A' ' 16' ' ' PRO . 85.6 m-85 -60.31 -37.98 82.26 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -60.29 -47.9 84.02 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 178.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -76.43 -18.18 58.95 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.741 179.698 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.655 ' O ' HG12 ' A' ' 24' ' ' VAL . 76.1 t80 -63.71 -38.63 91.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.564 -179.594 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -57.51 -36.95 72.22 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.115 -178.801 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.506 ' O ' ' N ' ' A' ' 27' ' ' GLY . 78.6 p -64.65 -25.34 67.91 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.677 -0.409 . . . . 0.0 110.552 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.655 HG12 ' O ' ' A' ' 21' ' ' TYR . 4.6 p -44.71 -23.19 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.553 -179.125 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 29.5 mmm-85 -71.47 -55.35 8.05 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 119.635 -0.826 . . . . 0.0 109.92 178.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -92.66 -2.85 55.75 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.833 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.53 -42.36 99.75 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 121.116 -0.564 . . . . 0.0 112.572 -178.813 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.72 -44.32 98.06 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.901 -179.009 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.7 tp -59.78 -48.18 82.71 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.616 -0.433 . . . . 0.0 110.801 -178.371 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 90.3 mt -61.7 -44.07 98.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.921 0.391 . . . . 0.0 111.427 -179.37 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -60.26 -46.41 89.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.441 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.74 -42.69 89.38 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.781 -177.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.49 -40.33 97.58 Favored Glycine 0 CA--C 1.526 0.759 0 C-N-CA 120.352 -0.928 . . . . 0.0 110.943 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 93.6 mt -65.8 -36.49 83.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.416 0.627 . . . . 0.0 109.792 178.494 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -59.81 -48.5 81.43 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.262 -179.488 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 54.1 m-85 -60.23 -41.39 93.02 Favored 'General case' 0 C--O 1.236 0.39 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -178.315 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 89.9 mt -58.26 -44.5 88.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 C-N-CA 120.188 -0.605 . . . . 0.0 110.284 -179.114 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.9 t -57.38 -40.32 73.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.839 -179.279 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.36 -37.1 92.6 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.0 tp -58.61 -47.5 84.13 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.284 -0.566 . . . . 0.0 109.711 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 59.3 tp -55.49 -35.46 65.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.151 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 87.0 mt -59.88 -42.22 88.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 120.948 0.404 . . . . 0.0 110.665 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 91.7 mt -58.76 -40.44 83.91 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.241 -0.583 . . . . 0.0 110.425 -179.196 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.47 HD12 ' N ' ' A' ' 44' ' ' LEU . 11.1 mp -60.73 -30.21 69.84 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.786 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 40.5 t -58.71 -41.44 86.35 Favored 'General case' 0 CA--C 1.518 -0.259 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 20.5 ttp180 -60.51 -36.95 79.61 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.485 -0.486 . . . . 0.0 110.155 179.294 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.427 ' O ' ' O ' ' A' ' 50' ' ' SER . 15.0 ttp180 -56.12 -31.16 63.04 Favored 'General case' 0 N--CA 1.462 0.163 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.403 -178.516 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -59.23 -37.72 78.21 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.002 -0.679 . . . . 0.0 110.146 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 84.5 mtp180 -87.99 -54.41 4.24 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 119.768 -0.773 . . . . 0.0 109.854 178.505 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.427 ' O ' ' O ' ' A' ' 47' ' ' ARG . 67.3 m -71.6 139.41 49.34 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.623 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 175.62 -171.16 44.27 Favored Glycine 0 CA--C 1.523 0.594 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -102.75 13.66 56.35 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -133.1 25.16 4.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.741 0.305 . . . . 0.0 110.549 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.715 ' NZ ' ' HE ' ' A' ' 56' ' ' ARG . 65.3 tttp 42.2 80.1 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.181 -179.573 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -100.41 -3.11 31.68 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.63 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.715 ' HE ' ' NZ ' ' A' ' 54' ' ' LYS . 41.7 ptt180 -70.1 -25.42 63.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.058 -179.7 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 55.3 ttp180 38.17 54.36 1.71 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.247 179.733 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 72.2 tp60 -135.18 131.46 36.76 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.615 -179.482 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 20.8 tt -142.56 136.69 27.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.166 179.706 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 84.2 m-20 -108.3 126.18 52.54 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.658 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -130.98 146.79 52.5 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.451 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -94.03 135.47 35.35 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.52 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.442 ' OE1' ' N ' ' A' ' 63' ' ' GLU . 39.1 mp0 -70.77 149.32 95.17 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.27 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo . . . . . 0 N--CA 1.493 1.468 0 C-N-CA 122.151 1.901 . . . . 0.0 111.964 179.941 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.452 ' CG ' ' H ' ' A' ' 3' ' ' ARG . 34.2 t0 -72.08 -173.41 1.04 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.739 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.452 ' H ' ' CG ' ' A' ' 2' ' ' ASP . 84.2 mtt85 -89.52 -3.05 58.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.357 179.687 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' TRP . . . . . . . . . . . . . 50.1 t-105 -85.4 -25.97 26.71 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.737 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -76.43 141.76 41.27 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.765 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.426 HD12 ' HA ' ' A' ' 6' ' ' LEU . 12.1 tp -116.9 -134.61 0.34 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.026 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 81.94 3.41 90.59 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 179.768 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.65 64.0 3.26 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 68.2 m -128.83 149.55 72.57 Favored Pre-proline 0 CA--C 1.532 0.268 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -69.36 148.63 68.06 Favored 'Trans proline' 0 N--CA 1.496 1.619 0 C-N-CA 121.975 1.784 . . . . 0.0 112.223 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 73.7 mmtt -94.54 -3.25 50.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.354 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 81.07 7.1 88.92 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -101.46 -37.24 8.52 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.955 0.407 . . . . 0.0 110.523 179.357 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.517 HG22 ' N ' ' A' ' 15' ' ' ASP . 10.7 p -155.76 161.46 2.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.45 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.517 ' N ' HG22 ' A' ' 14' ' ' VAL . 60.2 m-20 -125.66 76.28 70.02 Favored Pre-proline 0 C--N 1.331 -0.234 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.518 -179.581 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.513 ' HD3' HG13 ' A' ' 14' ' ' VAL . 90.6 Cg_endo -81.24 -5.49 12.78 Favored 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.958 2.439 . . . . 0.0 112.435 -179.293 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.5 ' O ' ' N ' ' A' ' 21' ' ' TYR . 91.2 t80 -59.78 -44.06 94.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.635 -179.568 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -59.44 -48.66 80.81 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 120.442 -0.503 . . . . 0.0 110.142 -179.243 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 86.2 m-85 -68.72 -36.66 78.72 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.012 0.434 . . . . 0.0 110.213 179.372 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -81.77 -7.98 59.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.085 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.573 ' O ' HG12 ' A' ' 24' ' ' VAL . 93.7 t80 -61.85 -46.08 91.0 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.405 -179.349 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -60.01 -38.47 82.75 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.846 0.355 . . . . 0.0 110.549 -179.558 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.52 ' O ' ' N ' ' A' ' 27' ' ' GLY . 98.8 m -61.57 -41.97 98.17 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.998 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.573 HG12 ' O ' ' A' ' 21' ' ' TYR . 0.6 OUTLIER -42.05 -24.05 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.287 -0.415 . . . . 0.0 112.107 -178.001 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.401 ' N ' ' O ' ' A' ' 23' ' ' THR . 78.4 ttt180 -73.54 -55.37 6.4 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 119.686 -0.805 . . . . 0.0 110.025 178.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 53.6 p30 -92.45 -1.76 56.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.848 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.52 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.3 -42.98 99.92 Favored Glycine 0 CA--C 1.526 0.76 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.265 -178.825 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.97 -43.59 98.97 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 120.734 -0.746 . . . . 0.0 111.728 -179.234 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.527 HD22 ' N ' ' A' ' 29' ' ' LEU . 4.0 mm? -59.53 -47.82 84.04 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.628 -0.429 . . . . 0.0 110.835 -178.436 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 90.7 mt -61.71 -44.11 98.22 Favored 'Isoleucine or valine' 0 C--O 1.237 0.422 0 CA-C-O 120.846 0.355 . . . . 0.0 111.414 -179.494 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -60.45 -46.8 88.76 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.335 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.79 -41.84 87.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.66 -178.214 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.38 -40.83 98.09 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 120.38 -0.914 . . . . 0.0 110.921 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 93.3 mt -67.0 -37.95 85.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.276 0.56 . . . . 0.0 109.952 178.729 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.28 -47.69 84.92 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.08 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.461 ' CE2' HD11 ' A' ' 40' ' ' LEU . 93.4 t80 -59.14 -46.99 86.93 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.958 -0.564 . . . . 0.0 112.318 -178.198 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.1 mt -57.98 -44.35 86.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 C-N-CA 120.726 -0.389 . . . . 0.0 111.013 -178.412 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 55.9 t -57.9 -40.5 76.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.599 -179.276 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.51 -36.4 91.23 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.75 -0.54 . . . . 0.0 111.75 -179.404 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.461 HD11 ' CE2' ' A' ' 36' ' ' PHE . 91.4 mt -60.02 -43.65 95.12 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.073 -0.651 . . . . 0.0 109.711 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.5 mt -58.43 -35.6 72.34 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.142 -178.792 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 86.6 mt -60.04 -43.04 91.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.067 0.46 . . . . 0.0 110.655 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 90.9 mt -58.91 -39.86 82.78 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 120.443 -0.503 . . . . 0.0 110.276 -179.24 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -60.07 -31.53 70.09 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-O 120.691 0.282 . . . . 0.0 110.912 -179.653 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 69.5 m -59.43 -40.37 86.53 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 59.0 ttt85 -60.72 -36.57 79.17 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 120.478 -0.489 . . . . 0.0 109.957 178.774 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 15.2 ttp180 -54.97 -29.96 58.07 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.527 -178.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 93.8 t80 -58.16 -47.56 82.99 Favored 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 120.653 -0.419 . . . . 0.0 110.136 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -86.38 -54.84 4.19 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 120.374 -0.53 . . . . 0.0 110.861 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 48.0 t -61.66 -43.79 98.18 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.688 -178.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 100.32 -18.66 55.1 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 -179.168 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.86 146.55 9.21 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 112.069 -0.413 . . . . 0.0 112.069 178.633 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 47.9 m-20 69.97 -147.84 0.1 Allowed 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.362 -0.419 . . . . 0.0 110.836 -179.695 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 82.1 tttt -163.21 161.51 24.96 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.307 -179.46 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -90.17 0.43 57.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.921 0.391 . . . . 0.0 110.555 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.564 ' HA ' HD11 ' A' ' 59' ' ' ILE . 77.9 ttt-85 -68.44 -30.19 69.01 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.445 -179.339 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 91.4 mtm180 -59.36 -40.65 87.13 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.588 -0.445 . . . . 0.0 110.655 -178.595 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -134.41 108.05 7.93 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.816 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.564 HD11 ' HA ' ' A' ' 56' ' ' ARG . 87.0 mt -124.36 131.67 72.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.873 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -64.73 127.82 33.17 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.443 -0.503 . . . . 0.0 110.231 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.441 ' HG3' ' H ' ' A' ' 63' ' ' GLU . 52.7 tp10 -153.18 148.77 27.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.092 -179.535 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -63.58 -39.68 95.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.789 0.328 . . . . 0.0 110.909 179.739 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.441 ' H ' ' HG3' ' A' ' 61' ' ' GLU . 96.3 mt-10 -128.98 75.95 79.78 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.881 -179.45 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo . . . . . 0 C--N 1.307 -1.654 0 C-N-CA 122.844 2.362 . . . . 0.0 112.21 -179.783 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' LEU . . . . . 0.52 ' N ' ' OD1' ' A' ' 20' ' ' ASP . 83.9 mt . . . . . 0 N--CA 1.492 1.641 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -87.58 103.19 15.32 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.627 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -77.66 152.26 33.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.637 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' TRP . . . . . . . . . . . . . 29.6 m-90 -99.1 15.69 25.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.461 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -108.26 112.9 25.61 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.504 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 98.0 mt -67.79 -40.05 83.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.129 0.49 . . . . 0.0 109.992 179.259 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.78 -8.3 79.82 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 -179.745 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 118.53 12.94 7.06 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 110.616 -0.993 . . . . 0.0 110.616 -179.29 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 80.7 p -82.65 150.63 63.23 Favored Pre-proline 0 CA--C 1.534 0.341 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -67.96 -84.24 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 121.949 1.766 . . . . 0.0 112.839 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -71.97 -22.68 61.41 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.68 -0.236 . . . . 0.0 111.408 -178.804 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.56 19.12 71.89 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.119 -0.793 . . . . 0.0 111.119 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -63.83 126.37 27.41 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 27.5 m -140.96 161.97 22.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.096 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.413 ' N ' ' OD1' ' A' ' 15' ' ' ASP . 37.5 p-10 -133.36 63.73 66.43 Favored Pre-proline 0 N--CA 1.463 0.181 0 C-N-CA 120.96 -0.296 . . . . 0.0 110.979 179.738 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -84.12 31.67 0.51 Allowed 'Trans proline' 0 C--N 1.307 -1.62 0 C-N-CA 122.981 2.454 . . . . 0.0 112.242 179.631 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.417 ' O ' ' N ' ' A' ' 21' ' ' TYR . 80.8 m-85 -61.86 -41.66 98.11 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 120.654 -0.419 . . . . 0.0 110.674 -179.449 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -60.55 -47.52 85.82 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.14 -0.624 . . . . 0.0 110.068 -179.183 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 86.9 t80 -65.92 -45.75 80.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.347 0.594 . . . . 0.0 110.07 178.755 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' A' ' 1' ' ' LEU . 97.8 m-20 -71.28 -14.28 62.17 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.191 -0.913 . . . . 0.0 111.441 -179.139 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.616 ' O ' HG12 ' A' ' 24' ' ' VAL . 94.4 t80 -62.69 -45.49 92.55 Favored 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 120.496 -0.482 . . . . 0.0 110.322 -179.755 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -60.08 -39.61 86.68 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.853 -179.207 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.528 ' O ' ' N ' ' A' ' 27' ' ' GLY . 68.3 p -66.09 -31.15 71.85 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 121.0 -0.28 . . . . 0.0 110.855 -179.793 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.616 HG12 ' O ' ' A' ' 21' ' ' TYR . 1.1 p -44.13 -24.1 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.822 -178.623 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 61.3 ttp180 -72.84 -54.41 8.86 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.019 179.023 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -92.94 -2.85 55.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.485 -0.78 . . . . 0.0 112.02 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.59 -43.16 99.65 Favored Glycine 0 CA--C 1.526 0.775 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.335 -178.724 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.89 -44.28 98.05 Favored Glycine 0 CA--C 1.526 0.731 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.012 -179.009 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.4 mt -60.4 -47.44 86.06 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.334 -0.546 . . . . 0.0 110.767 -178.523 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 5.0 mm -62.13 -43.9 98.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.739 0.304 . . . . 0.0 111.185 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.1 t80 -60.77 -46.58 89.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.255 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.66 -42.5 88.58 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.586 -178.213 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.72 -40.47 98.11 Favored Glycine 0 CA--C 1.524 0.642 0 C-N-CA 120.271 -0.966 . . . . 0.0 110.688 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 96.7 mt -67.23 -38.02 84.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.288 0.566 . . . . 0.0 109.811 178.691 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.6 -47.71 85.02 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.013 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 92.3 t80 -59.23 -47.2 86.22 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 115.903 -0.589 . . . . 0.0 112.146 -178.404 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 89.9 mt -57.8 -43.11 83.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 C-N-CA 120.868 -0.333 . . . . 0.0 110.437 -178.721 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 56.3 t -57.04 -40.06 70.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.451 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.83 -36.89 92.77 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 111.481 -0.648 . . . . 0.0 111.481 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 62.2 tp -58.25 -47.27 84.09 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.307 -0.557 . . . . 0.0 109.503 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 92.8 mt -57.49 -33.61 68.19 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.37 -178.711 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 41.2 mm -60.34 -42.86 92.28 Favored 'Isoleucine or valine' 0 C--O 1.236 0.387 0 CA-C-O 120.874 0.369 . . . . 0.0 110.237 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 92.1 mt -59.46 -39.39 83.47 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.115 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 59.2 tp -59.05 -35.28 73.06 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.53 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 46.7 t -59.15 -40.61 86.07 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 110.135 -0.321 . . . . 0.0 110.135 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.02 -39.17 81.11 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 120.354 -0.538 . . . . 0.0 110.186 179.61 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 80.3 ttt180 -58.8 -32.23 69.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.027 -179.646 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 93.9 t80 -59.17 -48.69 80.67 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 120.369 -0.532 . . . . 0.0 109.922 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.41 ' O ' ' CB ' ' A' ' 50' ' ' SER . 0.9 OUTLIER -65.19 -55.25 19.61 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.058 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.41 ' CB ' ' O ' ' A' ' 49' ' ' ARG . 0.7 OUTLIER 76.27 175.86 0.21 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.002 179.427 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 112.74 126.03 4.52 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.44 1.87 74.16 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -179.155 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 34.1 m120 -101.22 10.61 40.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.931 0.396 . . . . 0.0 110.04 179.577 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.435 ' O ' ' O ' ' A' ' 57' ' ' ARG . 73.8 mmtt -96.73 -0.67 47.88 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.335 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -62.26 -43.65 98.34 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.896 0.379 . . . . 0.0 110.269 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -73.6 -31.76 63.74 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.867 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.435 ' O ' ' O ' ' A' ' 54' ' ' LYS . 43.7 ttm180 -138.66 136.56 36.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.102 -179.532 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -66.72 152.6 45.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.241 179.662 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 21.4 tt -61.7 147.52 10.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.676 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -104.14 130.83 51.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.434 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 60.9 mp0 -63.22 -40.22 96.84 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.237 179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 60.2 p30 -158.66 170.46 22.12 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.041 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.6 tp10 -134.67 75.87 61.8 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.448 179.838 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo . . . . . 0 C--N 1.307 -1.613 0 C-N-CA 122.724 2.283 . . . . 0.0 112.184 -179.979 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 61.0 tp . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.52 ' O ' ' CD1' ' A' ' 4' ' ' TRP . 37.4 t70 -86.85 84.02 7.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.632 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.433 ' NE ' ' H ' ' A' ' 3' ' ' ARG . 0.0 OUTLIER 40.47 44.35 1.69 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.867 179.174 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 4' ' ' TRP . . . . . 0.52 ' CD1' ' O ' ' A' ' 2' ' ' ASP . 93.5 m95 -104.84 10.45 34.44 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.482 -0.327 . . . . 0.0 110.578 179.57 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 50.5 p90 -145.4 151.01 37.57 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.983 179.557 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 60.1 tp -65.05 -44.23 89.69 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-O 121.083 0.468 . . . . 0.0 110.129 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 71.43 29.32 68.29 Favored Glycine 0 CA--C 1.524 0.594 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.804 179.472 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -96.69 118.86 6.15 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 110.389 -1.084 . . . . 0.0 110.389 179.434 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 92.9 p -83.22 151.1 62.37 Favored Pre-proline 0 CA--C 1.535 0.382 0 C-N-CA 121.328 -0.149 . . . . 0.0 110.884 -178.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -63.96 -153.36 0.02 OUTLIER 'Trans proline' 0 N--CA 1.497 1.69 0 C-N-CA 122.282 1.988 . . . . 0.0 111.654 179.06 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -71.37 -22.15 61.93 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.83 0.348 . . . . 0.0 110.152 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.64 2.45 90.64 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.718 -0.553 . . . . 0.0 111.718 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.437 ' O ' ' OD1' ' A' ' 13' ' ' ASP . 52.6 t0 -117.42 19.54 13.98 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 120.904 0.383 . . . . 0.0 110.271 179.835 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 35.3 m -143.16 149.01 18.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.241 179.043 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -129.59 67.02 78.48 Favored Pre-proline 0 C--N 1.331 -0.202 0 CA-C-N 116.614 -0.266 . . . . 0.0 110.517 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -72.16 -14.57 28.77 Favored 'Trans proline' 0 N--CA 1.493 1.461 0 C-N-CA 122.686 2.257 . . . . 0.0 112.644 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.494 ' O ' ' N ' ' A' ' 21' ' ' TYR . 82.7 m-85 -59.94 -40.58 89.43 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.103 -179.042 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 44.7 m-85 -60.37 -42.11 95.14 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.571 -179.489 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -67.47 -41.03 85.27 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 178.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 20' ' ' ASP . 57.9 t0 -72.73 -25.83 61.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.457 179.123 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.642 ' O ' HG12 ' A' ' 24' ' ' VAL . 91.2 t80 -62.04 -43.48 98.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.093 -178.816 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -58.19 -39.62 79.42 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.82 -178.792 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.525 ' O ' ' N ' ' A' ' 27' ' ' GLY . 66.6 p -66.11 -26.93 67.69 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.718 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.642 HG12 ' O ' ' A' ' 21' ' ' TYR . 2.1 p -44.52 -23.51 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.85 -178.5 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 59.0 ttt85 -72.51 -54.83 8.13 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 119.884 -0.726 . . . . 0.0 110.06 179.033 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -93.09 -2.65 55.31 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.873 -179.785 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.46 -43.57 99.14 Favored Glycine 0 CA--C 1.527 0.829 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.299 -178.667 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -63.1 -43.47 98.69 Favored Glycine 0 CA--C 1.527 0.84 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.163 -179.186 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 89.5 mt -60.37 -47.12 87.42 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.447 -0.501 . . . . 0.0 111.386 -177.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 40.1 pt -69.34 -37.56 75.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 120.487 -0.485 . . . . 0.0 111.382 -179.257 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.3 t80 -61.94 -47.64 83.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.961 0.41 . . . . 0.0 110.889 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.74 -42.14 92.5 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.76 -178.468 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.17 -40.2 96.92 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.731 -0.948 . . . . 0.0 110.731 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.5 tp -67.28 -39.5 86.04 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.423 0.63 . . . . 0.0 109.61 178.338 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -59.5 -48.79 80.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.435 -179.157 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -60.77 -40.62 93.2 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 111.962 0.356 . . . . 0.0 111.962 -178.432 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.4 mt -58.92 -44.73 91.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 C-N-CA 120.404 -0.518 . . . . 0.0 110.53 -179.025 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 56.3 t -57.88 -39.73 72.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.731 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.83 -37.23 93.33 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.605 -0.598 . . . . 0.0 111.605 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.0 tp -58.89 -47.38 85.17 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.689 -0.405 . . . . 0.0 110.118 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.5 mt -58.39 -34.87 71.21 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.397 -178.385 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 86.8 mt -60.21 -43.52 93.43 Favored 'Isoleucine or valine' 0 C--O 1.238 0.489 0 CA-C-O 120.797 0.332 . . . . 0.0 110.963 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 92.1 mt -59.66 -39.1 83.3 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.924 -0.31 . . . . 0.0 110.483 -179.537 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 59.0 tp -59.92 -35.69 75.42 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.88 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 75.5 m -59.58 -39.22 83.4 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.347 -179.619 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.526 ' NH1' ' OG ' ' A' ' 50' ' ' SER . 0.3 OUTLIER -61.88 -38.14 87.2 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.23 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.68 HH12 ' N ' ' A' ' 52' ' ' GLY . 0.0 OUTLIER -57.29 -27.58 62.27 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.389 -179.776 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 93.7 t80 -59.85 -48.05 83.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.047 0.451 . . . . 0.0 110.173 179.796 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -61.76 -52.43 64.25 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 119.865 -0.734 . . . . 0.0 109.25 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.526 ' OG ' ' NH1' ' A' ' 46' ' ' ARG . 74.0 m -70.48 140.54 51.93 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.923 -179.847 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -64.0 -43.16 97.78 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 179.183 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.68 ' N ' HH12 ' A' ' 47' ' ' ARG . . . 73.19 54.36 7.01 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 -179.486 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 54.2 p30 -97.82 17.73 17.39 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.68 0.276 . . . . 0.0 111.005 -179.684 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 25.5 mmtp -60.81 -39.87 90.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.454 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -61.37 -42.0 97.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.111 0.481 . . . . 0.0 109.712 179.363 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -68.03 -36.15 79.44 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.847 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 93.9 mtm-85 57.5 36.72 27.26 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.611 -179.42 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 64.4 tt0 -135.4 131.99 36.97 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.227 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.422 ' O ' ' OD1' ' A' ' 60' ' ' ASN . 45.5 pt -130.17 148.24 33.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.857 179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' A' ' 59' ' ' ILE . 83.7 m-20 -146.85 143.44 28.58 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.962 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 49.76 42.74 24.14 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.303 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 60.1 p30 -155.68 170.86 21.05 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.802 179.64 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -142.33 74.68 20.28 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.663 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_exo . . . . . 0 C--N 1.306 -1.664 0 C-N-CA 122.704 2.269 . . . . 0.0 112.122 -179.996 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 81.0 mt . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.425 ' OD1' ' O ' ' A' ' 2' ' ' ASP . 53.6 p-10 -126.05 82.46 2.07 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.565 179.811 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 90.4 mtm180 -103.68 -2.24 26.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.134 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' TRP . . . . . 0.522 ' O ' ' CE3' ' A' ' 4' ' ' TRP . 77.0 t90 -120.64 2.73 10.67 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.489 -179.749 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.416 ' O ' ' C ' ' A' ' 6' ' ' LEU . 92.1 m-85 -123.42 140.29 53.16 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.467 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.416 ' C ' ' O ' ' A' ' 5' ' ' TYR . 90.3 mt -34.27 143.55 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.924 -179.124 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 93.18 -11.79 71.13 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.164 -1.174 . . . . 0.0 110.164 -179.005 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -83.85 174.55 51.45 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 179.666 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 68.9 m -84.27 148.86 53.99 Favored Pre-proline 0 CA--C 1.532 0.262 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.565 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -68.62 -85.02 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.429 0 C-N-CA 121.886 1.724 . . . . 0.0 112.113 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -93.97 -11.72 30.26 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.735 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.16 16.49 80.66 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 111.284 -0.726 . . . . 0.0 111.284 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.429 ' O ' ' OD1' ' A' ' 13' ' ' ASP . 67.6 t0 -160.24 51.5 0.31 Allowed 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.832 -0.347 . . . . 0.0 110.858 179.729 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 26.8 m -146.99 153.39 12.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.496 179.001 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.412 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 37.5 p-10 -132.89 65.57 74.42 Favored Pre-proline 0 C--N 1.331 -0.222 0 CA-C-O 120.772 0.32 . . . . 0.0 110.569 179.734 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -80.12 6.0 5.61 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 C-N-CA 123.229 2.619 . . . . 0.0 112.701 -179.654 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 82.3 m-85 -60.98 -42.45 98.37 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.4 -0.52 . . . . 0.0 111.339 -178.639 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 31.0 p90 -69.47 -27.38 65.17 Favored 'General case' 0 C--N 1.331 -0.206 0 C-N-CA 120.618 -0.433 . . . . 0.0 111.023 -179.64 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 93.8 t80 -61.01 -48.76 80.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.108 0.48 . . . . 0.0 109.869 179.501 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 -67.87 -28.82 67.86 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.755 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.704 ' O ' HG12 ' A' ' 24' ' ' VAL . 89.8 t80 -62.61 -44.29 96.66 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.694 -179.537 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.406 ' O ' ' CG ' ' A' ' 25' ' ' ARG . 98.4 mt-10 -58.33 -38.81 77.89 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -179.091 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.494 ' O ' ' N ' ' A' ' 27' ' ' GLY . 97.3 m -63.6 -37.03 85.79 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.866 0.365 . . . . 0.0 111.13 179.696 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.704 HG12 ' O ' ' A' ' 21' ' ' TYR . 2.7 p -38.27 -23.73 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.51 0 N-CA-C 113.471 0.915 . . . . 0.0 113.471 -176.714 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.451 ' N ' ' O ' ' A' ' 23' ' ' THR . 4.1 ptm180 -80.04 -54.26 5.95 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 119.576 -0.85 . . . . 0.0 110.712 178.781 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ASN . . . . . 0.445 ' OD1' ' NE ' ' A' ' 25' ' ' ARG . 34.3 m120 -91.44 -3.09 57.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.1 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -60.93 -42.0 99.53 Favored Glycine 0 CA--C 1.525 0.704 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.872 -179.243 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.28 -42.15 99.7 Favored Glycine 0 CA--C 1.525 0.668 0 C-N-CA 120.85 -0.69 . . . . 0.0 111.405 -179.536 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.4 mt -59.69 -46.81 87.93 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.367 -178.808 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 90.9 mt -60.82 -43.67 95.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.787 0.327 . . . . 0.0 110.917 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.0 t80 -60.29 -46.85 88.42 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.277 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.14 -42.6 86.21 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.875 -0.33 . . . . 0.0 111.417 -177.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.23 -40.08 96.84 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 60.3 tp -64.89 -39.85 94.19 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.214 0.53 . . . . 0.0 109.877 178.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.409 ' O ' HG22 ' A' ' 38' ' ' VAL . . . -60.94 -46.0 92.47 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.281 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -59.84 -48.62 80.96 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.354 -178.25 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 92.1 mt -59.19 -48.75 85.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 N-CA-C 112.185 0.439 . . . . 0.0 112.185 -177.562 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.409 HG22 ' O ' ' A' ' 35' ' ' ALA . 29.3 m -56.67 -35.45 45.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.485 -179.002 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -61.8 -38.51 96.08 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 111.815 -0.514 . . . . 0.0 111.815 -179.727 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.4 tp -59.0 -47.11 86.37 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.319 -0.552 . . . . 0.0 109.696 -179.521 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.9 mt -57.26 -34.13 68.32 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.278 -178.433 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 88.5 mt -60.74 -42.98 94.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.885 0.374 . . . . 0.0 110.822 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 91.6 mt -59.0 -39.49 81.99 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.141 -179.258 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 94.7 mt -60.71 -33.16 72.47 Favored 'General case' 0 C--O 1.238 0.455 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.975 -179.57 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 70.3 m -58.44 -40.51 82.76 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.517 ' HE ' ' N ' ' A' ' 51' ' ' GLY . 3.7 tmt_? -61.06 -37.43 82.62 Favored 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 120.677 -0.409 . . . . 0.0 110.522 178.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.26 -29.35 57.93 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.868 -178.509 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 34.7 m-85 -59.28 -39.53 83.24 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 119.693 -0.803 . . . . 0.0 109.926 179.449 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.487 ' O ' ' CB ' ' A' ' 50' ' ' SER . 71.7 mtp85 -93.11 -52.26 4.65 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 178.1 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.487 ' CB ' ' O ' ' A' ' 49' ' ' ARG . 1.0 OUTLIER 85.72 40.55 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.384 -179.539 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.517 ' N ' ' HE ' ' A' ' 46' ' ' ARG . . . 82.43 0.21 89.66 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 55.92 -129.01 46.7 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 179.902 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -75.84 149.93 37.75 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 110.151 -0.314 . . . . 0.0 110.151 179.467 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -140.35 133.98 30.25 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.62 179.35 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 26.1 pttm -113.52 -34.26 5.62 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.324 179.513 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.405 ' O ' ' C ' ' A' ' 57' ' ' ARG . 83.6 mtp180 -68.48 -37.87 80.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.521 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.405 ' C ' ' O ' ' A' ' 56' ' ' ARG . 81.1 mtp180 35.02 -130.35 0.08 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.329 179.799 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -136.36 129.58 31.52 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.57 179.185 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 44.9 pt -130.92 -32.04 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.926 0.393 . . . . 0.0 110.66 179.318 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.789 ' C ' HD21 ' A' ' 60' ' ' ASN . 0.1 OUTLIER -168.19 159.55 10.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.329 179.676 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 53.0 tp10 -63.21 -45.2 92.77 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.398 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 27.4 t0 -166.79 166.65 15.6 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.731 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -129.99 70.85 82.25 Favored Pre-proline 0 C--N 1.332 -0.164 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.627 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo . . . . . 0 C--N 1.308 -1.603 0 C-N-CA 122.665 2.243 . . . . 0.0 112.1 -179.88 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 80.7 mt . . . . . 0 N--CA 1.489 1.477 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -118.06 158.12 25.59 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.135 -0.484 . . . . 0.0 109.968 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -128.88 9.3 5.81 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.873 0.368 . . . . 0.0 110.073 179.278 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' TRP . . . . . . . . . . . . . 23.1 m-90 -105.74 13.55 29.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.649 -179.615 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.533 ' CD2' ' O ' ' A' ' 6' ' ' LEU . 38.9 p90 -91.32 164.31 13.9 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.967 0.413 . . . . 0.0 110.924 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.533 ' O ' ' CD2' ' A' ' 5' ' ' TYR . 90.5 mt -47.5 159.88 0.13 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.835 -178.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 84.69 2.45 88.71 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -88.07 131.86 10.88 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 81.0 p -105.81 150.43 39.16 Favored Pre-proline 0 CA--C 1.535 0.377 0 N-CA-C 110.504 -0.184 . . . . 0.0 110.504 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -71.39 84.35 0.95 Allowed 'Trans proline' 0 N--CA 1.494 1.552 0 C-N-CA 122.223 1.948 . . . . 0.0 112.135 179.67 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -73.86 -9.5 58.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.765 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.8 8.41 58.18 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.771 -0.931 . . . . 0.0 110.771 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -64.74 -66.02 0.6 Allowed 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.044 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.8 m -143.81 148.94 18.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.766 178.525 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.406 ' N ' ' OD1' ' A' ' 15' ' ' ASP . 40.9 p-10 -129.93 64.67 73.0 Favored Pre-proline 0 C--N 1.332 -0.164 0 CA-C-O 120.652 0.263 . . . . 0.0 110.636 -179.631 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -74.25 -6.88 19.06 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.847 2.364 . . . . 0.0 112.427 -179.743 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.448 ' O ' ' N ' ' A' ' 21' ' ' TYR . 81.6 m-85 -60.04 -40.46 89.46 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.09 -179.204 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -60.13 -45.65 92.3 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.165 -0.614 . . . . 0.0 109.939 -179.502 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -61.92 -46.62 88.54 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.275 0.559 . . . . 0.0 109.952 178.778 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.402 ' O ' ' OG1' ' A' ' 23' ' ' THR . 97.8 m-20 -75.75 -11.24 59.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.356 -0.838 . . . . 0.0 111.45 -179.697 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.645 ' O ' HG12 ' A' ' 24' ' ' VAL . 88.2 t80 -63.26 -44.04 96.28 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.43 -179.712 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 mm-40 -58.82 -38.5 78.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.803 -178.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.524 ' O ' ' N ' ' A' ' 27' ' ' GLY . 75.6 p -65.45 -26.64 68.04 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.781 -0.368 . . . . 0.0 110.577 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.645 HG12 ' O ' ' A' ' 21' ' ' TYR . 3.0 p -43.83 -23.36 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.717 -178.617 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 90.7 mtm180 -73.13 -55.35 6.6 Favored 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 119.716 -0.794 . . . . 0.0 110.109 178.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -93.42 -1.43 55.8 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.439 -0.8 . . . . 0.0 112.081 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.06 -43.32 99.58 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.529 -178.518 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.88 -43.9 98.58 Favored Glycine 0 CA--C 1.526 0.773 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.829 -179.134 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.6 tp -59.52 -48.38 81.89 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.642 -178.536 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 92.4 mt -61.66 -44.41 98.64 Favored 'Isoleucine or valine' 0 C--O 1.236 0.348 0 CA-C-O 120.894 0.378 . . . . 0.0 111.526 -179.443 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.6 t80 -60.72 -46.58 89.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.152 -179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.81 -41.79 87.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.482 -178.119 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.59 -41.02 98.66 Favored Glycine 0 CA--C 1.525 0.691 0 C-N-CA 120.427 -0.892 . . . . 0.0 111.002 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.404 HD23 ' HA ' ' A' ' 34' ' ' LEU . 95.0 mt -67.16 -37.91 84.57 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.18 0.514 . . . . 0.0 110.114 178.819 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.51 -47.65 85.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.162 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 93.1 t80 -59.4 -46.81 87.63 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 116.083 -0.508 . . . . 0.0 112.227 -178.426 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.7 mm -57.57 -44.35 84.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.705 -178.522 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.1 t -57.2 -39.79 69.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.701 -179.318 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.67 -36.91 92.6 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 -179.794 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.4 tp -58.9 -48.23 82.16 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.007 -0.677 . . . . 0.0 109.891 -179.573 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.454 ' N ' HD12 ' A' ' 41' ' ' LEU . 10.9 mp -56.19 -33.1 64.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.437 -178.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 4.7 mm -60.77 -43.81 96.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.455 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.414 HD13 ' HA ' ' A' ' 43' ' ' LEU . 4.2 mm? -57.12 -40.78 77.75 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.282 -0.567 . . . . 0.0 110.243 -179.738 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.46 HD12 ' N ' ' A' ' 44' ' ' LEU . 10.3 mp -60.96 -30.27 70.15 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.057 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 39.9 t -59.36 -41.44 89.25 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 -179.468 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.5 ttt-85 -62.34 -39.86 94.48 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.33 -0.548 . . . . 0.0 110.488 179.233 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.436 ' O ' ' OG ' ' A' ' 50' ' ' SER . 0.0 OUTLIER -56.8 -30.98 64.22 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.389 -178.761 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -64.24 -40.48 96.1 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.162 -0.615 . . . . 0.0 111.263 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -62.59 -53.36 55.81 Favored 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 119.328 -0.949 . . . . 0.0 108.976 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.53 ' O ' ' NH1' ' A' ' 57' ' ' ARG . 61.6 m 53.56 27.0 6.13 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.834 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 41.99 87.29 0.01 OUTLIER Glycine 0 CA--C 1.527 0.821 0 N-CA-C 110.931 -0.867 . . . . 0.0 110.931 179.807 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -174.84 171.39 44.55 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 179.79 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -63.75 -42.06 97.91 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.859 0.362 . . . . 0.0 110.62 179.534 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -129.11 150.4 50.52 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.424 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 62.3 mttp -59.88 -43.1 94.93 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.606 -178.829 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.519 ' O ' ' CB ' ' A' ' 57' ' ' ARG . 83.8 mtp180 -70.06 -20.06 63.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.631 -0.259 . . . . 0.0 110.88 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.53 ' NH1' ' O ' ' A' ' 50' ' ' SER . 12.1 tpp180 90.29 -138.76 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.369 0 O-C-N 123.699 0.624 . . . . 0.0 110.901 -179.596 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.416 ' O ' ' OD2' ' A' ' 62' ' ' ASP . 78.7 mt-30 -136.88 137.14 39.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.17 179.022 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.6 pt -62.04 -24.82 35.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.519 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 33.5 m120 -69.88 157.32 37.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.513 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 77.4 mm-40 37.35 -122.18 0.2 Allowed 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.181 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.416 ' OD2' ' O ' ' A' ' 58' ' ' GLN . 65.5 m-20 42.64 -128.97 0.68 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.453 -179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -70.51 149.16 95.56 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.276 179.855 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo . . . . . 0 N--CA 1.492 1.419 0 C-N-CA 122.134 1.89 . . . . 0.0 112.071 179.877 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' LEU . . . . . 0.529 ' O ' ' NE1' ' A' ' 4' ' ' TRP . 60.7 tp . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 53.1 p-10 -81.46 -176.92 6.28 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.835 -179.779 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 66.8 ttp85 60.83 65.27 1.04 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.677 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' TRP . . . . . 0.529 ' NE1' ' O ' ' A' ' 1' ' ' LEU . 98.3 m95 -88.03 -16.32 33.98 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.1 179.578 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.535 ' CD2' ' O ' ' A' ' 6' ' ' LEU . 81.0 t80 -143.64 140.61 30.19 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.197 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.535 ' O ' ' CD2' ' A' ' 5' ' ' TYR . 90.4 mt -69.26 154.99 41.15 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 -179.915 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 85.19 34.18 15.33 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 -178.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -85.11 116.32 4.29 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 179.604 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 69.7 m -128.58 152.17 78.07 Favored Pre-proline 0 CA--C 1.533 0.302 0 C-N-CA 121.362 -0.135 . . . . 0.0 110.944 -179.17 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_exo -51.33 143.34 34.51 Favored 'Trans proline' 0 N--CA 1.497 1.726 0 C-N-CA 121.963 1.776 . . . . 0.0 112.057 179.388 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -90.25 0.82 57.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.308 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 81.37 1.28 90.0 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 56.3 t0 44.0 67.72 0.63 Allowed 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.812 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 11.8 p -149.72 147.28 16.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.054 -179.64 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.9 m-20 -118.03 84.72 22.1 Favored Pre-proline 0 CA--C 1.533 0.292 0 CA-C-N 115.923 -0.58 . . . . 0.0 109.815 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -83.27 34.88 0.55 Allowed 'Trans proline' 0 N--CA 1.49 1.312 0 C-N-CA 122.889 2.392 . . . . 0.0 113.412 -178.909 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 -59.65 -16.0 23.19 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.711 -0.395 . . . . 0.0 110.224 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 92.5 t80 -59.22 -43.8 92.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.792 179.504 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 90.6 t80 -57.72 -37.72 74.03 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.029 0.442 . . . . 0.0 109.935 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.738 ' O ' HG23 ' A' ' 24' ' ' VAL . 97.8 m-20 -70.72 -7.91 48.26 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.535 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 78.6 t80 -61.47 -43.28 99.15 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.51 -178.762 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 53.1 tp10 -58.91 -46.5 87.76 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.231 -0.588 . . . . 0.0 109.515 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.518 ' O ' ' N ' ' A' ' 27' ' ' GLY . 97.8 m -64.52 -44.46 90.8 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 121.019 0.437 . . . . 0.0 110.473 179.198 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.738 HG23 ' O ' ' A' ' 20' ' ' ASP . 45.4 t -44.86 -24.8 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.919 -178.212 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -72.95 -54.23 9.2 Favored 'General case' 0 C--N 1.323 -0.584 0 C-N-CA 119.472 -0.891 . . . . 0.0 109.855 178.482 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -91.99 -1.14 57.41 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.336 -179.094 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.41 -41.86 99.63 Favored Glycine 0 CA--C 1.528 0.872 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.353 -178.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.71 -44.83 97.38 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.926 -179.161 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.7 tp -59.77 -47.92 83.75 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.865 -178.358 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.1 mt -62.11 -43.6 97.96 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 CA-C-O 120.904 0.383 . . . . 0.0 111.458 -179.523 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 91.6 t80 -60.62 -46.14 91.41 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.272 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.77 -42.36 88.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.341 -0.391 . . . . 0.0 111.622 -178.209 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.23 -40.13 96.92 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.6 tp -67.7 -39.87 84.36 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-O 121.422 0.63 . . . . 0.0 109.918 178.526 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -59.56 -49.02 79.38 Favored 'General case' 0 C--O 1.225 -0.236 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.581 -178.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -60.78 -40.48 92.72 Favored 'General case' 0 C--O 1.236 0.351 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -178.567 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.3 mt -58.55 -44.76 90.01 Favored 'Isoleucine or valine' 0 C--O 1.235 0.326 0 C-N-CA 120.256 -0.578 . . . . 0.0 110.549 -179.065 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 53.7 t -58.66 -40.15 78.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.794 -179.596 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.28 -36.05 89.85 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 111.773 -0.531 . . . . 0.0 111.773 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 40' ' ' LEU . 92.6 mt -60.28 -43.23 96.42 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 119.934 -0.706 . . . . 0.0 109.515 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 59.4 tp -56.69 -37.25 70.62 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.905 -179.193 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 4.7 mm -59.52 -42.14 87.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.89 0.376 . . . . 0.0 110.614 -179.495 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 91.0 mt -58.64 -39.99 82.11 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.303 -0.559 . . . . 0.0 110.416 -179.093 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.407 HD12 ' N ' ' A' ' 44' ' ' LEU . 10.8 mp -60.96 -30.11 70.05 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 120.709 0.29 . . . . 0.0 111.12 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 42.6 t -58.74 -42.34 88.56 Favored 'General case' 0 CA--C 1.518 -0.266 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 179.623 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 15.8 tpt180 -61.0 -36.91 80.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.769 178.707 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.445 ' O ' ' O ' ' A' ' 50' ' ' SER . 12.5 ttp180 -55.25 -26.9 42.72 Favored 'General case' 0 C--O 1.231 0.127 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.514 -178.425 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -60.18 -37.9 81.6 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 119.905 -0.718 . . . . 0.0 110.358 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 84.9 mtp180 -89.07 -54.96 3.88 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 119.919 -0.712 . . . . 0.0 110.282 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.445 ' O ' ' O ' ' A' ' 47' ' ' ARG . 90.3 p -95.4 159.25 15.09 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.782 -179.759 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 70.07 22.56 77.28 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.431 ' O ' ' OD1' ' A' ' 53' ' ' ASN . . . -59.18 132.78 52.4 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.431 ' OD1' ' O ' ' A' ' 52' ' ' GLY . 82.9 m-20 -147.34 137.23 23.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.648 0.261 . . . . 0.0 110.66 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 56.7 mtmt -141.23 58.67 1.53 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.338 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -111.87 5.7 19.11 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.604 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 5.4 tpp85 -118.75 8.38 11.82 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.847 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 96.3 mtm-85 -133.78 148.53 51.37 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.232 179.68 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 98.5 mt-30 -134.42 153.29 51.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.661 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 47.5 pt -122.84 156.54 28.29 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.813 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 32.5 m120 -115.53 153.47 31.11 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.932 -179.631 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -67.61 154.07 42.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.462 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -61.68 144.64 54.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.998 0.427 . . . . 0.0 110.697 -179.83 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -70.67 149.38 95.33 Favored Pre-proline 0 CA--C 1.532 0.272 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.259 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo . . . . . 0 N--CA 1.494 1.541 0 C-N-CA 122.077 1.851 . . . . 0.0 112.021 179.862 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' LEU . . . . . 0.444 ' H1 ' ' H ' ' A' ' 7' ' ' GLY . 1.9 mp . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 58.0 p30 -127.02 177.73 6.45 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.666 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 16.3 ttm180 39.91 -146.67 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.363 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' TRP . . . . . . . . . . . . . 86.7 t90 -85.97 -26.17 25.63 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.794 0.33 . . . . 0.0 110.831 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -79.57 143.9 34.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.623 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 89.9 mt -127.63 135.92 50.92 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.025 179.289 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.444 ' H ' ' H1 ' ' A' ' 1' ' ' LEU . . . 78.91 5.1 88.83 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.214 -0.754 . . . . 0.0 111.214 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -68.54 149.26 49.51 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 111.575 -0.61 . . . . 0.0 111.575 -179.358 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 46.4 t -86.23 133.26 41.06 Favored Pre-proline 0 CA--C 1.538 0.505 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.517 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_exo -46.91 133.37 17.8 Favored 'Trans proline' 0 N--CA 1.495 1.576 0 C-N-CA 121.133 1.222 . . . . 0.0 111.501 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -94.39 2.37 55.79 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.07 -0.513 . . . . 0.0 111.319 -179.175 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.04 20.76 75.31 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 -179.467 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 -53.4 -67.44 0.25 Allowed 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.67 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 35.6 m -142.59 145.97 22.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.998 -0.547 . . . . 0.0 109.806 178.488 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -129.67 68.2 80.2 Favored Pre-proline 0 C--N 1.331 -0.197 0 CA-C-O 120.755 0.312 . . . . 0.0 110.471 -179.841 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -74.56 -6.38 18.19 Favored 'Trans proline' 0 N--CA 1.493 1.455 0 C-N-CA 122.717 2.278 . . . . 0.0 112.373 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.451 ' O ' ' N ' ' A' ' 21' ' ' TYR . 81.9 m-85 -61.27 -40.23 93.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.148 -179.278 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 82.9 m-85 -59.83 -45.49 92.2 Favored 'General case' 0 C--N 1.331 -0.234 0 C-N-CA 120.315 -0.554 . . . . 0.0 110.277 -178.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 88.7 m-85 -69.5 -37.71 77.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.213 0.53 . . . . 0.0 109.864 178.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -75.43 -15.67 60.42 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.43 -0.804 . . . . 0.0 110.969 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.663 ' O ' HG12 ' A' ' 24' ' ' VAL . 90.5 t80 -62.5 -44.23 96.89 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.948 -179.358 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 79.2 mm-40 -57.58 -38.86 75.56 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 120.721 -0.391 . . . . 0.0 110.67 -178.469 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.533 ' O ' ' N ' ' A' ' 27' ' ' GLY . 72.3 p -67.83 -27.52 66.79 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.651 179.686 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.663 HG12 ' O ' ' A' ' 21' ' ' TYR . 2.4 p -42.5 -24.05 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.149 -0.478 . . . . 0.0 112.112 -177.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 63.2 ttm-85 -75.26 -54.64 6.76 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.273 179.04 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -93.19 -1.32 56.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.589 -0.732 . . . . 0.0 112.141 -179.485 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -62.18 -43.63 98.84 Favored Glycine 0 CA--C 1.528 0.86 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.688 -178.624 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -62.05 -45.44 96.09 Favored Glycine 0 CA--C 1.527 0.813 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.088 -179.015 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.1 mt -60.18 -46.23 90.44 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.533 -0.467 . . . . 0.0 111.281 -178.124 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.3 mt -62.08 -45.51 98.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 CA-C-O 120.815 0.341 . . . . 0.0 111.565 -179.532 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.1 t80 -61.77 -47.03 87.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.922 0.391 . . . . 0.0 111.253 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.53 -41.63 90.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.495 -178.375 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.94 -40.36 98.28 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 120.589 -0.815 . . . . 0.0 111.164 -179.609 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 98.5 mt -69.85 -39.36 76.42 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.324 0.583 . . . . 0.0 110.019 178.682 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.9 -48.0 83.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.192 -179.685 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -59.64 -46.54 88.69 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.102 -0.499 . . . . 0.0 112.297 -178.478 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 89.3 mt -58.44 -44.53 89.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 C-N-CA 121.016 -0.273 . . . . 0.0 111.283 -178.23 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.9 t -58.33 -39.57 74.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 120.818 0.342 . . . . 0.0 110.722 -179.485 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.86 -37.3 93.49 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.2 tp -58.8 -48.46 81.21 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.372 -179.321 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.481 ' N ' HD12 ' A' ' 41' ' ' LEU . 10.8 mp -57.36 -34.07 68.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.536 -178.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 39.5 mm -60.58 -43.32 94.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.391 0 CA-C-O 121.026 0.441 . . . . 0.0 110.922 -179.276 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 90.9 mt -60.51 -39.86 89.31 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.684 -0.406 . . . . 0.0 110.67 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 9.8 mp -60.59 -30.98 70.16 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.261 -179.404 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 74.2 m -63.08 -39.61 95.24 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.783 0.325 . . . . 0.0 110.463 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.2 tpm_? -61.8 -39.97 93.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.649 179.694 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.778 HH22 ' H ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -65.27 -24.15 67.23 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.811 -178.974 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 89.6 t80 -60.51 -49.86 75.88 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.053 179.636 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 42.3 mmm-85 -62.0 -51.97 65.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.609 -179.19 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.527 ' OG ' ' NH2' ' A' ' 47' ' ' ARG . 88.2 p -68.72 -21.95 64.37 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.546 -0.297 . . . . 0.0 111.278 -179.757 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.475 ' N ' ' O ' ' A' ' 47' ' ' ARG . . . 60.31 -130.46 48.83 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.498 ' O ' ' N ' ' A' ' 54' ' ' LYS . . . -44.16 145.23 1.79 Allowed Glycine 0 CA--C 1.526 0.748 0 N-CA-C 111.449 -0.661 . . . . 0.0 111.449 -178.861 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.421 ' O ' ' O ' ' A' ' 54' ' ' LYS . 8.0 p-10 -45.66 88.38 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.859 0.362 . . . . 0.0 111.437 -179.217 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.778 ' H ' HH22 ' A' ' 47' ' ' ARG . 10.6 tptp 44.86 98.32 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.923 179.477 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -62.96 -38.78 92.46 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.197 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 13.6 tpp85 -67.81 -37.07 81.51 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.845 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 55.69 -150.62 0.42 Allowed 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.703 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 72.3 tp60 -132.56 132.6 42.73 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.818 0.342 . . . . 0.0 110.268 179.823 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 20.2 tt -71.14 -35.28 57.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.505 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -99.78 153.07 19.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.876 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 58.09 62.58 2.0 Allowed 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.415 -179.707 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -63.07 145.23 55.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.168 179.534 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.432 ' OE1' ' N ' ' A' ' 63' ' ' GLU . 40.4 mp0 -70.5 149.2 95.58 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.291 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo . . . . . 0 N--CA 1.493 1.45 0 C-N-CA 122.163 1.908 . . . . 0.0 112.062 179.895 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' LEU . . . . . 0.564 ' H3 ' HD12 ' A' ' 1' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.655 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 . . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -67.8 174.01 3.95 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.22 -178.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.788 HH11 HD22 ' A' ' 6' ' ' LEU . 97.2 mtt180 62.71 171.29 0.14 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.399 -0.819 . . . . 0.0 109.68 -179.225 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' TRP . . . . . . . . . . . . . 37.6 p90 -126.13 -27.9 3.2 Favored 'General case' 0 C--O 1.232 0.154 0 CA-C-O 120.777 0.322 . . . . 0.0 110.642 179.308 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.436 ' OH ' ' O ' ' A' ' 8' ' ' GLY . 91.3 t80 -140.35 127.31 20.73 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.242 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.788 HD22 HH11 ' A' ' 3' ' ' ARG . 55.6 tp -158.32 156.09 29.96 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 109.93 -179.645 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.74 -3.47 81.28 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 179.724 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.436 ' O ' ' OH ' ' A' ' 5' ' ' TYR . . . 60.78 -125.18 37.65 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.773 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 23.2 t -126.83 79.9 71.63 Favored Pre-proline 0 C--N 1.331 -0.219 0 N-CA-C 110.432 -0.21 . . . . 0.0 110.432 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -77.25 160.19 32.84 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 C-N-CA 122.557 2.171 . . . . 0.0 112.582 -179.575 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 57.4 mtmt -77.69 -7.92 57.17 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.435 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.73 1.29 57.53 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 66.9 t0 -100.45 104.71 16.13 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 179.128 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.514 ' O ' HG13 ' A' ' 14' ' ' VAL . 11.6 p -135.25 124.73 42.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-O 120.851 0.358 . . . . 0.0 110.735 -179.494 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 42.2 p-10 -162.74 58.56 0.8 Allowed Pre-proline 0 CA--C 1.531 0.225 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.827 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.482 ' C ' ' H ' ' A' ' 18' ' ' TYR . 51.5 Cg_endo -68.77 -20.24 40.07 Favored 'Trans proline' 0 N--CA 1.496 1.653 0 C-N-CA 122.823 2.348 . . . . 0.0 112.891 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -57.48 -1.1 0.08 Allowed 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.94 -0.304 . . . . 0.0 111.701 -177.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.482 ' H ' ' C ' ' A' ' 16' ' ' PRO . 96.9 m-85 -110.05 -46.04 3.52 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.814 0.34 . . . . 0.0 110.404 178.794 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -90.26 -14.51 33.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.562 -179.521 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.758 ' O ' HG13 ' A' ' 24' ' ' VAL . 35.1 t70 -61.62 -45.5 93.79 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.891 -0.324 . . . . 0.0 111.217 -179.576 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -65.15 -40.99 95.14 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.565 -179.607 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -70.62 -50.03 41.28 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.541 -179.649 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.554 ' O ' ' N ' ' A' ' 27' ' ' GLY . 97.2 m -65.55 -50.45 65.11 Favored 'General case' 0 C--O 1.222 -0.364 0 N-CA-C 113.315 0.857 . . . . 0.0 113.315 -177.845 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.758 HG13 ' O ' ' A' ' 20' ' ' ASP . 35.5 m -46.98 -25.55 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 112.632 0.605 . . . . 0.0 112.632 -177.41 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 18.7 tpp180 -73.08 -54.95 7.24 Favored 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 119.689 -0.804 . . . . 0.0 110.244 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -91.86 -2.06 57.03 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 115.543 -0.753 . . . . 0.0 111.95 -179.089 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.554 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.45 -42.79 99.85 Favored Glycine 0 CA--C 1.526 0.751 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.576 -178.678 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.04 -45.17 97.14 Favored Glycine 0 CA--C 1.525 0.713 0 C-N-CA 120.652 -0.785 . . . . 0.0 111.879 -178.818 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.588 ' N ' HD12 ' A' ' 29' ' ' LEU . 10.2 mp -60.09 -47.96 83.71 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.755 -178.676 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.1 mt -62.37 -44.62 99.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.722 0.296 . . . . 0.0 111.624 -179.413 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -61.22 -46.97 88.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.63 0.252 . . . . 0.0 111.526 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.18 -42.6 91.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.547 -178.05 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.84 -40.81 98.77 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.811 -0.915 . . . . 0.0 110.811 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.6 tp -67.22 -41.37 85.83 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.436 0.636 . . . . 0.0 109.713 178.689 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.61 -47.84 84.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.001 -1.0 . . . . 0.0 110.224 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 92.3 t80 -59.39 -47.41 85.54 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.933 -0.576 . . . . 0.0 112.506 -178.242 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 5.4 mm -58.13 -43.34 85.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.545 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.3 t -57.76 -39.72 72.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.558 -179.36 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.412 ' HA2' HD12 ' A' ' 42' ' ' ILE . . . -61.08 -37.44 93.92 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.577 -0.609 . . . . 0.0 111.577 -179.762 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.5 tp -58.17 -46.47 85.68 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 94.7 mt -58.31 -33.89 69.99 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.714 -0.676 . . . . 0.0 111.431 -178.719 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.412 HD12 ' HA2' ' A' ' 39' ' ' GLY . 89.4 mt -60.35 -45.13 96.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 CA-C-O 120.745 0.307 . . . . 0.0 111.416 -179.208 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.472 HD22 ' N ' ' A' ' 43' ' ' LEU . 4.0 mm? -59.39 -38.95 81.83 Favored 'General case' 0 C--O 1.234 0.254 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.529 -179.83 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 59.2 tp -59.42 -35.88 74.84 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.697 -179.646 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 75.7 m -60.28 -38.34 83.29 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.667 -0.242 . . . . 0.0 110.49 -179.68 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.3 tmt_? -59.54 -44.09 93.31 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 119.999 -0.68 . . . . 0.0 110.027 179.75 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.44 -27.42 64.34 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.682 -179.554 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 93.1 t80 -61.04 -49.3 77.95 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.048 -0.661 . . . . 0.0 109.746 179.299 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.418 ' O ' ' C ' ' A' ' 50' ' ' SER . 0.0 OUTLIER -64.01 -56.65 13.55 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.398 -179.9 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.43 ' O ' ' OD1' ' A' ' 53' ' ' ASN . 39.3 m 35.1 -113.16 0.07 Allowed 'General case' 0 N--CA 1.462 0.162 0 CA-C-O 120.993 0.425 . . . . 0.0 110.968 179.811 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -55.92 146.08 32.29 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 110.44 -1.064 . . . . 0.0 110.44 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 95.93 19.72 28.14 Favored Glycine 0 CA--C 1.528 0.872 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 -179.269 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.43 ' OD1' ' O ' ' A' ' 50' ' ' SER . 55.1 p30 -156.48 174.86 14.81 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.674 0.273 . . . . 0.0 110.556 179.29 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 73.3 mmtt 52.49 55.43 9.11 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.244 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -60.56 -40.07 90.27 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.553 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.517 ' NH1' ' O ' ' A' ' 64' ' ' PRO . 99.5 mtt180 -68.32 -37.86 81.01 Favored 'General case' 0 C--N 1.331 -0.216 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.412 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 28.0 ttm105 58.89 33.26 22.93 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.024 179.336 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -106.23 148.6 27.74 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.913 0.387 . . . . 0.0 110.449 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.2 pt -94.52 5.8 7.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.911 -179.81 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 64.6 t30 -82.84 112.39 19.61 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.472 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 80.7 mm-40 -89.13 -4.95 58.13 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.616 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -60.82 -43.03 98.75 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.635 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -130.94 79.69 71.03 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.677 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' PRO . . . . . 0.517 ' O ' ' NH1' ' A' ' 56' ' ' ARG . 37.3 Cg_exo . . . . . 0 C--N 1.308 -1.561 0 C-N-CA 122.677 2.251 . . . . 0.0 112.08 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' LEU . . . . . 0.526 ' O ' ' NH1' ' A' ' 3' ' ' ARG . 0.2 OUTLIER . . . . . 0 N--CA 1.489 1.512 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 . . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -69.22 147.3 51.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.674 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.526 ' NH1' ' O ' ' A' ' 1' ' ' LEU . 7.5 ptp85 -164.67 69.81 0.17 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.755 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' TRP . . . . . . . . . . . . . 5.1 p90 -116.06 -5.06 11.94 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.509 179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 54.6 p90 -76.85 174.06 10.98 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.958 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 8.5 mp -38.48 143.67 0.13 Allowed 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.785 -179.393 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.81 -9.47 77.62 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -178.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 57.35 -118.32 12.17 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 179.532 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 55.5 m -123.54 79.56 54.77 Favored Pre-proline 0 CA--C 1.532 0.28 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -74.7 160.93 40.34 Favored 'Trans proline' 0 N--CA 1.495 1.567 0 C-N-CA 122.355 2.036 . . . . 0.0 112.977 -178.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -94.07 -23.19 18.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.555 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.49 9.44 77.97 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 111.106 -0.798 . . . . 0.0 111.106 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 57.7 p30 -142.83 32.76 1.4 Allowed 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.081 -179.537 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.55 HG22 ' HD3' ' A' ' 16' ' ' PRO . 10.7 p -140.73 137.75 35.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.017 0.437 . . . . 0.0 110.756 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 33.0 t70 -131.42 76.52 75.41 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.889 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.55 ' HD3' HG22 ' A' ' 14' ' ' VAL . 73.0 Cg_endo -77.0 -8.38 17.71 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.643 2.228 . . . . 0.0 113.094 -178.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -61.74 -41.46 97.69 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.687 -179.58 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -60.11 -48.83 80.07 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.546 -179.222 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 85.6 m-85 -69.74 -35.32 74.87 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.882 0.373 . . . . 0.0 110.57 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.695 ' O ' HG23 ' A' ' 24' ' ' VAL . 97.4 m-20 -77.43 -8.37 57.63 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.87 -179.836 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -62.06 -45.28 94.23 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.837 -0.345 . . . . 0.0 110.169 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -59.89 -40.91 90.36 Favored 'General case' 0 C--N 1.324 -0.521 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.238 -179.462 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.538 ' O ' ' N ' ' A' ' 27' ' ' GLY . 73.6 p -70.97 -39.38 72.57 Favored 'General case' 0 C--O 1.224 -0.288 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.747 179.69 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.695 HG23 ' O ' ' A' ' 20' ' ' ASP . 38.4 t -45.16 -24.36 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.75 -178.619 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 62.8 ttm-85 -71.82 -54.04 11.4 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 119.562 -0.855 . . . . 0.0 109.705 178.273 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 33.8 m120 -92.58 -1.54 56.83 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.366 -0.834 . . . . 0.0 112.083 -179.284 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.538 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.42 -42.28 99.73 Favored Glycine 0 CA--C 1.528 0.878 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.289 -178.886 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.83 -43.91 98.58 Favored Glycine 0 CA--C 1.526 0.76 0 C-N-CA 120.747 -0.74 . . . . 0.0 111.709 -179.195 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.8 tp -59.5 -47.9 83.74 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.622 -178.464 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.5 mt -61.85 -44.06 98.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 120.94 0.4 . . . . 0.0 111.59 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 91.8 t80 -60.65 -46.3 90.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.221 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.88 -41.73 87.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.46 -178.202 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.61 -40.49 97.98 Favored Glycine 0 CA--C 1.525 0.684 0 C-N-CA 120.434 -0.889 . . . . 0.0 111.043 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.2 tp -67.53 -40.69 85.07 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.396 0.617 . . . . 0.0 109.776 178.738 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.03 -47.49 85.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.179 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 93.3 t80 -58.97 -46.73 87.38 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -178.124 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 91.0 mt -58.24 -43.68 86.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.96 -178.423 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.6 t -58.38 -40.73 79.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.77 -179.322 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.58 -36.6 91.81 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 111.609 -0.597 . . . . 0.0 111.609 -179.53 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.3 tp -58.79 -45.81 89.0 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 91.5 mt -57.66 -35.81 71.05 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.277 -178.454 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 85.8 mt -59.89 -43.41 92.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.051 0.453 . . . . 0.0 110.501 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 60.3 tp -56.95 -41.06 77.58 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.134 -179.485 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 95.0 mt -60.4 -34.29 73.71 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.658 -178.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 96.3 p -57.73 -38.52 75.45 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.726 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 2.8 tmt_? -63.06 -35.35 79.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.509 178.676 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? -54.08 -29.08 42.96 Favored 'General case' 0 CA--C 1.52 -0.194 0 CA-C-N 116.59 -0.277 . . . . 0.0 111.187 -177.835 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -62.12 -39.77 93.64 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 119.936 -0.705 . . . . 0.0 110.135 178.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.592 ' CB ' ' HE ' ' A' ' 56' ' ' ARG . 11.3 mpt_? -88.73 -6.95 57.09 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.253 -179.757 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 48.9 p -81.18 -150.93 0.08 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.764 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.79 4.56 88.73 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 112.57 -162.43 12.39 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 57.27 84.59 0.09 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.654 0.264 . . . . 0.0 110.78 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -69.94 60.52 0.17 Allowed 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 121.077 0.465 . . . . 0.0 110.304 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 62.4 mttp -108.15 17.38 22.35 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.72 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.592 ' HE ' ' CB ' ' A' ' 49' ' ' ARG . 80.4 mmt-85 -101.76 5.59 41.33 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.521 -179.774 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 17.8 ptm180 -138.11 159.46 41.98 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.774 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.444 ' CD ' ' H ' ' A' ' 58' ' ' GLN . 25.0 mp0 -71.61 141.24 49.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.948 -179.605 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.1 pt -127.43 0.52 3.74 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.587 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 55.7 p30 -160.34 159.87 31.72 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.807 179.69 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 80.8 mm-40 -82.58 -13.53 56.39 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.481 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -61.96 -42.5 99.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.542 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -131.0 79.56 71.2 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.483 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo . . . . . 0 C--N 1.308 -1.556 0 C-N-CA 122.636 2.224 . . . . 0.0 112.205 -179.946 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.6 p . . . . . 0 N--CA 1.463 0.206 0 N-CA-C 111.553 0.205 . . . . 0.0 111.553 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 29.5 mmm-85 -71.47 -55.35 8.05 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 119.635 -0.826 . . . . 0.0 109.92 178.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -92.66 -2.85 55.75 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.833 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.53 -42.36 99.75 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 121.116 -0.564 . . . . 0.0 112.572 -178.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.72 -44.32 98.06 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.901 -179.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.7 tp -59.78 -48.18 82.71 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.616 -0.433 . . . . 0.0 110.801 -178.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 90.3 mt -61.7 -44.07 98.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.921 0.391 . . . . 0.0 111.427 -179.37 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -60.26 -46.41 89.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.441 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.74 -42.69 89.38 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.781 -177.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.49 -40.33 97.58 Favored Glycine 0 CA--C 1.526 0.759 0 C-N-CA 120.352 -0.928 . . . . 0.0 110.943 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 93.6 mt -65.8 -36.49 83.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.416 0.627 . . . . 0.0 109.792 178.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -59.81 -48.5 81.43 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.262 -179.488 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 54.1 m-85 -60.23 -41.39 93.02 Favored 'General case' 0 C--O 1.236 0.39 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -178.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 89.9 mt -58.26 -44.5 88.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 C-N-CA 120.188 -0.605 . . . . 0.0 110.284 -179.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.9 t -57.38 -40.32 73.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.839 -179.279 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.36 -37.1 92.6 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.0 tp -58.61 -47.5 84.13 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.284 -0.566 . . . . 0.0 109.711 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 59.3 tp -55.49 -35.46 65.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.151 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 87.0 mt -59.88 -42.22 88.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 120.948 0.404 . . . . 0.0 110.665 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 91.7 mt -58.76 -40.44 83.91 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.241 -0.583 . . . . 0.0 110.425 -179.196 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.47 ' N ' HD12 ' A' ' 44' ' ' LEU . 11.1 mp -60.73 -30.21 69.84 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.786 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 40.5 t -58.71 -41.44 86.35 Favored 'General case' 0 CA--C 1.518 -0.259 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 20.5 ttp180 . . . . . 0 C--N 1.328 -0.356 0 C-N-CA 120.485 -0.486 . . . . 0.0 110.155 179.294 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.464 0.242 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 78.4 ttt180 -73.54 -55.37 6.4 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 119.686 -0.805 . . . . 0.0 110.025 178.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 53.6 p30 -92.45 -1.76 56.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.848 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.3 -42.98 99.92 Favored Glycine 0 CA--C 1.526 0.76 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.265 -178.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.97 -43.59 98.97 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 120.734 -0.746 . . . . 0.0 111.728 -179.234 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.527 HD22 ' N ' ' A' ' 29' ' ' LEU . 4.0 mm? -59.53 -47.82 84.04 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.628 -0.429 . . . . 0.0 110.835 -178.436 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 90.7 mt -61.71 -44.11 98.22 Favored 'Isoleucine or valine' 0 C--O 1.237 0.422 0 CA-C-O 120.846 0.355 . . . . 0.0 111.414 -179.494 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -60.45 -46.8 88.76 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.335 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.79 -41.84 87.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.66 -178.214 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.38 -40.83 98.09 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 120.38 -0.914 . . . . 0.0 110.921 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 93.3 mt -67.0 -37.95 85.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.276 0.56 . . . . 0.0 109.952 178.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.28 -47.69 84.92 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.08 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.461 ' CE2' HD11 ' A' ' 40' ' ' LEU . 93.4 t80 -59.14 -46.99 86.93 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.958 -0.564 . . . . 0.0 112.318 -178.198 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.1 mt -57.98 -44.35 86.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 C-N-CA 120.726 -0.389 . . . . 0.0 111.013 -178.412 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 55.9 t -57.9 -40.5 76.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.599 -179.276 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.51 -36.4 91.23 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.75 -0.54 . . . . 0.0 111.75 -179.404 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.461 HD11 ' CE2' ' A' ' 36' ' ' PHE . 91.4 mt -60.02 -43.65 95.12 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.073 -0.651 . . . . 0.0 109.711 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.5 mt -58.43 -35.6 72.34 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.142 -178.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 86.6 mt -60.04 -43.04 91.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.067 0.46 . . . . 0.0 110.655 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 90.9 mt -58.91 -39.86 82.78 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 120.443 -0.503 . . . . 0.0 110.276 -179.24 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -60.07 -31.53 70.09 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-O 120.691 0.282 . . . . 0.0 110.912 -179.653 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 69.5 m -59.43 -40.37 86.53 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 59.0 ttt85 . . . . . 0 C--N 1.33 -0.263 0 C-N-CA 120.478 -0.489 . . . . 0.0 109.957 178.774 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 1.1 p . . . . . 0 N--CA 1.462 0.17 0 N-CA-C 111.822 0.305 . . . . 0.0 111.822 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 61.3 ttp180 -72.84 -54.41 8.86 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.019 179.023 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -92.94 -2.85 55.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.485 -0.78 . . . . 0.0 112.02 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.59 -43.16 99.65 Favored Glycine 0 CA--C 1.526 0.775 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.335 -178.724 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.89 -44.28 98.05 Favored Glycine 0 CA--C 1.526 0.731 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.012 -179.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.4 mt -60.4 -47.44 86.06 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.334 -0.546 . . . . 0.0 110.767 -178.523 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 5.0 mm -62.13 -43.9 98.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.739 0.304 . . . . 0.0 111.185 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.1 t80 -60.77 -46.58 89.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.255 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.66 -42.5 88.58 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.586 -178.213 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.72 -40.47 98.11 Favored Glycine 0 CA--C 1.524 0.642 0 C-N-CA 120.271 -0.966 . . . . 0.0 110.688 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 96.7 mt -67.23 -38.02 84.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.288 0.566 . . . . 0.0 109.811 178.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.6 -47.71 85.02 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.013 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 92.3 t80 -59.23 -47.2 86.22 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 115.903 -0.589 . . . . 0.0 112.146 -178.404 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 89.9 mt -57.8 -43.11 83.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 C-N-CA 120.868 -0.333 . . . . 0.0 110.437 -178.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 56.3 t -57.04 -40.06 70.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.451 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.83 -36.89 92.77 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 111.481 -0.648 . . . . 0.0 111.481 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 62.2 tp -58.25 -47.27 84.09 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.307 -0.557 . . . . 0.0 109.503 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 92.8 mt -57.49 -33.61 68.19 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.37 -178.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 41.2 mm -60.34 -42.86 92.28 Favored 'Isoleucine or valine' 0 C--O 1.236 0.387 0 CA-C-O 120.874 0.369 . . . . 0.0 110.237 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 92.1 mt -59.46 -39.39 83.47 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.115 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 59.2 tp -59.05 -35.28 73.06 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.53 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 46.7 t -59.15 -40.61 86.07 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 110.135 -0.321 . . . . 0.0 110.135 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.276 0 C-N-CA 120.354 -0.538 . . . . 0.0 110.186 179.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 2.1 p . . . . . 0 N--CA 1.465 0.278 0 N-CA-C 111.85 0.315 . . . . 0.0 111.85 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 59.0 ttt85 -72.51 -54.83 8.13 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 119.884 -0.726 . . . . 0.0 110.06 179.033 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -93.09 -2.65 55.31 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.873 -179.785 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.46 -43.57 99.14 Favored Glycine 0 CA--C 1.527 0.829 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.299 -178.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -63.1 -43.47 98.69 Favored Glycine 0 CA--C 1.527 0.84 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.163 -179.186 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 89.5 mt -60.37 -47.12 87.42 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.447 -0.501 . . . . 0.0 111.386 -177.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 40.1 pt -69.34 -37.56 75.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 120.487 -0.485 . . . . 0.0 111.382 -179.257 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.3 t80 -61.94 -47.64 83.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.961 0.41 . . . . 0.0 110.889 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.74 -42.14 92.5 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.76 -178.468 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.17 -40.2 96.92 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.731 -0.948 . . . . 0.0 110.731 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.5 tp -67.28 -39.5 86.04 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.423 0.63 . . . . 0.0 109.61 178.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -59.5 -48.79 80.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.435 -179.157 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -60.77 -40.62 93.2 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 111.962 0.356 . . . . 0.0 111.962 -178.432 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.4 mt -58.92 -44.73 91.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 C-N-CA 120.404 -0.518 . . . . 0.0 110.53 -179.025 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 56.3 t -57.88 -39.73 72.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.731 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.83 -37.23 93.33 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.605 -0.598 . . . . 0.0 111.605 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.0 tp -58.89 -47.38 85.17 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.689 -0.405 . . . . 0.0 110.118 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.5 mt -58.39 -34.87 71.21 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.397 -178.385 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 86.8 mt -60.21 -43.52 93.43 Favored 'Isoleucine or valine' 0 C--O 1.238 0.489 0 CA-C-O 120.797 0.332 . . . . 0.0 110.963 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 92.1 mt -59.66 -39.1 83.3 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.924 -0.31 . . . . 0.0 110.483 -179.537 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 59.0 tp -59.92 -35.69 75.42 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.88 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 75.5 m -59.58 -39.22 83.4 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.347 -179.619 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.313 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.23 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 2.7 p . . . . . 0 N--CA 1.469 0.51 0 N-CA-C 113.471 0.915 . . . . 0.0 113.471 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.445 ' NE ' ' OD1' ' A' ' 26' ' ' ASN . 4.1 ptm180 -80.04 -54.26 5.95 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 119.576 -0.85 . . . . 0.0 110.712 178.781 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . 0.445 ' OD1' ' NE ' ' A' ' 25' ' ' ARG . 34.3 m120 -91.44 -3.09 57.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.1 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -60.93 -42.0 99.53 Favored Glycine 0 CA--C 1.525 0.704 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.872 -179.243 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.28 -42.15 99.7 Favored Glycine 0 CA--C 1.525 0.668 0 C-N-CA 120.85 -0.69 . . . . 0.0 111.405 -179.536 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.4 mt -59.69 -46.81 87.93 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.367 -178.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 90.9 mt -60.82 -43.67 95.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.787 0.327 . . . . 0.0 110.917 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.0 t80 -60.29 -46.85 88.42 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.277 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.14 -42.6 86.21 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.875 -0.33 . . . . 0.0 111.417 -177.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.23 -40.08 96.84 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 60.3 tp -64.89 -39.85 94.19 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.214 0.53 . . . . 0.0 109.877 178.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.409 ' O ' HG22 ' A' ' 38' ' ' VAL . . . -60.94 -46.0 92.47 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.281 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -59.84 -48.62 80.96 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.354 -178.25 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 92.1 mt -59.19 -48.75 85.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 N-CA-C 112.185 0.439 . . . . 0.0 112.185 -177.562 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.409 HG22 ' O ' ' A' ' 35' ' ' ALA . 29.3 m -56.67 -35.45 45.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.485 -179.002 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -61.8 -38.51 96.08 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 111.815 -0.514 . . . . 0.0 111.815 -179.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.4 tp -59.0 -47.11 86.37 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.319 -0.552 . . . . 0.0 109.696 -179.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.9 mt -57.26 -34.13 68.32 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.278 -178.433 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 88.5 mt -60.74 -42.98 94.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.885 0.374 . . . . 0.0 110.822 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 91.6 mt -59.0 -39.49 81.99 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.141 -179.258 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 94.7 mt -60.71 -33.16 72.47 Favored 'General case' 0 C--O 1.238 0.455 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.975 -179.57 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 70.3 m -58.44 -40.51 82.76 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? . . . . . 0 C--N 1.328 -0.335 0 C-N-CA 120.677 -0.409 . . . . 0.0 110.522 178.967 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.0 p . . . . . 0 N--CA 1.464 0.256 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 90.7 mtm180 -73.13 -55.35 6.6 Favored 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 119.716 -0.794 . . . . 0.0 110.109 178.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -93.42 -1.43 55.8 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.439 -0.8 . . . . 0.0 112.081 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.06 -43.32 99.58 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.529 -178.518 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.88 -43.9 98.58 Favored Glycine 0 CA--C 1.526 0.773 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.829 -179.134 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.6 tp -59.52 -48.38 81.89 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.642 -178.536 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 92.4 mt -61.66 -44.41 98.64 Favored 'Isoleucine or valine' 0 C--O 1.236 0.348 0 CA-C-O 120.894 0.378 . . . . 0.0 111.526 -179.443 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.6 t80 -60.72 -46.58 89.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.152 -179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.81 -41.79 87.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.482 -178.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.59 -41.02 98.66 Favored Glycine 0 CA--C 1.525 0.691 0 C-N-CA 120.427 -0.892 . . . . 0.0 111.002 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.404 HD23 ' HA ' ' A' ' 34' ' ' LEU . 95.0 mt -67.16 -37.91 84.57 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.18 0.514 . . . . 0.0 110.114 178.819 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.51 -47.65 85.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.162 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 93.1 t80 -59.4 -46.81 87.63 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 116.083 -0.508 . . . . 0.0 112.227 -178.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.7 mm -57.57 -44.35 84.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.705 -178.522 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.1 t -57.2 -39.79 69.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.701 -179.318 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.67 -36.91 92.6 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 -179.794 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.4 tp -58.9 -48.23 82.16 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.007 -0.677 . . . . 0.0 109.891 -179.573 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.454 ' N ' HD12 ' A' ' 41' ' ' LEU . 10.9 mp -56.19 -33.1 64.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.437 -178.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 4.7 mm -60.77 -43.81 96.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.455 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . 0.414 HD13 ' HA ' ' A' ' 43' ' ' LEU . 4.2 mm? -57.12 -40.78 77.75 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.282 -0.567 . . . . 0.0 110.243 -179.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.46 ' N ' HD12 ' A' ' 44' ' ' LEU . 10.3 mp -60.96 -30.27 70.15 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.057 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 39.9 t -59.36 -41.44 89.25 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 -179.468 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.5 ttt-85 . . . . . 0 C--N 1.329 -0.289 0 C-N-CA 120.33 -0.548 . . . . 0.0 110.488 179.233 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.4 t . . . . . 0 C--O 1.226 -0.181 0 N-CA-C 111.919 0.341 . . . . 0.0 111.919 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -72.95 -54.23 9.2 Favored 'General case' 0 C--N 1.323 -0.584 0 C-N-CA 119.472 -0.891 . . . . 0.0 109.855 178.482 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -91.99 -1.14 57.41 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.336 -179.094 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.41 -41.86 99.63 Favored Glycine 0 CA--C 1.528 0.872 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.353 -178.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.71 -44.83 97.38 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.926 -179.161 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.7 tp -59.77 -47.92 83.75 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.865 -178.358 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.1 mt -62.11 -43.6 97.96 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 CA-C-O 120.904 0.383 . . . . 0.0 111.458 -179.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 91.6 t80 -60.62 -46.14 91.41 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.272 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.77 -42.36 88.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.341 -0.391 . . . . 0.0 111.622 -178.209 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.23 -40.13 96.92 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.6 tp -67.7 -39.87 84.36 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-O 121.422 0.63 . . . . 0.0 109.918 178.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -59.56 -49.02 79.38 Favored 'General case' 0 C--O 1.225 -0.236 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.581 -178.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -60.78 -40.48 92.72 Favored 'General case' 0 C--O 1.236 0.351 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -178.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.3 mt -58.55 -44.76 90.01 Favored 'Isoleucine or valine' 0 C--O 1.235 0.326 0 C-N-CA 120.256 -0.578 . . . . 0.0 110.549 -179.065 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 53.7 t -58.66 -40.15 78.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.794 -179.596 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.28 -36.05 89.85 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 111.773 -0.531 . . . . 0.0 111.773 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 40' ' ' LEU . 92.6 mt -60.28 -43.23 96.42 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 119.934 -0.706 . . . . 0.0 109.515 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 59.4 tp -56.69 -37.25 70.62 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.905 -179.193 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 4.7 mm -59.52 -42.14 87.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.89 0.376 . . . . 0.0 110.614 -179.495 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 91.0 mt -58.64 -39.99 82.11 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.303 -0.559 . . . . 0.0 110.416 -179.093 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.407 ' N ' HD12 ' A' ' 44' ' ' LEU . 10.8 mp -60.96 -30.11 70.05 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 120.709 0.29 . . . . 0.0 111.12 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 42.6 t -58.74 -42.34 88.56 Favored 'General case' 0 CA--C 1.518 -0.266 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 179.623 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 15.8 tpt180 . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.769 178.707 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 2.4 p . . . . . 0 N--CA 1.465 0.318 0 N-CA-C 112.112 0.412 . . . . 0.0 112.112 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 63.2 ttm-85 -75.26 -54.64 6.76 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.273 179.04 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -93.19 -1.32 56.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.589 -0.732 . . . . 0.0 112.141 -179.485 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -62.18 -43.63 98.84 Favored Glycine 0 CA--C 1.528 0.86 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.688 -178.624 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -62.05 -45.44 96.09 Favored Glycine 0 CA--C 1.527 0.813 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.088 -179.015 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.1 mt -60.18 -46.23 90.44 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.533 -0.467 . . . . 0.0 111.281 -178.124 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.3 mt -62.08 -45.51 98.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 CA-C-O 120.815 0.341 . . . . 0.0 111.565 -179.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.1 t80 -61.77 -47.03 87.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.922 0.391 . . . . 0.0 111.253 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.53 -41.63 90.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.495 -178.375 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.94 -40.36 98.28 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 120.589 -0.815 . . . . 0.0 111.164 -179.609 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 98.5 mt -69.85 -39.36 76.42 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.324 0.583 . . . . 0.0 110.019 178.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.9 -48.0 83.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.192 -179.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -59.64 -46.54 88.69 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.102 -0.499 . . . . 0.0 112.297 -178.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 89.3 mt -58.44 -44.53 89.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 C-N-CA 121.016 -0.273 . . . . 0.0 111.283 -178.23 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.9 t -58.33 -39.57 74.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 120.818 0.342 . . . . 0.0 110.722 -179.485 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.86 -37.3 93.49 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.2 tp -58.8 -48.46 81.21 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.372 -179.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.481 ' N ' HD12 ' A' ' 41' ' ' LEU . 10.8 mp -57.36 -34.07 68.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.536 -178.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 39.5 mm -60.58 -43.32 94.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.391 0 CA-C-O 121.026 0.441 . . . . 0.0 110.922 -179.276 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 90.9 mt -60.51 -39.86 89.31 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.684 -0.406 . . . . 0.0 110.67 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 9.8 mp -60.59 -30.98 70.16 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.261 -179.404 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 74.2 m -63.08 -39.61 95.24 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.783 0.325 . . . . 0.0 110.463 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.2 tpm_? . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.649 179.694 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 35.5 m . . . . . 0 N--CA 1.466 0.351 0 N-CA-C 112.632 0.605 . . . . 0.0 112.632 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 18.7 tpp180 -73.08 -54.95 7.24 Favored 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 119.689 -0.804 . . . . 0.0 110.244 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -91.86 -2.06 57.03 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 115.543 -0.753 . . . . 0.0 111.95 -179.089 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.45 -42.79 99.85 Favored Glycine 0 CA--C 1.526 0.751 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.576 -178.678 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.04 -45.17 97.14 Favored Glycine 0 CA--C 1.525 0.713 0 C-N-CA 120.652 -0.785 . . . . 0.0 111.879 -178.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.588 ' N ' HD12 ' A' ' 29' ' ' LEU . 10.2 mp -60.09 -47.96 83.71 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.755 -178.676 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.1 mt -62.37 -44.62 99.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.722 0.296 . . . . 0.0 111.624 -179.413 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -61.22 -46.97 88.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.63 0.252 . . . . 0.0 111.526 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.18 -42.6 91.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.547 -178.05 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.84 -40.81 98.77 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.811 -0.915 . . . . 0.0 110.811 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.6 tp -67.22 -41.37 85.83 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.436 0.636 . . . . 0.0 109.713 178.689 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.61 -47.84 84.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.001 -1.0 . . . . 0.0 110.224 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 92.3 t80 -59.39 -47.41 85.54 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.933 -0.576 . . . . 0.0 112.506 -178.242 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 5.4 mm -58.13 -43.34 85.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.545 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.3 t -57.76 -39.72 72.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.558 -179.36 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.412 ' HA2' HD12 ' A' ' 42' ' ' ILE . . . -61.08 -37.44 93.92 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.577 -0.609 . . . . 0.0 111.577 -179.762 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.5 tp -58.17 -46.47 85.68 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 94.7 mt -58.31 -33.89 69.99 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.714 -0.676 . . . . 0.0 111.431 -178.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.412 HD12 ' HA2' ' A' ' 39' ' ' GLY . 89.4 mt -60.35 -45.13 96.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 CA-C-O 120.745 0.307 . . . . 0.0 111.416 -179.208 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . 0.472 HD22 ' N ' ' A' ' 43' ' ' LEU . 4.0 mm? -59.39 -38.95 81.83 Favored 'General case' 0 C--O 1.234 0.254 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.529 -179.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 59.2 tp -59.42 -35.88 74.84 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.697 -179.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 75.7 m -60.28 -38.34 83.29 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.667 -0.242 . . . . 0.0 110.49 -179.68 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.3 tmt_? . . . . . 0 C--N 1.33 -0.272 0 C-N-CA 119.999 -0.68 . . . . 0.0 110.027 179.75 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.4 t . . . . . 0 N--CA 1.464 0.225 0 N-CA-C 111.75 0.278 . . . . 0.0 111.75 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 62.8 ttm-85 -71.82 -54.04 11.4 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 119.562 -0.855 . . . . 0.0 109.705 178.273 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 33.8 m120 -92.58 -1.54 56.83 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.366 -0.834 . . . . 0.0 112.083 -179.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -61.42 -42.28 99.73 Favored Glycine 0 CA--C 1.528 0.878 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.289 -178.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.83 -43.91 98.58 Favored Glycine 0 CA--C 1.526 0.76 0 C-N-CA 120.747 -0.74 . . . . 0.0 111.709 -179.195 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.8 tp -59.5 -47.9 83.74 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.622 -178.464 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.5 mt -61.85 -44.06 98.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 120.94 0.4 . . . . 0.0 111.59 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 91.8 t80 -60.65 -46.3 90.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.221 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.88 -41.73 87.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.46 -178.202 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.61 -40.49 97.98 Favored Glycine 0 CA--C 1.525 0.684 0 C-N-CA 120.434 -0.889 . . . . 0.0 111.043 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.2 tp -67.53 -40.69 85.07 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.396 0.617 . . . . 0.0 109.776 178.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.03 -47.49 85.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.179 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 93.3 t80 -58.97 -46.73 87.38 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -178.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 91.0 mt -58.24 -43.68 86.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.96 -178.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.6 t -58.38 -40.73 79.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.77 -179.322 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.58 -36.6 91.81 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 111.609 -0.597 . . . . 0.0 111.609 -179.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.3 tp -58.79 -45.81 89.0 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 91.5 mt -57.66 -35.81 71.05 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.277 -178.454 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 85.8 mt -59.89 -43.41 92.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.051 0.453 . . . . 0.0 110.501 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 60.3 tp -56.95 -41.06 77.58 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.134 -179.485 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 95.0 mt -60.4 -34.29 73.71 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.658 -178.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 96.3 p -57.73 -38.52 75.45 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 2.8 tmt_? . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.509 178.676 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . 0.555 ' C ' ' HE1' ' A' ' 4' ' ' TRP . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -119.13 151.74 37.77 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.004 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 84.2 mtt85 57.45 60.6 2.81 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.343 179.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' TRP . . . . . 0.555 ' HE1' ' C ' ' A' ' 1' ' ' LEU . 95.5 m95 -85.85 -4.66 59.22 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.527 179.582 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 94.0 t80 -75.31 135.48 40.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.534 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.9 pp -117.19 176.33 5.19 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.483 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 82.83 2.91 90.68 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.557 -1.017 . . . . 0.0 110.557 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.81 31.73 8.05 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.0 t -121.08 88.75 45.5 Favored Pre-proline 0 CA--C 1.533 0.298 0 N-CA-C 110.599 -0.149 . . . . 0.0 110.599 -179.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -58.57 -172.26 0.05 OUTLIER 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.622 2.215 . . . . 0.0 112.072 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -71.48 -18.88 62.27 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.393 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 83.89 2.35 89.66 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.448 -0.661 . . . . 0.0 111.448 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -85.88 -74.17 0.42 Allowed 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.672 -0.411 . . . . 0.0 110.272 179.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.603 HG12 ' HD3' ' A' ' 16' ' ' PRO . 58.0 t -127.8 125.99 66.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.062 179.685 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.6 m-20 -126.32 77.77 72.06 Favored Pre-proline 0 C--N 1.332 -0.181 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.744 -179.131 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.603 ' HD3' HG12 ' A' ' 14' ' ' VAL . 92.0 Cg_endo -83.9 32.14 0.51 Allowed 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 123.011 2.474 . . . . 0.0 112.635 -179.491 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 47.9 m-85 -60.07 -3.2 0.54 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.144 -179.445 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.423 ' H ' ' C ' ' A' ' 16' ' ' PRO . 85.6 m-85 -60.31 -37.98 82.26 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -60.29 -47.9 84.02 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 178.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -76.43 -18.18 58.95 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.741 179.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.655 ' O ' HG12 ' A' ' 24' ' ' VAL . 76.1 t80 -63.71 -38.63 91.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.564 -179.594 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -57.51 -36.95 72.22 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.115 -178.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.506 ' O ' ' N ' ' A' ' 27' ' ' GLY . 78.6 p -64.65 -25.34 67.91 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.677 -0.409 . . . . 0.0 110.552 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.655 HG12 ' O ' ' A' ' 21' ' ' TYR . 4.6 p -44.71 -23.19 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.553 -179.125 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 29.5 mmm-85 -71.47 -55.35 8.05 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 119.635 -0.826 . . . . 0.0 109.92 178.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -92.66 -2.85 55.75 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.833 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.53 -42.36 99.75 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 121.116 -0.564 . . . . 0.0 112.572 -178.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.72 -44.32 98.06 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.901 -179.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.7 tp -59.78 -48.18 82.71 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.616 -0.433 . . . . 0.0 110.801 -178.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 90.3 mt -61.7 -44.07 98.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.921 0.391 . . . . 0.0 111.427 -179.37 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -60.26 -46.41 89.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.441 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.74 -42.69 89.38 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.781 -177.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.49 -40.33 97.58 Favored Glycine 0 CA--C 1.526 0.759 0 C-N-CA 120.352 -0.928 . . . . 0.0 110.943 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 93.6 mt -65.8 -36.49 83.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.416 0.627 . . . . 0.0 109.792 178.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -59.81 -48.5 81.43 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.262 -179.488 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 54.1 m-85 -60.23 -41.39 93.02 Favored 'General case' 0 C--O 1.236 0.39 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -178.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 89.9 mt -58.26 -44.5 88.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 C-N-CA 120.188 -0.605 . . . . 0.0 110.284 -179.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.9 t -57.38 -40.32 73.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.839 -179.279 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.36 -37.1 92.6 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.0 tp -58.61 -47.5 84.13 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.284 -0.566 . . . . 0.0 109.711 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 59.3 tp -55.49 -35.46 65.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.151 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 87.0 mt -59.88 -42.22 88.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 120.948 0.404 . . . . 0.0 110.665 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 91.7 mt -58.76 -40.44 83.91 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.241 -0.583 . . . . 0.0 110.425 -179.196 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.47 ' N ' HD12 ' A' ' 44' ' ' LEU . 11.1 mp -60.73 -30.21 69.84 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.786 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 40.5 t -58.71 -41.44 86.35 Favored 'General case' 0 CA--C 1.518 -0.259 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 20.5 ttp180 -60.51 -36.95 79.61 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.485 -0.486 . . . . 0.0 110.155 179.294 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.427 ' O ' ' O ' ' A' ' 50' ' ' SER . 15.0 ttp180 -56.12 -31.16 63.04 Favored 'General case' 0 N--CA 1.462 0.163 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.403 -178.516 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -59.23 -37.72 78.21 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.002 -0.679 . . . . 0.0 110.146 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 84.5 mtp180 -87.99 -54.41 4.24 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 119.768 -0.773 . . . . 0.0 109.854 178.505 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.427 ' O ' ' O ' ' A' ' 47' ' ' ARG . 67.3 m -71.6 139.41 49.34 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.623 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 175.62 -171.16 44.27 Favored Glycine 0 CA--C 1.523 0.594 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -102.75 13.66 56.35 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -133.1 25.16 4.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.741 0.305 . . . . 0.0 110.549 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.715 ' NZ ' ' HE ' ' A' ' 56' ' ' ARG . 65.3 tttp 42.2 80.1 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.181 -179.573 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -100.41 -3.11 31.68 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.63 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.715 ' HE ' ' NZ ' ' A' ' 54' ' ' LYS . 41.7 ptt180 -70.1 -25.42 63.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.058 -179.7 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 55.3 ttp180 38.17 54.36 1.71 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.247 179.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 72.2 tp60 -135.18 131.46 36.76 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.615 -179.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 20.8 tt -142.56 136.69 27.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.166 179.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 84.2 m-20 -108.3 126.18 52.54 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.658 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -130.98 146.79 52.5 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.451 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -94.03 135.47 35.35 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.52 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.442 ' OE1' ' N ' ' A' ' 63' ' ' GLU . 39.1 mp0 -70.77 149.32 95.17 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.27 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo . . . . . 0 N--CA 1.493 1.468 0 C-N-CA 122.151 1.901 . . . . 0.0 111.964 179.941 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.452 ' CG ' ' H ' ' A' ' 3' ' ' ARG . 34.2 t0 -72.08 -173.41 1.04 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.739 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.452 ' H ' ' CG ' ' A' ' 2' ' ' ASP . 84.2 mtt85 -89.52 -3.05 58.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.357 179.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' TRP . . . . . . . . . . . . . 50.1 t-105 -85.4 -25.97 26.71 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.737 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -76.43 141.76 41.27 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.765 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.426 ' HA ' HD12 ' A' ' 6' ' ' LEU . 12.1 tp -116.9 -134.61 0.34 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.026 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 81.94 3.41 90.59 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 179.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.65 64.0 3.26 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 68.2 m -128.83 149.55 72.57 Favored Pre-proline 0 CA--C 1.532 0.268 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -69.36 148.63 68.06 Favored 'Trans proline' 0 N--CA 1.496 1.619 0 C-N-CA 121.975 1.784 . . . . 0.0 112.223 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 73.7 mmtt -94.54 -3.25 50.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.354 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 81.07 7.1 88.92 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -101.46 -37.24 8.52 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.955 0.407 . . . . 0.0 110.523 179.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.517 HG22 ' N ' ' A' ' 15' ' ' ASP . 10.7 p -155.76 161.46 2.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.45 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.517 ' N ' HG22 ' A' ' 14' ' ' VAL . 60.2 m-20 -125.66 76.28 70.02 Favored Pre-proline 0 C--N 1.331 -0.234 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.518 -179.581 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.513 ' HD3' HG13 ' A' ' 14' ' ' VAL . 90.6 Cg_endo -81.24 -5.49 12.78 Favored 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.958 2.439 . . . . 0.0 112.435 -179.293 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.5 ' O ' ' N ' ' A' ' 21' ' ' TYR . 91.2 t80 -59.78 -44.06 94.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.635 -179.568 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -59.44 -48.66 80.81 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 120.442 -0.503 . . . . 0.0 110.142 -179.243 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 86.2 m-85 -68.72 -36.66 78.72 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.012 0.434 . . . . 0.0 110.213 179.372 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -81.77 -7.98 59.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.085 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.573 ' O ' HG12 ' A' ' 24' ' ' VAL . 93.7 t80 -61.85 -46.08 91.0 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.405 -179.349 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -60.01 -38.47 82.75 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.846 0.355 . . . . 0.0 110.549 -179.558 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.52 ' O ' ' N ' ' A' ' 27' ' ' GLY . 98.8 m -61.57 -41.97 98.17 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.998 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.573 HG12 ' O ' ' A' ' 21' ' ' TYR . 0.6 OUTLIER -42.05 -24.05 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.287 -0.415 . . . . 0.0 112.107 -178.001 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.401 ' N ' ' O ' ' A' ' 23' ' ' THR . 78.4 ttt180 -73.54 -55.37 6.4 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 119.686 -0.805 . . . . 0.0 110.025 178.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 53.6 p30 -92.45 -1.76 56.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.848 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.52 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.3 -42.98 99.92 Favored Glycine 0 CA--C 1.526 0.76 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.265 -178.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.97 -43.59 98.97 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 120.734 -0.746 . . . . 0.0 111.728 -179.234 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.527 HD22 ' N ' ' A' ' 29' ' ' LEU . 4.0 mm? -59.53 -47.82 84.04 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.628 -0.429 . . . . 0.0 110.835 -178.436 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 90.7 mt -61.71 -44.11 98.22 Favored 'Isoleucine or valine' 0 C--O 1.237 0.422 0 CA-C-O 120.846 0.355 . . . . 0.0 111.414 -179.494 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -60.45 -46.8 88.76 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.335 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.79 -41.84 87.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.66 -178.214 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.38 -40.83 98.09 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 120.38 -0.914 . . . . 0.0 110.921 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 93.3 mt -67.0 -37.95 85.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.276 0.56 . . . . 0.0 109.952 178.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.28 -47.69 84.92 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.08 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.461 ' CE2' HD11 ' A' ' 40' ' ' LEU . 93.4 t80 -59.14 -46.99 86.93 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.958 -0.564 . . . . 0.0 112.318 -178.198 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.1 mt -57.98 -44.35 86.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 C-N-CA 120.726 -0.389 . . . . 0.0 111.013 -178.412 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 55.9 t -57.9 -40.5 76.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.599 -179.276 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.51 -36.4 91.23 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.75 -0.54 . . . . 0.0 111.75 -179.404 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.461 HD11 ' CE2' ' A' ' 36' ' ' PHE . 91.4 mt -60.02 -43.65 95.12 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.073 -0.651 . . . . 0.0 109.711 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.5 mt -58.43 -35.6 72.34 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.142 -178.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 86.6 mt -60.04 -43.04 91.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.067 0.46 . . . . 0.0 110.655 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 90.9 mt -58.91 -39.86 82.78 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 120.443 -0.503 . . . . 0.0 110.276 -179.24 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -60.07 -31.53 70.09 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-O 120.691 0.282 . . . . 0.0 110.912 -179.653 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 69.5 m -59.43 -40.37 86.53 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 59.0 ttt85 -60.72 -36.57 79.17 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 120.478 -0.489 . . . . 0.0 109.957 178.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 15.2 ttp180 -54.97 -29.96 58.07 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.527 -178.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 93.8 t80 -58.16 -47.56 82.99 Favored 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 120.653 -0.419 . . . . 0.0 110.136 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -86.38 -54.84 4.19 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 120.374 -0.53 . . . . 0.0 110.861 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 48.0 t -61.66 -43.79 98.18 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.688 -178.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 100.32 -18.66 55.1 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 -179.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.86 146.55 9.21 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 112.069 -0.413 . . . . 0.0 112.069 178.633 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 47.9 m-20 69.97 -147.84 0.1 Allowed 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.362 -0.419 . . . . 0.0 110.836 -179.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 82.1 tttt -163.21 161.51 24.96 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.307 -179.46 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -90.17 0.43 57.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.921 0.391 . . . . 0.0 110.555 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.564 ' HA ' HD11 ' A' ' 59' ' ' ILE . 77.9 ttt-85 -68.44 -30.19 69.01 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.445 -179.339 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 91.4 mtm180 -59.36 -40.65 87.13 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.588 -0.445 . . . . 0.0 110.655 -178.595 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -134.41 108.05 7.93 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.816 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.564 HD11 ' HA ' ' A' ' 56' ' ' ARG . 87.0 mt -124.36 131.67 72.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.873 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -64.73 127.82 33.17 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.443 -0.503 . . . . 0.0 110.231 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.441 ' HG3' ' H ' ' A' ' 63' ' ' GLU . 52.7 tp10 -153.18 148.77 27.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.092 -179.535 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -63.58 -39.68 95.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.789 0.328 . . . . 0.0 110.909 179.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.441 ' H ' ' HG3' ' A' ' 61' ' ' GLU . 96.3 mt-10 -128.98 75.95 79.78 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.881 -179.45 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo . . . . . 0 C--N 1.307 -1.654 0 C-N-CA 122.844 2.362 . . . . 0.0 112.21 -179.783 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . 0.52 ' N ' ' OD1' ' A' ' 20' ' ' ASP . 83.9 mt . . . . . 0 N--CA 1.492 1.641 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -87.58 103.19 15.32 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.627 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -77.66 152.26 33.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.637 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' TRP . . . . . . . . . . . . . 29.6 m-90 -99.1 15.69 25.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.461 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -108.26 112.9 25.61 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.504 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 98.0 mt -67.79 -40.05 83.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.129 0.49 . . . . 0.0 109.992 179.259 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.78 -8.3 79.82 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 -179.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 118.53 12.94 7.06 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 110.616 -0.993 . . . . 0.0 110.616 -179.29 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 80.7 p -82.65 150.63 63.23 Favored Pre-proline 0 CA--C 1.534 0.341 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -67.96 -84.24 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 121.949 1.766 . . . . 0.0 112.839 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -71.97 -22.68 61.41 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.68 -0.236 . . . . 0.0 111.408 -178.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.56 19.12 71.89 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.119 -0.793 . . . . 0.0 111.119 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -63.83 126.37 27.41 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 27.5 m -140.96 161.97 22.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.096 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.413 ' N ' ' OD1' ' A' ' 15' ' ' ASP . 37.5 p-10 -133.36 63.73 66.43 Favored Pre-proline 0 N--CA 1.463 0.181 0 C-N-CA 120.96 -0.296 . . . . 0.0 110.979 179.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -84.12 31.67 0.51 Allowed 'Trans proline' 0 C--N 1.307 -1.62 0 C-N-CA 122.981 2.454 . . . . 0.0 112.242 179.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.417 ' O ' ' N ' ' A' ' 21' ' ' TYR . 80.8 m-85 -61.86 -41.66 98.11 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 120.654 -0.419 . . . . 0.0 110.674 -179.449 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -60.55 -47.52 85.82 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.14 -0.624 . . . . 0.0 110.068 -179.183 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 86.9 t80 -65.92 -45.75 80.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.347 0.594 . . . . 0.0 110.07 178.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' A' ' 1' ' ' LEU . 97.8 m-20 -71.28 -14.28 62.17 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.191 -0.913 . . . . 0.0 111.441 -179.139 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.616 ' O ' HG12 ' A' ' 24' ' ' VAL . 94.4 t80 -62.69 -45.49 92.55 Favored 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 120.496 -0.482 . . . . 0.0 110.322 -179.755 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -60.08 -39.61 86.68 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.853 -179.207 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.528 ' O ' ' N ' ' A' ' 27' ' ' GLY . 68.3 p -66.09 -31.15 71.85 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 121.0 -0.28 . . . . 0.0 110.855 -179.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.616 HG12 ' O ' ' A' ' 21' ' ' TYR . 1.1 p -44.13 -24.1 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.822 -178.623 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 61.3 ttp180 -72.84 -54.41 8.86 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.019 179.023 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -92.94 -2.85 55.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.485 -0.78 . . . . 0.0 112.02 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.59 -43.16 99.65 Favored Glycine 0 CA--C 1.526 0.775 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.335 -178.724 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.89 -44.28 98.05 Favored Glycine 0 CA--C 1.526 0.731 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.012 -179.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.4 mt -60.4 -47.44 86.06 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.334 -0.546 . . . . 0.0 110.767 -178.523 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 5.0 mm -62.13 -43.9 98.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.739 0.304 . . . . 0.0 111.185 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.1 t80 -60.77 -46.58 89.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.255 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.66 -42.5 88.58 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.586 -178.213 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.72 -40.47 98.11 Favored Glycine 0 CA--C 1.524 0.642 0 C-N-CA 120.271 -0.966 . . . . 0.0 110.688 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 96.7 mt -67.23 -38.02 84.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.288 0.566 . . . . 0.0 109.811 178.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.6 -47.71 85.02 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.013 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 92.3 t80 -59.23 -47.2 86.22 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 115.903 -0.589 . . . . 0.0 112.146 -178.404 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 89.9 mt -57.8 -43.11 83.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 C-N-CA 120.868 -0.333 . . . . 0.0 110.437 -178.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 56.3 t -57.04 -40.06 70.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.451 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.83 -36.89 92.77 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 111.481 -0.648 . . . . 0.0 111.481 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 62.2 tp -58.25 -47.27 84.09 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.307 -0.557 . . . . 0.0 109.503 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 92.8 mt -57.49 -33.61 68.19 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.37 -178.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 41.2 mm -60.34 -42.86 92.28 Favored 'Isoleucine or valine' 0 C--O 1.236 0.387 0 CA-C-O 120.874 0.369 . . . . 0.0 110.237 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 92.1 mt -59.46 -39.39 83.47 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.115 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 59.2 tp -59.05 -35.28 73.06 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.53 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 46.7 t -59.15 -40.61 86.07 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 110.135 -0.321 . . . . 0.0 110.135 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.02 -39.17 81.11 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 120.354 -0.538 . . . . 0.0 110.186 179.61 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 80.3 ttt180 -58.8 -32.23 69.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.027 -179.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 93.9 t80 -59.17 -48.69 80.67 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 120.369 -0.532 . . . . 0.0 109.922 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.41 ' O ' ' CB ' ' A' ' 50' ' ' SER . 0.9 OUTLIER -65.19 -55.25 19.61 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.058 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.41 ' CB ' ' O ' ' A' ' 49' ' ' ARG . 0.7 OUTLIER 76.27 175.86 0.21 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.002 179.427 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 112.74 126.03 4.52 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.44 1.87 74.16 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -179.155 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 34.1 m120 -101.22 10.61 40.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.931 0.396 . . . . 0.0 110.04 179.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.435 ' O ' ' O ' ' A' ' 57' ' ' ARG . 73.8 mmtt -96.73 -0.67 47.88 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.335 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -62.26 -43.65 98.34 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.896 0.379 . . . . 0.0 110.269 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -73.6 -31.76 63.74 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.867 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.435 ' O ' ' O ' ' A' ' 54' ' ' LYS . 43.7 ttm180 -138.66 136.56 36.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.102 -179.532 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -66.72 152.6 45.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.241 179.662 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 21.4 tt -61.7 147.52 10.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.676 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -104.14 130.83 51.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.434 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 60.9 mp0 -63.22 -40.22 96.84 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.237 179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 60.2 p30 -158.66 170.46 22.12 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.041 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.6 tp10 -134.67 75.87 61.8 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.448 179.838 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo . . . . . 0 C--N 1.307 -1.613 0 C-N-CA 122.724 2.283 . . . . 0.0 112.184 -179.979 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 61.0 tp . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.52 ' O ' ' CD1' ' A' ' 4' ' ' TRP . 37.4 t70 -86.85 84.02 7.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.632 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.433 ' H ' ' NE ' ' A' ' 3' ' ' ARG . 0.0 OUTLIER 40.47 44.35 1.69 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.867 179.174 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' TRP . . . . . 0.52 ' CD1' ' O ' ' A' ' 2' ' ' ASP . 93.5 m95 -104.84 10.45 34.44 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.482 -0.327 . . . . 0.0 110.578 179.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 50.5 p90 -145.4 151.01 37.57 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.983 179.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 60.1 tp -65.05 -44.23 89.69 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-O 121.083 0.468 . . . . 0.0 110.129 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 71.43 29.32 68.29 Favored Glycine 0 CA--C 1.524 0.594 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.804 179.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -96.69 118.86 6.15 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 110.389 -1.084 . . . . 0.0 110.389 179.434 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 92.9 p -83.22 151.1 62.37 Favored Pre-proline 0 CA--C 1.535 0.382 0 C-N-CA 121.328 -0.149 . . . . 0.0 110.884 -178.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -63.96 -153.36 0.02 OUTLIER 'Trans proline' 0 N--CA 1.497 1.69 0 C-N-CA 122.282 1.988 . . . . 0.0 111.654 179.06 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -71.37 -22.15 61.93 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.83 0.348 . . . . 0.0 110.152 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.64 2.45 90.64 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.718 -0.553 . . . . 0.0 111.718 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.437 ' OD1' ' O ' ' A' ' 13' ' ' ASP . 52.6 t0 -117.42 19.54 13.98 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 120.904 0.383 . . . . 0.0 110.271 179.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 35.3 m -143.16 149.01 18.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.241 179.043 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -129.59 67.02 78.48 Favored Pre-proline 0 C--N 1.331 -0.202 0 CA-C-N 116.614 -0.266 . . . . 0.0 110.517 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -72.16 -14.57 28.77 Favored 'Trans proline' 0 N--CA 1.493 1.461 0 C-N-CA 122.686 2.257 . . . . 0.0 112.644 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.494 ' O ' ' N ' ' A' ' 21' ' ' TYR . 82.7 m-85 -59.94 -40.58 89.43 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.103 -179.042 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 44.7 m-85 -60.37 -42.11 95.14 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.571 -179.489 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -67.47 -41.03 85.27 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 178.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.43 ' O ' ' OD1' ' A' ' 20' ' ' ASP . 57.9 t0 -72.73 -25.83 61.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.457 179.123 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.642 ' O ' HG12 ' A' ' 24' ' ' VAL . 91.2 t80 -62.04 -43.48 98.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.093 -178.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -58.19 -39.62 79.42 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.82 -178.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.525 ' O ' ' N ' ' A' ' 27' ' ' GLY . 66.6 p -66.11 -26.93 67.69 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.718 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.642 HG12 ' O ' ' A' ' 21' ' ' TYR . 2.1 p -44.52 -23.51 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.85 -178.5 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 59.0 ttt85 -72.51 -54.83 8.13 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 119.884 -0.726 . . . . 0.0 110.06 179.033 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -93.09 -2.65 55.31 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.873 -179.785 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.46 -43.57 99.14 Favored Glycine 0 CA--C 1.527 0.829 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.299 -178.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -63.1 -43.47 98.69 Favored Glycine 0 CA--C 1.527 0.84 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.163 -179.186 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 89.5 mt -60.37 -47.12 87.42 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.447 -0.501 . . . . 0.0 111.386 -177.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 40.1 pt -69.34 -37.56 75.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 120.487 -0.485 . . . . 0.0 111.382 -179.257 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.3 t80 -61.94 -47.64 83.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.961 0.41 . . . . 0.0 110.889 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.74 -42.14 92.5 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.76 -178.468 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.17 -40.2 96.92 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.731 -0.948 . . . . 0.0 110.731 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.5 tp -67.28 -39.5 86.04 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.423 0.63 . . . . 0.0 109.61 178.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -59.5 -48.79 80.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.435 -179.157 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -60.77 -40.62 93.2 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 111.962 0.356 . . . . 0.0 111.962 -178.432 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.4 mt -58.92 -44.73 91.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 C-N-CA 120.404 -0.518 . . . . 0.0 110.53 -179.025 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 56.3 t -57.88 -39.73 72.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.731 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.83 -37.23 93.33 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.605 -0.598 . . . . 0.0 111.605 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.0 tp -58.89 -47.38 85.17 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.689 -0.405 . . . . 0.0 110.118 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.5 mt -58.39 -34.87 71.21 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.397 -178.385 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 86.8 mt -60.21 -43.52 93.43 Favored 'Isoleucine or valine' 0 C--O 1.238 0.489 0 CA-C-O 120.797 0.332 . . . . 0.0 110.963 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 92.1 mt -59.66 -39.1 83.3 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.924 -0.31 . . . . 0.0 110.483 -179.537 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 59.0 tp -59.92 -35.69 75.42 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.88 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 75.5 m -59.58 -39.22 83.4 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.347 -179.619 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.526 ' NH1' ' OG ' ' A' ' 50' ' ' SER . 0.3 OUTLIER -61.88 -38.14 87.2 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.23 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.68 HH12 ' N ' ' A' ' 52' ' ' GLY . 0.0 OUTLIER -57.29 -27.58 62.27 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.389 -179.776 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 93.7 t80 -59.85 -48.05 83.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.047 0.451 . . . . 0.0 110.173 179.796 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -61.76 -52.43 64.25 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 119.865 -0.734 . . . . 0.0 109.25 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.526 ' OG ' ' NH1' ' A' ' 46' ' ' ARG . 74.0 m -70.48 140.54 51.93 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.923 -179.847 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -64.0 -43.16 97.78 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 179.183 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.68 ' N ' HH12 ' A' ' 47' ' ' ARG . . . 73.19 54.36 7.01 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 -179.486 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 54.2 p30 -97.82 17.73 17.39 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.68 0.276 . . . . 0.0 111.005 -179.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 25.5 mmtp -60.81 -39.87 90.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.454 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -61.37 -42.0 97.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.111 0.481 . . . . 0.0 109.712 179.363 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -68.03 -36.15 79.44 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.847 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 93.9 mtm-85 57.5 36.72 27.26 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.611 -179.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 64.4 tt0 -135.4 131.99 36.97 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.227 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.422 ' O ' ' OD1' ' A' ' 60' ' ' ASN . 45.5 pt -130.17 148.24 33.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.857 179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' A' ' 59' ' ' ILE . 83.7 m-20 -146.85 143.44 28.58 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.962 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 49.76 42.74 24.14 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.303 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 60.1 p30 -155.68 170.86 21.05 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.802 179.64 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -142.33 74.68 20.28 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.663 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_exo . . . . . 0 C--N 1.306 -1.664 0 C-N-CA 122.704 2.269 . . . . 0.0 112.122 -179.996 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 81.0 mt . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.425 ' OD1' ' O ' ' A' ' 2' ' ' ASP . 53.6 p-10 -126.05 82.46 2.07 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.565 179.811 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 90.4 mtm180 -103.68 -2.24 26.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.134 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' TRP . . . . . 0.522 ' CE3' ' O ' ' A' ' 4' ' ' TRP . 77.0 t90 -120.64 2.73 10.67 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.489 -179.749 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.416 ' O ' ' C ' ' A' ' 6' ' ' LEU . 92.1 m-85 -123.42 140.29 53.16 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.467 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.416 ' C ' ' O ' ' A' ' 5' ' ' TYR . 90.3 mt -34.27 143.55 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.924 -179.124 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 93.18 -11.79 71.13 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.164 -1.174 . . . . 0.0 110.164 -179.005 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -83.85 174.55 51.45 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 179.666 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 68.9 m -84.27 148.86 53.99 Favored Pre-proline 0 CA--C 1.532 0.262 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.565 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -68.62 -85.02 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.429 0 C-N-CA 121.886 1.724 . . . . 0.0 112.113 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -93.97 -11.72 30.26 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.735 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.16 16.49 80.66 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 111.284 -0.726 . . . . 0.0 111.284 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.429 ' OD1' ' O ' ' A' ' 13' ' ' ASP . 67.6 t0 -160.24 51.5 0.31 Allowed 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.832 -0.347 . . . . 0.0 110.858 179.729 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 26.8 m -146.99 153.39 12.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.496 179.001 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.412 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 37.5 p-10 -132.89 65.57 74.42 Favored Pre-proline 0 C--N 1.331 -0.222 0 CA-C-O 120.772 0.32 . . . . 0.0 110.569 179.734 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -80.12 6.0 5.61 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 C-N-CA 123.229 2.619 . . . . 0.0 112.701 -179.654 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 82.3 m-85 -60.98 -42.45 98.37 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.4 -0.52 . . . . 0.0 111.339 -178.639 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 31.0 p90 -69.47 -27.38 65.17 Favored 'General case' 0 C--N 1.331 -0.206 0 C-N-CA 120.618 -0.433 . . . . 0.0 111.023 -179.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 93.8 t80 -61.01 -48.76 80.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.108 0.48 . . . . 0.0 109.869 179.501 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 -67.87 -28.82 67.86 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.755 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.704 ' O ' HG12 ' A' ' 24' ' ' VAL . 89.8 t80 -62.61 -44.29 96.66 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.694 -179.537 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.406 ' O ' ' CG ' ' A' ' 25' ' ' ARG . 98.4 mt-10 -58.33 -38.81 77.89 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -179.091 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.494 ' O ' ' N ' ' A' ' 27' ' ' GLY . 97.3 m -63.6 -37.03 85.79 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.866 0.365 . . . . 0.0 111.13 179.696 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.704 HG12 ' O ' ' A' ' 21' ' ' TYR . 2.7 p -38.27 -23.73 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.51 0 N-CA-C 113.471 0.915 . . . . 0.0 113.471 -176.714 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.451 ' N ' ' O ' ' A' ' 23' ' ' THR . 4.1 ptm180 -80.04 -54.26 5.95 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 119.576 -0.85 . . . . 0.0 110.712 178.781 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . 0.445 ' OD1' ' NE ' ' A' ' 25' ' ' ARG . 34.3 m120 -91.44 -3.09 57.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.1 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -60.93 -42.0 99.53 Favored Glycine 0 CA--C 1.525 0.704 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.872 -179.243 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.28 -42.15 99.7 Favored Glycine 0 CA--C 1.525 0.668 0 C-N-CA 120.85 -0.69 . . . . 0.0 111.405 -179.536 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.4 mt -59.69 -46.81 87.93 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.367 -178.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 90.9 mt -60.82 -43.67 95.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.787 0.327 . . . . 0.0 110.917 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.0 t80 -60.29 -46.85 88.42 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.277 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.14 -42.6 86.21 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.875 -0.33 . . . . 0.0 111.417 -177.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.23 -40.08 96.84 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 60.3 tp -64.89 -39.85 94.19 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.214 0.53 . . . . 0.0 109.877 178.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.409 ' O ' HG22 ' A' ' 38' ' ' VAL . . . -60.94 -46.0 92.47 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.281 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -59.84 -48.62 80.96 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.354 -178.25 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 92.1 mt -59.19 -48.75 85.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 N-CA-C 112.185 0.439 . . . . 0.0 112.185 -177.562 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.409 HG22 ' O ' ' A' ' 35' ' ' ALA . 29.3 m -56.67 -35.45 45.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.485 -179.002 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -61.8 -38.51 96.08 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 111.815 -0.514 . . . . 0.0 111.815 -179.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.4 tp -59.0 -47.11 86.37 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.319 -0.552 . . . . 0.0 109.696 -179.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.9 mt -57.26 -34.13 68.32 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.278 -178.433 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 88.5 mt -60.74 -42.98 94.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.885 0.374 . . . . 0.0 110.822 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 91.6 mt -59.0 -39.49 81.99 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.141 -179.258 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 94.7 mt -60.71 -33.16 72.47 Favored 'General case' 0 C--O 1.238 0.455 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.975 -179.57 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 70.3 m -58.44 -40.51 82.76 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.517 ' HE ' ' N ' ' A' ' 51' ' ' GLY . 3.7 tmt_? -61.06 -37.43 82.62 Favored 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 120.677 -0.409 . . . . 0.0 110.522 178.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.26 -29.35 57.93 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.868 -178.509 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 34.7 m-85 -59.28 -39.53 83.24 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 119.693 -0.803 . . . . 0.0 109.926 179.449 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.487 ' O ' ' CB ' ' A' ' 50' ' ' SER . 71.7 mtp85 -93.11 -52.26 4.65 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 178.1 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.487 ' CB ' ' O ' ' A' ' 49' ' ' ARG . 1.0 OUTLIER 85.72 40.55 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.384 -179.539 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.517 ' N ' ' HE ' ' A' ' 46' ' ' ARG . . . 82.43 0.21 89.66 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 55.92 -129.01 46.7 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 179.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -75.84 149.93 37.75 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 110.151 -0.314 . . . . 0.0 110.151 179.467 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -140.35 133.98 30.25 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.62 179.35 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 26.1 pttm -113.52 -34.26 5.62 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.324 179.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.405 ' O ' ' C ' ' A' ' 57' ' ' ARG . 83.6 mtp180 -68.48 -37.87 80.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.521 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.405 ' C ' ' O ' ' A' ' 56' ' ' ARG . 81.1 mtp180 35.02 -130.35 0.08 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.329 179.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 24.0 mp0 -136.36 129.58 31.52 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.57 179.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 44.9 pt -130.92 -32.04 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.926 0.393 . . . . 0.0 110.66 179.318 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.627 HD21 ' CG ' ' A' ' 63' ' ' GLU . 47.2 p30 -168.19 159.55 10.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.329 179.676 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 53.0 tp10 -63.21 -45.2 92.77 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.398 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 27.4 t0 -166.79 166.65 15.6 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.731 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.627 ' CG ' HD21 ' A' ' 60' ' ' ASN . 97.0 mt-10 -129.99 70.85 82.25 Favored Pre-proline 0 C--N 1.332 -0.164 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.627 179.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo . . . . . 0 C--N 1.308 -1.603 0 C-N-CA 122.665 2.243 . . . . 0.0 112.1 -179.88 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 80.7 mt . . . . . 0 N--CA 1.489 1.477 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -118.06 158.12 25.59 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.135 -0.484 . . . . 0.0 109.968 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -128.88 9.3 5.81 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.873 0.368 . . . . 0.0 110.073 179.278 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' TRP . . . . . . . . . . . . . 23.1 m-90 -105.74 13.55 29.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.649 -179.615 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.533 ' CD2' ' O ' ' A' ' 6' ' ' LEU . 38.9 p90 -91.32 164.31 13.9 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.967 0.413 . . . . 0.0 110.924 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.533 ' O ' ' CD2' ' A' ' 5' ' ' TYR . 90.5 mt -47.5 159.88 0.13 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.835 -178.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 84.69 2.45 88.71 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -88.07 131.86 10.88 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 81.0 p -105.81 150.43 39.16 Favored Pre-proline 0 CA--C 1.535 0.377 0 N-CA-C 110.504 -0.184 . . . . 0.0 110.504 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -71.39 84.35 0.95 Allowed 'Trans proline' 0 N--CA 1.494 1.552 0 C-N-CA 122.223 1.948 . . . . 0.0 112.135 179.67 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -73.86 -9.5 58.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.765 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.8 8.41 58.18 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.771 -0.931 . . . . 0.0 110.771 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -64.74 -66.02 0.6 Allowed 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.044 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.8 m -143.81 148.94 18.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.766 178.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.406 ' N ' ' OD1' ' A' ' 15' ' ' ASP . 40.9 p-10 -129.93 64.67 73.0 Favored Pre-proline 0 C--N 1.332 -0.164 0 CA-C-O 120.652 0.263 . . . . 0.0 110.636 -179.631 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -74.25 -6.88 19.06 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.847 2.364 . . . . 0.0 112.427 -179.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.448 ' O ' ' N ' ' A' ' 21' ' ' TYR . 81.6 m-85 -60.04 -40.46 89.46 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.09 -179.204 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -60.13 -45.65 92.3 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.165 -0.614 . . . . 0.0 109.939 -179.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -61.92 -46.62 88.54 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.275 0.559 . . . . 0.0 109.952 178.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.402 ' O ' ' OG1' ' A' ' 23' ' ' THR . 97.8 m-20 -75.75 -11.24 59.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.356 -0.838 . . . . 0.0 111.45 -179.697 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.645 ' O ' HG12 ' A' ' 24' ' ' VAL . 88.2 t80 -63.26 -44.04 96.28 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.43 -179.712 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 mm-40 -58.82 -38.5 78.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.803 -178.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.524 ' O ' ' N ' ' A' ' 27' ' ' GLY . 75.6 p -65.45 -26.64 68.04 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.781 -0.368 . . . . 0.0 110.577 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.645 HG12 ' O ' ' A' ' 21' ' ' TYR . 3.0 p -43.83 -23.36 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.717 -178.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 90.7 mtm180 -73.13 -55.35 6.6 Favored 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 119.716 -0.794 . . . . 0.0 110.109 178.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -93.42 -1.43 55.8 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.439 -0.8 . . . . 0.0 112.081 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.06 -43.32 99.58 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.529 -178.518 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.88 -43.9 98.58 Favored Glycine 0 CA--C 1.526 0.773 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.829 -179.134 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.6 tp -59.52 -48.38 81.89 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.642 -178.536 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 92.4 mt -61.66 -44.41 98.64 Favored 'Isoleucine or valine' 0 C--O 1.236 0.348 0 CA-C-O 120.894 0.378 . . . . 0.0 111.526 -179.443 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.6 t80 -60.72 -46.58 89.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.152 -179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.81 -41.79 87.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.482 -178.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.59 -41.02 98.66 Favored Glycine 0 CA--C 1.525 0.691 0 C-N-CA 120.427 -0.892 . . . . 0.0 111.002 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.404 HD23 ' HA ' ' A' ' 34' ' ' LEU . 95.0 mt -67.16 -37.91 84.57 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.18 0.514 . . . . 0.0 110.114 178.819 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.51 -47.65 85.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.162 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 93.1 t80 -59.4 -46.81 87.63 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 116.083 -0.508 . . . . 0.0 112.227 -178.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.7 mm -57.57 -44.35 84.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.705 -178.522 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.1 t -57.2 -39.79 69.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.701 -179.318 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.67 -36.91 92.6 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 -179.794 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.4 tp -58.9 -48.23 82.16 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.007 -0.677 . . . . 0.0 109.891 -179.573 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.454 ' N ' HD12 ' A' ' 41' ' ' LEU . 10.9 mp -56.19 -33.1 64.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.437 -178.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 4.7 mm -60.77 -43.81 96.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.455 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.414 HD13 ' HA ' ' A' ' 43' ' ' LEU . 4.2 mm? -57.12 -40.78 77.75 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.282 -0.567 . . . . 0.0 110.243 -179.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.46 ' N ' HD12 ' A' ' 44' ' ' LEU . 10.3 mp -60.96 -30.27 70.15 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.057 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 39.9 t -59.36 -41.44 89.25 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 -179.468 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.5 ttt-85 -62.34 -39.86 94.48 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.33 -0.548 . . . . 0.0 110.488 179.233 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.436 ' O ' ' OG ' ' A' ' 50' ' ' SER . 0.0 OUTLIER -56.8 -30.98 64.22 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.389 -178.761 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -64.24 -40.48 96.1 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.162 -0.615 . . . . 0.0 111.263 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -62.59 -53.36 55.81 Favored 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 119.328 -0.949 . . . . 0.0 108.976 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.53 ' O ' ' NH1' ' A' ' 57' ' ' ARG . 61.6 m 53.56 27.0 6.13 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.834 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 41.99 87.29 0.01 OUTLIER Glycine 0 CA--C 1.527 0.821 0 N-CA-C 110.931 -0.867 . . . . 0.0 110.931 179.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -174.84 171.39 44.55 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 179.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -63.75 -42.06 97.91 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.859 0.362 . . . . 0.0 110.62 179.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -129.11 150.4 50.52 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.424 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 62.3 mttp -59.88 -43.1 94.93 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.606 -178.829 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.519 ' O ' ' CB ' ' A' ' 57' ' ' ARG . 83.8 mtp180 -70.06 -20.06 63.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.631 -0.259 . . . . 0.0 110.88 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.53 ' NH1' ' O ' ' A' ' 50' ' ' SER . 12.1 tpp180 90.29 -138.76 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.369 0 O-C-N 123.699 0.624 . . . . 0.0 110.901 -179.596 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.416 ' O ' ' OD2' ' A' ' 62' ' ' ASP . 78.7 mt-30 -136.88 137.14 39.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.17 179.022 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.6 pt -62.04 -24.82 35.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.519 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 33.5 m120 -69.88 157.32 37.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.513 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 77.4 mm-40 37.35 -122.18 0.2 Allowed 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.181 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.416 ' OD2' ' O ' ' A' ' 58' ' ' GLN . 65.5 m-20 42.64 -128.97 0.68 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.453 -179.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -70.51 149.16 95.56 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.276 179.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo . . . . . 0 N--CA 1.492 1.419 0 C-N-CA 122.134 1.89 . . . . 0.0 112.071 179.877 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . 0.529 ' O ' ' NE1' ' A' ' 4' ' ' TRP . 60.7 tp . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 53.1 p-10 -81.46 -176.92 6.28 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.835 -179.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 66.8 ttp85 60.83 65.27 1.04 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.677 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' TRP . . . . . 0.529 ' NE1' ' O ' ' A' ' 1' ' ' LEU . 98.3 m95 -88.03 -16.32 33.98 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.1 179.578 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.535 ' CD2' ' O ' ' A' ' 6' ' ' LEU . 81.0 t80 -143.64 140.61 30.19 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.197 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.535 ' O ' ' CD2' ' A' ' 5' ' ' TYR . 90.4 mt -69.26 154.99 41.15 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 -179.915 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 85.19 34.18 15.33 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 -178.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -85.11 116.32 4.29 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 179.604 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 69.7 m -128.58 152.17 78.07 Favored Pre-proline 0 CA--C 1.533 0.302 0 C-N-CA 121.362 -0.135 . . . . 0.0 110.944 -179.17 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_exo -51.33 143.34 34.51 Favored 'Trans proline' 0 N--CA 1.497 1.726 0 C-N-CA 121.963 1.776 . . . . 0.0 112.057 179.388 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -90.25 0.82 57.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.308 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 81.37 1.28 90.0 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 56.3 t0 44.0 67.72 0.63 Allowed 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 11.8 p -149.72 147.28 16.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.054 -179.64 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.9 m-20 -118.03 84.72 22.1 Favored Pre-proline 0 CA--C 1.533 0.292 0 CA-C-N 115.923 -0.58 . . . . 0.0 109.815 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -83.27 34.88 0.55 Allowed 'Trans proline' 0 N--CA 1.49 1.312 0 C-N-CA 122.889 2.392 . . . . 0.0 113.412 -178.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 -59.65 -16.0 23.19 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.711 -0.395 . . . . 0.0 110.224 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 92.5 t80 -59.22 -43.8 92.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.792 179.504 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 90.6 t80 -57.72 -37.72 74.03 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.029 0.442 . . . . 0.0 109.935 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.738 ' O ' HG23 ' A' ' 24' ' ' VAL . 97.8 m-20 -70.72 -7.91 48.26 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.535 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 78.6 t80 -61.47 -43.28 99.15 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.51 -178.762 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 53.1 tp10 -58.91 -46.5 87.76 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.231 -0.588 . . . . 0.0 109.515 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.518 ' O ' ' N ' ' A' ' 27' ' ' GLY . 97.8 m -64.52 -44.46 90.8 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 121.019 0.437 . . . . 0.0 110.473 179.198 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.738 HG23 ' O ' ' A' ' 20' ' ' ASP . 45.4 t -44.86 -24.8 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.919 -178.212 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -72.95 -54.23 9.2 Favored 'General case' 0 C--N 1.323 -0.584 0 C-N-CA 119.472 -0.891 . . . . 0.0 109.855 178.482 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -91.99 -1.14 57.41 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.336 -179.094 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.41 -41.86 99.63 Favored Glycine 0 CA--C 1.528 0.872 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.353 -178.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.71 -44.83 97.38 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.926 -179.161 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.7 tp -59.77 -47.92 83.75 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.865 -178.358 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.1 mt -62.11 -43.6 97.96 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 CA-C-O 120.904 0.383 . . . . 0.0 111.458 -179.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 91.6 t80 -60.62 -46.14 91.41 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.272 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.77 -42.36 88.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.341 -0.391 . . . . 0.0 111.622 -178.209 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.23 -40.13 96.92 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.6 tp -67.7 -39.87 84.36 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-O 121.422 0.63 . . . . 0.0 109.918 178.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -59.56 -49.02 79.38 Favored 'General case' 0 C--O 1.225 -0.236 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.581 -178.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -60.78 -40.48 92.72 Favored 'General case' 0 C--O 1.236 0.351 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -178.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.3 mt -58.55 -44.76 90.01 Favored 'Isoleucine or valine' 0 C--O 1.235 0.326 0 C-N-CA 120.256 -0.578 . . . . 0.0 110.549 -179.065 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 53.7 t -58.66 -40.15 78.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.794 -179.596 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.28 -36.05 89.85 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 111.773 -0.531 . . . . 0.0 111.773 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 40' ' ' LEU . 92.6 mt -60.28 -43.23 96.42 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 119.934 -0.706 . . . . 0.0 109.515 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 59.4 tp -56.69 -37.25 70.62 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.905 -179.193 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 4.7 mm -59.52 -42.14 87.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.89 0.376 . . . . 0.0 110.614 -179.495 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 91.0 mt -58.64 -39.99 82.11 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.303 -0.559 . . . . 0.0 110.416 -179.093 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.407 ' N ' HD12 ' A' ' 44' ' ' LEU . 10.8 mp -60.96 -30.11 70.05 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 120.709 0.29 . . . . 0.0 111.12 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 42.6 t -58.74 -42.34 88.56 Favored 'General case' 0 CA--C 1.518 -0.266 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 179.623 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 15.8 tpt180 -61.0 -36.91 80.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.769 178.707 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.445 ' O ' ' O ' ' A' ' 50' ' ' SER . 12.5 ttp180 -55.25 -26.9 42.72 Favored 'General case' 0 C--O 1.231 0.127 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.514 -178.425 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -60.18 -37.9 81.6 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 119.905 -0.718 . . . . 0.0 110.358 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 84.9 mtp180 -89.07 -54.96 3.88 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 119.919 -0.712 . . . . 0.0 110.282 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.445 ' O ' ' O ' ' A' ' 47' ' ' ARG . 90.3 p -95.4 159.25 15.09 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.782 -179.759 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 70.07 22.56 77.28 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.431 ' O ' ' OD1' ' A' ' 53' ' ' ASN . . . -59.18 132.78 52.4 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.431 ' OD1' ' O ' ' A' ' 52' ' ' GLY . 82.9 m-20 -147.34 137.23 23.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.648 0.261 . . . . 0.0 110.66 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 56.7 mtmt -141.23 58.67 1.53 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.338 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -111.87 5.7 19.11 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.604 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 5.4 tpp85 -118.75 8.38 11.82 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.847 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 96.3 mtm-85 -133.78 148.53 51.37 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.232 179.68 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 98.5 mt-30 -134.42 153.29 51.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.661 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 47.5 pt -122.84 156.54 28.29 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.813 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 32.5 m120 -115.53 153.47 31.11 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.932 -179.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -67.61 154.07 42.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.462 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -61.68 144.64 54.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.998 0.427 . . . . 0.0 110.697 -179.83 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -70.67 149.38 95.33 Favored Pre-proline 0 CA--C 1.532 0.272 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.259 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo . . . . . 0 N--CA 1.494 1.541 0 C-N-CA 122.077 1.851 . . . . 0.0 112.021 179.862 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . 0.444 ' H1 ' ' H ' ' A' ' 7' ' ' GLY . 1.9 mp . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 58.0 p30 -127.02 177.73 6.45 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.666 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 16.3 ttm180 39.91 -146.67 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.363 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' TRP . . . . . . . . . . . . . 86.7 t90 -85.97 -26.17 25.63 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.794 0.33 . . . . 0.0 110.831 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -79.57 143.9 34.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.623 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 89.9 mt -127.63 135.92 50.92 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.025 179.289 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.444 ' H ' ' H1 ' ' A' ' 1' ' ' LEU . . . 78.91 5.1 88.83 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.214 -0.754 . . . . 0.0 111.214 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -68.54 149.26 49.51 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 111.575 -0.61 . . . . 0.0 111.575 -179.358 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 46.4 t -86.23 133.26 41.06 Favored Pre-proline 0 CA--C 1.538 0.505 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_exo -46.91 133.37 17.8 Favored 'Trans proline' 0 N--CA 1.495 1.576 0 C-N-CA 121.133 1.222 . . . . 0.0 111.501 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -94.39 2.37 55.79 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.07 -0.513 . . . . 0.0 111.319 -179.175 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.04 20.76 75.31 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 -179.467 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 -53.4 -67.44 0.25 Allowed 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 35.6 m -142.59 145.97 22.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.998 -0.547 . . . . 0.0 109.806 178.488 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -129.67 68.2 80.2 Favored Pre-proline 0 C--N 1.331 -0.197 0 CA-C-O 120.755 0.312 . . . . 0.0 110.471 -179.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -74.56 -6.38 18.19 Favored 'Trans proline' 0 N--CA 1.493 1.455 0 C-N-CA 122.717 2.278 . . . . 0.0 112.373 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.451 ' O ' ' N ' ' A' ' 21' ' ' TYR . 81.9 m-85 -61.27 -40.23 93.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.148 -179.278 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 82.9 m-85 -59.83 -45.49 92.2 Favored 'General case' 0 C--N 1.331 -0.234 0 C-N-CA 120.315 -0.554 . . . . 0.0 110.277 -178.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 88.7 m-85 -69.5 -37.71 77.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.213 0.53 . . . . 0.0 109.864 178.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -75.43 -15.67 60.42 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.43 -0.804 . . . . 0.0 110.969 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.663 ' O ' HG12 ' A' ' 24' ' ' VAL . 90.5 t80 -62.5 -44.23 96.89 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.948 -179.358 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 79.2 mm-40 -57.58 -38.86 75.56 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 120.721 -0.391 . . . . 0.0 110.67 -178.469 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.533 ' O ' ' N ' ' A' ' 27' ' ' GLY . 72.3 p -67.83 -27.52 66.79 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.651 179.686 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.663 HG12 ' O ' ' A' ' 21' ' ' TYR . 2.4 p -42.5 -24.05 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.149 -0.478 . . . . 0.0 112.112 -177.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 63.2 ttm-85 -75.26 -54.64 6.76 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.273 179.04 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -93.19 -1.32 56.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.589 -0.732 . . . . 0.0 112.141 -179.485 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -62.18 -43.63 98.84 Favored Glycine 0 CA--C 1.528 0.86 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.688 -178.624 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -62.05 -45.44 96.09 Favored Glycine 0 CA--C 1.527 0.813 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.088 -179.015 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.1 mt -60.18 -46.23 90.44 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.533 -0.467 . . . . 0.0 111.281 -178.124 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.3 mt -62.08 -45.51 98.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 CA-C-O 120.815 0.341 . . . . 0.0 111.565 -179.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.1 t80 -61.77 -47.03 87.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.922 0.391 . . . . 0.0 111.253 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.53 -41.63 90.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.495 -178.375 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.94 -40.36 98.28 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 120.589 -0.815 . . . . 0.0 111.164 -179.609 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 98.5 mt -69.85 -39.36 76.42 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.324 0.583 . . . . 0.0 110.019 178.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.9 -48.0 83.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.192 -179.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -59.64 -46.54 88.69 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.102 -0.499 . . . . 0.0 112.297 -178.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 89.3 mt -58.44 -44.53 89.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 C-N-CA 121.016 -0.273 . . . . 0.0 111.283 -178.23 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.9 t -58.33 -39.57 74.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 120.818 0.342 . . . . 0.0 110.722 -179.485 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.86 -37.3 93.49 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.2 tp -58.8 -48.46 81.21 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.372 -179.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.481 ' N ' HD12 ' A' ' 41' ' ' LEU . 10.8 mp -57.36 -34.07 68.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.536 -178.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 39.5 mm -60.58 -43.32 94.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.391 0 CA-C-O 121.026 0.441 . . . . 0.0 110.922 -179.276 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 90.9 mt -60.51 -39.86 89.31 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.684 -0.406 . . . . 0.0 110.67 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 9.8 mp -60.59 -30.98 70.16 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.261 -179.404 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 74.2 m -63.08 -39.61 95.24 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.783 0.325 . . . . 0.0 110.463 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.2 tpm_? -61.8 -39.97 93.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.649 179.694 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.778 HH22 ' H ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -65.27 -24.15 67.23 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.811 -178.974 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 89.6 t80 -60.51 -49.86 75.88 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.053 179.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 42.3 mmm-85 -62.0 -51.97 65.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.609 -179.19 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.527 ' OG ' ' NH2' ' A' ' 47' ' ' ARG . 88.2 p -68.72 -21.95 64.37 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.546 -0.297 . . . . 0.0 111.278 -179.757 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.475 ' N ' ' O ' ' A' ' 47' ' ' ARG . . . 60.31 -130.46 48.83 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.498 ' O ' ' N ' ' A' ' 54' ' ' LYS . . . -44.16 145.23 1.79 Allowed Glycine 0 CA--C 1.526 0.748 0 N-CA-C 111.449 -0.661 . . . . 0.0 111.449 -178.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.421 ' O ' ' O ' ' A' ' 54' ' ' LYS . 8.0 p-10 -45.66 88.38 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.859 0.362 . . . . 0.0 111.437 -179.217 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.778 ' H ' HH22 ' A' ' 47' ' ' ARG . 10.6 tptp 44.86 98.32 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.923 179.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -62.96 -38.78 92.46 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.197 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 13.6 tpp85 -67.81 -37.07 81.51 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.845 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 55.69 -150.62 0.42 Allowed 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.703 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 72.3 tp60 -132.56 132.6 42.73 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.818 0.342 . . . . 0.0 110.268 179.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 20.2 tt -71.14 -35.28 57.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.505 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -99.78 153.07 19.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.876 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 58.09 62.58 2.0 Allowed 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.415 -179.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -63.07 145.23 55.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.168 179.534 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.432 ' OE1' ' N ' ' A' ' 63' ' ' GLU . 40.4 mp0 -70.5 149.2 95.58 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.291 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo . . . . . 0 N--CA 1.493 1.45 0 C-N-CA 122.163 1.908 . . . . 0.0 112.062 179.895 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . 0.564 ' H3 ' HD12 ' A' ' 1' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.655 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -67.8 174.01 3.95 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.22 -178.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.788 HH11 HD22 ' A' ' 6' ' ' LEU . 97.2 mtt180 62.71 171.29 0.14 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.399 -0.819 . . . . 0.0 109.68 -179.225 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' TRP . . . . . . . . . . . . . 37.6 p90 -126.13 -27.9 3.2 Favored 'General case' 0 C--O 1.232 0.154 0 CA-C-O 120.777 0.322 . . . . 0.0 110.642 179.308 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.436 ' OH ' ' O ' ' A' ' 8' ' ' GLY . 91.3 t80 -140.35 127.31 20.73 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.242 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.788 HD22 HH11 ' A' ' 3' ' ' ARG . 55.6 tp -158.32 156.09 29.96 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 109.93 -179.645 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.74 -3.47 81.28 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 179.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.436 ' O ' ' OH ' ' A' ' 5' ' ' TYR . . . 60.78 -125.18 37.65 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.773 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 23.2 t -126.83 79.9 71.63 Favored Pre-proline 0 C--N 1.331 -0.219 0 N-CA-C 110.432 -0.21 . . . . 0.0 110.432 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -77.25 160.19 32.84 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 C-N-CA 122.557 2.171 . . . . 0.0 112.582 -179.575 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 57.4 mtmt -77.69 -7.92 57.17 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.435 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.73 1.29 57.53 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 66.9 t0 -100.45 104.71 16.13 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 179.128 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.514 HG13 ' O ' ' A' ' 14' ' ' VAL . 11.6 p -135.25 124.73 42.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-O 120.851 0.358 . . . . 0.0 110.735 -179.494 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 42.2 p-10 -162.74 58.56 0.8 Allowed Pre-proline 0 CA--C 1.531 0.225 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.827 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.482 ' C ' ' H ' ' A' ' 18' ' ' TYR . 51.5 Cg_endo -68.77 -20.24 40.07 Favored 'Trans proline' 0 N--CA 1.496 1.653 0 C-N-CA 122.823 2.348 . . . . 0.0 112.891 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -57.48 -1.1 0.08 Allowed 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.94 -0.304 . . . . 0.0 111.701 -177.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.482 ' H ' ' C ' ' A' ' 16' ' ' PRO . 96.9 m-85 -110.05 -46.04 3.52 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.814 0.34 . . . . 0.0 110.404 178.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -90.26 -14.51 33.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.562 -179.521 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.758 ' O ' HG13 ' A' ' 24' ' ' VAL . 35.1 t70 -61.62 -45.5 93.79 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.891 -0.324 . . . . 0.0 111.217 -179.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -65.15 -40.99 95.14 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.565 -179.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -70.62 -50.03 41.28 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.541 -179.649 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.554 ' O ' ' N ' ' A' ' 27' ' ' GLY . 97.2 m -65.55 -50.45 65.11 Favored 'General case' 0 C--O 1.222 -0.364 0 N-CA-C 113.315 0.857 . . . . 0.0 113.315 -177.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.758 HG13 ' O ' ' A' ' 20' ' ' ASP . 35.5 m -46.98 -25.55 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 112.632 0.605 . . . . 0.0 112.632 -177.41 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 18.7 tpp180 -73.08 -54.95 7.24 Favored 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 119.689 -0.804 . . . . 0.0 110.244 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -91.86 -2.06 57.03 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 115.543 -0.753 . . . . 0.0 111.95 -179.089 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.554 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.45 -42.79 99.85 Favored Glycine 0 CA--C 1.526 0.751 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.576 -178.678 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.04 -45.17 97.14 Favored Glycine 0 CA--C 1.525 0.713 0 C-N-CA 120.652 -0.785 . . . . 0.0 111.879 -178.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.588 ' N ' HD12 ' A' ' 29' ' ' LEU . 10.2 mp -60.09 -47.96 83.71 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.755 -178.676 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.1 mt -62.37 -44.62 99.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.722 0.296 . . . . 0.0 111.624 -179.413 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -61.22 -46.97 88.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.63 0.252 . . . . 0.0 111.526 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.18 -42.6 91.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.547 -178.05 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.84 -40.81 98.77 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.811 -0.915 . . . . 0.0 110.811 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.6 tp -67.22 -41.37 85.83 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.436 0.636 . . . . 0.0 109.713 178.689 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.61 -47.84 84.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.001 -1.0 . . . . 0.0 110.224 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 92.3 t80 -59.39 -47.41 85.54 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.933 -0.576 . . . . 0.0 112.506 -178.242 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 5.4 mm -58.13 -43.34 85.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.545 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.3 t -57.76 -39.72 72.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.558 -179.36 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.412 ' HA2' HD12 ' A' ' 42' ' ' ILE . . . -61.08 -37.44 93.92 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.577 -0.609 . . . . 0.0 111.577 -179.762 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.5 tp -58.17 -46.47 85.68 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 94.7 mt -58.31 -33.89 69.99 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.714 -0.676 . . . . 0.0 111.431 -178.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.412 HD12 ' HA2' ' A' ' 39' ' ' GLY . 89.4 mt -60.35 -45.13 96.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 CA-C-O 120.745 0.307 . . . . 0.0 111.416 -179.208 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.472 HD22 ' N ' ' A' ' 43' ' ' LEU . 4.0 mm? -59.39 -38.95 81.83 Favored 'General case' 0 C--O 1.234 0.254 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.529 -179.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 59.2 tp -59.42 -35.88 74.84 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.697 -179.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 75.7 m -60.28 -38.34 83.29 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.667 -0.242 . . . . 0.0 110.49 -179.68 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.3 tmt_? -59.54 -44.09 93.31 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 119.999 -0.68 . . . . 0.0 110.027 179.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.44 -27.42 64.34 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.682 -179.554 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 93.1 t80 -61.04 -49.3 77.95 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.048 -0.661 . . . . 0.0 109.746 179.299 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.418 ' O ' ' C ' ' A' ' 50' ' ' SER . 0.0 OUTLIER -64.01 -56.65 13.55 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.398 -179.9 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.43 ' O ' ' OD1' ' A' ' 53' ' ' ASN . 39.3 m 35.1 -113.16 0.07 Allowed 'General case' 0 N--CA 1.462 0.162 0 CA-C-O 120.993 0.425 . . . . 0.0 110.968 179.811 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -55.92 146.08 32.29 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 110.44 -1.064 . . . . 0.0 110.44 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 95.93 19.72 28.14 Favored Glycine 0 CA--C 1.528 0.872 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 -179.269 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.43 ' OD1' ' O ' ' A' ' 50' ' ' SER . 55.1 p30 -156.48 174.86 14.81 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.674 0.273 . . . . 0.0 110.556 179.29 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 73.3 mmtt 52.49 55.43 9.11 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.244 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -60.56 -40.07 90.27 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.553 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.517 ' NH1' ' O ' ' A' ' 64' ' ' PRO . 99.5 mtt180 -68.32 -37.86 81.01 Favored 'General case' 0 C--N 1.331 -0.216 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.412 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 28.0 ttm105 58.89 33.26 22.93 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.024 179.336 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -106.23 148.6 27.74 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.913 0.387 . . . . 0.0 110.449 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.2 pt -94.52 5.8 7.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.911 -179.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 64.6 t30 -82.84 112.39 19.61 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.472 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 80.7 mm-40 -89.13 -4.95 58.13 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.616 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -60.82 -43.03 98.75 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.635 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -130.94 79.69 71.03 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.677 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . 0.517 ' O ' ' NH1' ' A' ' 56' ' ' ARG . 37.3 Cg_exo . . . . . 0 C--N 1.308 -1.561 0 C-N-CA 122.677 2.251 . . . . 0.0 112.08 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . 0.526 ' O ' ' NH1' ' A' ' 3' ' ' ARG . 0.2 OUTLIER . . . . . 0 N--CA 1.489 1.512 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -69.22 147.3 51.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.674 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.526 ' NH1' ' O ' ' A' ' 1' ' ' LEU . 7.5 ptp85 -164.67 69.81 0.17 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.755 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' TRP . . . . . . . . . . . . . 5.1 p90 -116.06 -5.06 11.94 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.509 179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 54.6 p90 -76.85 174.06 10.98 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.958 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 8.5 mp -38.48 143.67 0.13 Allowed 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.785 -179.393 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.81 -9.47 77.62 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -178.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 57.35 -118.32 12.17 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 179.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 55.5 m -123.54 79.56 54.77 Favored Pre-proline 0 CA--C 1.532 0.28 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -74.7 160.93 40.34 Favored 'Trans proline' 0 N--CA 1.495 1.567 0 C-N-CA 122.355 2.036 . . . . 0.0 112.977 -178.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -94.07 -23.19 18.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.555 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.49 9.44 77.97 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 111.106 -0.798 . . . . 0.0 111.106 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 57.7 p30 -142.83 32.76 1.4 Allowed 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.081 -179.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.55 HG22 ' HD3' ' A' ' 16' ' ' PRO . 10.7 p -140.73 137.75 35.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.017 0.437 . . . . 0.0 110.756 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 33.0 t70 -131.42 76.52 75.41 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.889 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.55 ' HD3' HG22 ' A' ' 14' ' ' VAL . 73.0 Cg_endo -77.0 -8.38 17.71 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.643 2.228 . . . . 0.0 113.094 -178.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -61.74 -41.46 97.69 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.687 -179.58 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -60.11 -48.83 80.07 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.546 -179.222 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 85.6 m-85 -69.74 -35.32 74.87 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.882 0.373 . . . . 0.0 110.57 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.695 ' O ' HG23 ' A' ' 24' ' ' VAL . 97.4 m-20 -77.43 -8.37 57.63 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.87 -179.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -62.06 -45.28 94.23 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.837 -0.345 . . . . 0.0 110.169 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -59.89 -40.91 90.36 Favored 'General case' 0 C--N 1.324 -0.521 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.238 -179.462 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.538 ' O ' ' N ' ' A' ' 27' ' ' GLY . 73.6 p -70.97 -39.38 72.57 Favored 'General case' 0 C--O 1.224 -0.288 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.747 179.69 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.695 HG23 ' O ' ' A' ' 20' ' ' ASP . 38.4 t -45.16 -24.36 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.75 -178.619 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 62.8 ttm-85 -71.82 -54.04 11.4 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 119.562 -0.855 . . . . 0.0 109.705 178.273 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 33.8 m120 -92.58 -1.54 56.83 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.366 -0.834 . . . . 0.0 112.083 -179.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.538 ' N ' ' O ' ' A' ' 23' ' ' THR . . . -61.42 -42.28 99.73 Favored Glycine 0 CA--C 1.528 0.878 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.289 -178.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.83 -43.91 98.58 Favored Glycine 0 CA--C 1.526 0.76 0 C-N-CA 120.747 -0.74 . . . . 0.0 111.709 -179.195 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.8 tp -59.5 -47.9 83.74 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.622 -178.464 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 91.5 mt -61.85 -44.06 98.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 120.94 0.4 . . . . 0.0 111.59 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 91.8 t80 -60.65 -46.3 90.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.221 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.88 -41.73 87.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.46 -178.202 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.61 -40.49 97.98 Favored Glycine 0 CA--C 1.525 0.684 0 C-N-CA 120.434 -0.889 . . . . 0.0 111.043 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 59.2 tp -67.53 -40.69 85.07 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.396 0.617 . . . . 0.0 109.776 178.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.03 -47.49 85.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.179 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 93.3 t80 -58.97 -46.73 87.38 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -178.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 91.0 mt -58.24 -43.68 86.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.96 -178.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.6 t -58.38 -40.73 79.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.77 -179.322 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.58 -36.6 91.81 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 111.609 -0.597 . . . . 0.0 111.609 -179.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.3 tp -58.79 -45.81 89.0 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 91.5 mt -57.66 -35.81 71.05 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.277 -178.454 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 85.8 mt -59.89 -43.41 92.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.051 0.453 . . . . 0.0 110.501 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 60.3 tp -56.95 -41.06 77.58 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.134 -179.485 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 95.0 mt -60.4 -34.29 73.71 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.658 -178.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 96.3 p -57.73 -38.52 75.45 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 2.8 tmt_? -63.06 -35.35 79.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.509 178.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? -54.08 -29.08 42.96 Favored 'General case' 0 CA--C 1.52 -0.194 0 CA-C-N 116.59 -0.277 . . . . 0.0 111.187 -177.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -62.12 -39.77 93.64 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 119.936 -0.705 . . . . 0.0 110.135 178.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.592 ' CB ' ' HE ' ' A' ' 56' ' ' ARG . 11.3 mpt_? -88.73 -6.95 57.09 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.253 -179.757 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 48.9 p -81.18 -150.93 0.08 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.764 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.79 4.56 88.73 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 112.57 -162.43 12.39 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 57.27 84.59 0.09 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.654 0.264 . . . . 0.0 110.78 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -69.94 60.52 0.17 Allowed 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 121.077 0.465 . . . . 0.0 110.304 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 62.4 mttp -108.15 17.38 22.35 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.72 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.592 ' HE ' ' CB ' ' A' ' 49' ' ' ARG . 80.4 mmt-85 -101.76 5.59 41.33 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.521 -179.774 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 17.8 ptm180 -138.11 159.46 41.98 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.774 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.444 ' CD ' ' H ' ' A' ' 58' ' ' GLN . 25.0 mp0 -71.61 141.24 49.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.948 -179.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.1 pt -127.43 0.52 3.74 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.587 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 55.7 p30 -160.34 159.87 31.72 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.807 179.69 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 80.8 mm-40 -82.58 -13.53 56.39 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.481 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -61.96 -42.5 99.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.542 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -131.0 79.56 71.2 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.483 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo . . . . . 0 C--N 1.308 -1.556 0 C-N-CA 122.636 2.224 . . . . 0.0 112.205 -179.946 . . . . . . . . 0 0 . 1 stop_ save_